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Abstract 
Cysteine based phosphatases (CBPs) are a diverse family of enzymes that act to remove the 
phosphate group from proteins, phosphatidylinositols and other biomolecules, thereby 
counteracting the effects of kinases. Due to the wide range of roles they play in the cell, the CBPs are 
implicated in many diseases such as cancer, diabetes and neurodegenerative disorders, and 
therefore it is of interest to develop compounds to study these enzymes. 
Within our group, vanadium compounds have been shown to inhibit the CBPs with a potency and 
selectivity that can be tuned by varying the ligand and the oxidation state of the vanadium centre. 
One subset of interest is the vanadium complexes of 3-hydroxypicolinic acid which have an inhibition 
range against phosphatases of low nanomolar to high micromolar depending on the oxidation state 
of vanadium and the enzyme studied.  
A small selection of novel fluorescent vanadyl complexes based on the hydroxypicolinic acid motif 
have been synthesised as novel phosphatase inhibitors. Incorporation of an amine-functionalised 
spacer between the picolinate ligands provided a handle for incorporation of a fluorescent group 
away from the picolinate-vanadyl core. These compounds were then tested against a range of 
phosphatases to determine their potency and selectivity as inhibitors of CBPs. The complexes 
showed good inhibition properties against the CBPs investigated in a range similar to that of free 
vanadyl. 
The fluorophore was used to study the interaction of the vanadyl complexes with the enzymes, and 
to investigate cell uptake. Fluorescence quenching and anisotropy assays were carried out to look at 
the stability of complexes in assay conditions. From the data obtained it appears that the vanadyl 
complexes are stable in the presence of the enzymes and under assay conditions. Preliminary data 
also indicate that the complexes are taken up into cells and therefore can be investigated as 
intracellular probes.  
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Chapter 1: Introduction 
The phosphatases are a broad class of enzymes that hydrolyse phosphoesters, thereby 
counteracting the effects of kinases1,2. Protein phosphorylation is implicated in almost all cell 
signalling pathways and therefore cellular functions. The addition or removal of a phosphate group 
from proteins or other molecules has a role in almost every known signalling cascade and is 
associated with apoptosis, cell adhesion, cell differentiation and cell proliferation3,4. The role of the 
phosphatases in cells is to balance the activity of the kinases in order to control cellular 
phosphorylation levels5,6. Due to the large number of roles played by the phosphatases they have 
been implicated in a wide range of diseases including cancer, diabetes and infectious diseases7.  
Although phosphatases have now been identified as druggable targets, there is still limited progress 
towards targeted inhibitors when compared to the kinases, and more work is needed to fully 
understand the roles of different phosphatases under physiological and diseased conditions8. Due to 
the varied roles these enzymes play, it is of interest to study their functions and localisation in cells, 
for which appropriate chemical tools are required. 
This chapter will look at a specific family of phosphatases, the cysteine based phosphatases (CBPs), a 
family of enzymes which includes the classical protein tyrosine phosphatases (PTPs) and dual-
specificity PTPs (DSPs). Their roles in disease as well as their structure, function and regulation will 
be discussed before moving on to look at current inhibitors and chemical probes that have been 
developed to target these enzymes.  
1.1 The roles of PTPs in health and disease. 
CBPs play important roles in several different signalling pathways. They are now considered to be 
implicated in a wide range of diseases (Table 1) such as diabetes mellitus (PTP1B, LAR and PTPMT1), 
cancer (PTEN, LMW-PTP and VHR) and neuronal diseases (CD45) as well as involvement in allergy 
and inflammation (SHP1 and SHP2)6,8,9. PTPs can play different roles in these diseases, acting as 
either positive or negative regulators of different signalling pathways (Table 1, physiological effects). 
Some CBPs have been identified as oncogenes, such as VHR which is overexpressed in certain 
cancers10,11; some have been identified as regulators of tumorigenesis such as LMW-PTP, which acts 
in the protein derived growth factor pathway to decrease cell proliferation whilst potentiating cell-
cell contacts contributing to cancer progression12,13; and some CBPs have been identified as tumour 
suppressors such as PTEN which acts to negatively regulate the Akt pathway through 
dephosphorylation of PIP314–16. There are also examples where CBPs of the same class can act via 
opposing mechanisms in the same pathway, for example SHP1 acts as a negative regulator of 
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cytokine pathways (tumour suppressor) whilst SHP2 acts as a positive regulator5,17 (oncogenic). A 
summary of some CBPs that are implicated in disease progression are given in Table 1. 
Table 1: CBPs implicated in a selection of diseases.  
PTP Disease(s) Physiological effects 
SHP1 Cancer 
Neurological diseases 
Tumour suppressor18 
Neuroprotection19 
SHP2 Cancer 
Neurological diseases 
Oncogenic20 
Neuroprotection21 
PTEN Cancer Tumour suppressor22 
PTP1B Cancer 
Obesity and diabetes 
Activates c-Src in breast cancer23 
Positive regulator24 
LAR Diabetes Overexpression gives insulin resistance25 
CD45 Neurological diseases 
Cancer 
Alzheimer’s disease26 
Proliferation of mylenoma27 
LMW-PTP Cancer Oncogenic12,13 
 
As discussed in Section 1.3, CBPs can be regulated in cells which can lead to them being either 
switched on or off. In the cases where these enzymes are negative regulators of diseases, for 
example tumour suppressors, loss of function or reduced expression can lead to disease progression 
as regulation of key signalling pathways is lost. Oxidation of, for example, tumour suppressors can 
sometimes exceed physiological levels in cancer cells and lead to over-activation of proliferative or 
oncogenic pathways28,29. Overexpression of enzymes and mutations that cause over-activation have 
been implicated in certain diseases20,30. SHP2 has been identified as an oncogene and is mostly 
present in its inactivated form. However, certain mutations are activating and this activated form 
has been implicated in leukaemia as well as some solid human tumours30. 
Considering the wide range of roles these enzymes play in diseases it is clearly of great interest to 
design molecules to study their function and localisation not only as a family but also on an 
individual enzyme basis.  
 
 
22 
 
1.2 Cysteine Based Phosphatases (CBPs): Function and regulation 
The cysteine based phosphatases are a large family of enzymes which includes the protein tyrosine 
phosphatases (PTPs), dual-specificity phosphatases (DSPs) and inositol phosphatases (IPs). This 
family is characterised by a shared structural feature in the catalytic domain, the CX5R motif (Figure 
1), which contains the catalytic cysteine residue31. A key feature of this cysteine residue is its low pKa 
compared to that of a free cysteine. The local environment around the catalytic cysteine means that 
the pKa is lowered from ≈ 8 to around 5-732 and therefore the catalytic cysteine is deprotonated at 
physiological pH. Hydrogen bonding interactions with backbone NH groups in the protein as well as 
with the OH group of either a serine or threonine residue help to stabilise the thiolate form of 
cysteine. This increases the nucleophilic character of the sulphur, thereby increasing its reactivity 
towards substrates. The catalytic motif or phosphate binding loop (P-loop) also contains an arginine 
residue (Figure 1) that is crucial in defining the structure of the transition states that are essential for 
catalysis.  
Figure 1: Consensus sequence alignment in CBPs and active site molecular surface overlay. Sequence 
alignment for the catalytic domains of Human PTP1B (a classical PTP, Gene ID: 5770), VHR (a DSP, 
Gene ID: 1845) and PTEN (an IP, Gene ID: 5728) showing the conserved cysteine and arginine residues 
(highlighted in red)15,33. Active site overlay comparing the structures of PTEN, VHR and PTP1B is used 
with permission of Elsevier15.  
 
All of the CBPs act by the same mechanism (Figure 2) to remove phosphate groups from a range of 
substrates including phosphorylated tyrosine and serine residues and inositol phosphates1,6. The 
Human PTP1B: 210 PVVVBCSAGIGRSGTFCLADTC 
Human VHR:  119 RVLVHCREGYSRSPTLVIAYLM 
Human PTEN: 119 VAAIHCKAGKGRTGVMICAYLL 
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phosphate group and transition states are held in place by backbone nitrogen atoms and the 
arginine group, for example Arginine-221 (PTP1B), which are well positioned in the P-loop to display 
the correct interactions1 and will be protonated at physiological pH.  
 
Figure 2: Mechanism of action of a generic CBP under physiological conditions (pH 7.4). Scheme 
showing the nucleophilic attack of the cysteine residue on phosphate and the phosphocysteine 
transition state. 
 
In the first catalytic step the cysteine attacks the phosphate group to form a phosphorylated 
cysteine intermediate. This step also requires the presence of a general acid, shown in Figure 2 as 
aspartic acid, to donate a proton to the phosphate. The deprotonated acid then acts as a base to 
activate a water molecule for regeneration of the catalytic cysteine in the second step of catalysis. 
The protonated form of the aspartic acid residue is present in the enzyme-substrate complex due to 
the ability to hydrogen bond with an oxygen in the substrate. The increased pKa form of this residue 
is also present for the second step of catalysis where it acts as base to deprotonate water1. 
Although all CBPs contain the CX5R signature motif in the catalytic domain (Figure 1) there is broad 
structural diversity both between and within the different classes of CBPs30,31. This structural 
diversity means that phosphatases can display substrate specificity through additional interactions 
with the substrate beyond the active site pocket. Within the classical PTPs there are the 
transmembrane receptor-like enzymes and the cytoplasmic enzymes which have different structural 
domains depending on their function and localisation in the cell (Figure 3: PTP1B, SHP2 and 
receptor-like PTPs).  
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Figure 3: Schematic representation of a small selection of CBPs. Receptor-like PTPs have 
transmembrane domains that allow them to anchor in the cell membrane. They also contain an 
extracellular domain, often containing cell adhesion groups30. Cytoplasmic PTPs do not contain these 
domains but have a selection of structural motifs to target them to subcellular locations. Classical 
(PTP1B, SHP2 and LMW-PTP) and DSPs (PTEN and VHR) have different domains depending on 
function and localisation31. 
 
Within the cytoplasmic PTPs, domains that affect cellular localisation regulate access to certain 
substrates, thereby regulating the activity of the enzyme34. For example, the cytoplasmic PTP SHP2 is 
recruited to the cell surface by the SH2 domain (Figure 3), whereas PTP1B has structural features to 
target it to both the cell membrane (catalytic domain contained in the WPD loop35) and the 
endoplasmic reticulum (ER-anchoring hydrophobic sequence, C-terminal domain)2. Dual-specificity 
phosphatases have minimal sequence similarity beyond the catalytic domain (Figure 3, VHR and 
PTEN), with active site structures allowing access to a variety of substrates including phosphorylated 
serine (Figure 4c) and threonine (Figure 4d), and some phosphatidylinositol phosphates (e.g. Figure 
4b). Some of the DSPs, such as VHR36, still preferentially dephosphorylate tyrosine residues whereas 
others have different substrate preferences, for example PTEN for PIP3 (Figure 4b).  
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Figure 4: Structures of the CBP substrates: (a) tyrosine phosphate; (b) the phosphorylated headgroup 
of PIP3 (R = fatty acid chains); (c) phosphoserine and (d) phosphothreonine. 
 
Because of the large number of possible substrates available for phosphatase regulation, within each 
class of CBPs there is substrate specificity beyond the preferred phosphorylated residue. Kinetic 
studies of a selection of PTPs have shown sequence specificity between enzymes for 
dephosphorylation of peptides37. Structures both within the catalytic domain and beyond have been 
shown to play a role in determining the specificity of PTPs for certain enzymes, receptors or 
biomolecules31. For example, PTP1B contains a secondary phosphotyrosine binding pocket, as well as 
peptide recognition motifs, and selectively dephosphorylates the insulin kinase receptor. This 
receptor contains a pair of phosphotyrosine residues37, allowing it to bind to both the catalytic and 
allosteric pockets. Alternatively, LMW-PTP has very little sequence homology to other PTPs and, as a 
result, has structural features for binding different types of tyrosine-phosphorylated substrates38. 
SHP1 and SHP2 are also known to act on different substrates, with a single amino acid (arginine or 
lysine respectively) conferring specificity for N-terminal residues of protein substrates39. This range 
of substrate specificity is also seen within the DSPs. One example is VHR which shows binding of the 
peptide substrate in a groove close to the active site40. This variation in CBP substrate specificity and 
the necessary structural variation within this class of enzymes can be used to target specific CBPs. 
The diversity in subcellular localisation and substrate specificity allows for the CBP family to perform 
a wide range of functions. It has been shown that CBPs can be both positive and negative regulators 
of cell signalling pathways (e.g. the SHPs, Table 2) and are involved in a variety of cellular processes 
from cell growth and proliferation to cell-cell interactions. Some examples of CBP functions are 
shown in Table 2. 
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Table 2: Cellular function of a selection of classical and dual-specificity PTPs.  
Enzyme Class Function/Pathway 
PTP1B Classical PTP Insulin-dependent signalling cascade41 
VHR DSP MAP-kinase inactivation42 
LMW-PTP Classical PTP Platelet-derived growth factor receptor 
inactivation12,13 
SHP1 Classical PTP Negative regulation of cytokine receptors 
and receptor tyrosine kinases43 
SHP2 Classical PTP Positive regulation of receptor tyrosine 
kinases7 
PTEN DSP (IP) Akt pathway, acts on PIP314 
PTPMT1 DSP Dephosphorylates phosphatidylglycero-
phosphate.44 
 
1.3 Regulation of CBPs 
In order to regulate phosphorylation in cells, phosphatase and kinase activity and function need to 
be carefully controlled. Some methods by which CBPs can be regulated are: differential expression in 
different cell and tissue types; subcellular localisation (Section 1.2); and post-translational 
modifications. Examples of the post-translational modifications include phosphorylation, 
ubiquitination, glycosylation and oxidation, all of which affect the activity and localisation of the 
PTPs and DSPs, thereby regulating their ability to function2. Dimerization, protein-protein interaction 
and ligand interactions can also affect the CBP activity34. For example, it is thought that the 
dimerization of VHR blocks the active site thereby reducing catalytic activity11. It should be noted 
that post-translational modifications to CBPs can be either activating or inactivating, such as in the 
case of oxidation where some enzymes are activated by the formation of disulfide bridges whilst 
others are inactivated by oxidation of the catalytic cysteine45. Oxidation occurs in a large selection of 
CBPs, and the effects on structure and function vary depending on the enzyme and the site of 
modification. In PTP1B oxidation of the cysteine residue is followed by the formation of a sulfenyl 
amide bond between a backbone nitrogen and the oxidised cysteine46 (Figure 5d) whilst in PTEN47 
and SHP1/217 a reaction with a backdoor cysteine occurs (Figure 5c), both of which are inactivating34.  
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Figure 5: Scheme showing the reversible oxidation products of activated cysteine residues (a): (b) 
sulfenic acid, (c) disulfide, (d) sulfenamide. 
 
Considering the many routes available for regulation of CBPs, having methods to probe the changes 
in activity and localisation under various conditions is of considerable interest. In the following 
sections, compounds currently available to both regulate and probe PTPs and DSPs are discussed. 
 
1.4 CBP inhibitors 
Since CBPs have been identified as desirable drug targets48 there has been a lot of work carried out 
to design molecules7–9,44,48–51 that selectively inhibit the family of enzymes (the CBPs), enzyme classes 
(such as classical PTPs and DSPs) and specific enzymes of interest. The fact that all of the CBPs 
contain the same catalytic motif and share a general mechanism makes it challenging to design 
selective inhibitors or probes that target the active site of one specific phosphatase52. However, 
beyond the catalytic motif there is more structural diversity that can be exploited such as variation 
in the size and shape of the catalytic pocket to accommodate the different substrates15, and 
different structural features beyond the catalytic domain depending on cellular localisation2 (see 
Section 1.2). A good example of this is the difference in catalytic pocket size between PTP1B, a 
classical tyrosine phosphatase, and PTEN, a phosphatidylinositol phosphatase. The PTP1B active site 
only has to accommodate phosphorylated tyrosine (Figure 4a) and therefore has a deep, narrow 
active site whilst PTEN has to accommodate the far larger inositol phosphate structure (Figure 4b) 
and therefore requires a more open catalytic pocket15 (Figure 1). There is also structural variation 
seen between enzymes specific for tyrosine compared to DSPs that can accommodate serine or 
threonine residues, with the former having much deeper active site pockets (around 9 Å,)53 than the 
latter (around 6 Å)7. The shallower active site pocket means that the bulkier substrates can reach the 
catalytic cysteine (Figure 6c) which would not be possible in a deeper catalytic pocket of the same 
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width (Figure 6b). As discussed above, CBPs also have structural variation to give the desired 
substrate specificity. This requires substrate specific binding motifs beyond the catalytic pocket that 
can interact with the substrate away from the phosphorylated residue.  
Figure 6: Schematic showing how active site structure affects substrate specificity in PTPs. (a) 
phosphotyrosine in a classical PTP active site pocket; (b) phosphoserine in a Classical PTP active site 
pocket; (c) phosphoserine in a DSP active site pocket; and (d) structures of LMW-PTP (PDB code 4z99) 
and VHR (PDB code 1VHR) showing the active site (pink) and catalytic residue (yellow). Structures 
were edited in PyMol. 
 
This variation in the structure of the catalytic and substrate binding domains between different 
CBPs, as well as the common phosphate binding motif, has opened up possibilities for development 
of targeted compounds to inhibit these enzymes. The compounds discovered to date include small 
molecules7,9, peptides and peptide mimetics7,9, natural products and metal based compounds24.  
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Figure 7: Structures of a selection of known PTP inhibitors. (a) a peptide-based bidentate inhibitor of 
PTP1B; (b) a trifluoromethane sulfonylamine based bidentate inhibitor of SHP2; (c) a reversible 
allosteric inhibitor of PTP1B; (d) a covalent allosteric inhibitor of PTP1B; (e) ReAsH, a biarsenical 
inhibitor of SHP2; and (f-h) examples of natural products and analogues that inhibit VHR and CD45 in 
the low micromolar range. 
 
Due to the size of some inhibitors it is unlikely that the full compound will interact with that catalytic 
site. Many of the compounds shown above contain groups that specifically target the catalytic 
cysteine (such as the sufonyl groups) whilst the rest of the molecule interacts beyond the active site. 
Others, such as compound (b) in Figure 7, have two targeted groups and can therefore interact with 
the enzyme at two different sites (see Section 1.4.2 for further discussion). The binding of some 
inhibitors has been shown by X-ray crystallography and the interaction of phosphate mimetic groups 
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at the catalytic cysteine can be clearly seen. Figure 8 shows two inhibitors, one a peptide mimetic (a) 
and the other a bidentate inhibitor (b), interacting with PTP1B as described. 
Figure 8: X-ray crystallographic structures of inhibitors bound to PTP1B. (a) Peptidomimetic 
compound with a phosphate mimetic group interacting at the enzyme catalytic cysteine (yellow)54; (b) 
bidentate inhibitor interacting both at the catalytic site of the enzyme and a secondary binding site55.  
 
1.4.1 Peptide and peptide mimetic inhibitors 
Earlier classical PTP inhibitors relied on peptides as the basis of inhibitor design, for example the 
hexapeptide inhibitor (Asp-Ala-Asp-Glu-F2Pmp-Leu-NH2) of PTP1B. However, peptides have poor 
bioavailability due to low membrane permeability and susceptibility to protease degradation. They 
also tend to be non-specific, inhibiting a selection of PTPs that accept phosphotyrosine substrates. 
The area of peptide-based inhibitors was, therefore, developed leading to small molecule inhibitors 
with peptidic fragments or modified peptide mimetics. A large number of peptide-based inhibitors 
have been tested against PTP1B with the majority inhibiting with a Ki or IC50 in the low nanomolar to 
high micromolar range. Some have also been reported as inhibitors of other enzymes such as VHR, 
SHP1 and LAR7. Modifications made to the peptide structures gave improved potency, bioavailability 
and specificity to allow rational design of peptide based inhibitors to selectively target PTPs in a 
cellular environment. They have also been developed to act as bidentate inhibitors (see Section 
1.4.2) for PTPs containing two binding sites, for example PTP1B, through the incorporation of two 
phosphate or phosphate mimetic groups7–9 (for example, Figure 7a). This approach utilises the 
structural diversity of the PTPs beyond the active site pocket to increase the specificity of the 
peptides for certain enzymes (see Section 1.4.2). Although the use of peptides to inhibit CBPs is 
developing, there are still issues with the size, lipophilicity and charged nature of some compounds 
which could affect cell permeability56.   
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1.4.2 Allosteric versus Competitive inhibitors 
Allosteric inhibitors are compounds which bind to sites distinct from the catalytic domain to cause 
inhibition, unlike competitive inhibitors that interact with the enzyme active site. Although some 
enzyme-specific competitive inhibitors have been synthesised (see Sections 1.4.1, 1.4.3 and 1.4.4), 
more recent work has focused on the more structurally diverse regions away from the catalytic site. 
As mentioned in Section 1.2, substrate specificity extends beyond the active site pocket and so 
substrate-specific regions of PTPs are possible drug targets. The fact that the activity of some 
enzymes (such as PTP1B, CD45, DUSP6 and MPK-4) rely on conformational changes away from the 
active site region57 makes targeting allosteric sites an attractive option for specifically targeting CBPs. 
A selection of small molecule allosteric inhibitors57 has been reported to act against some CBPs 
(PTP1B, CD45, DUSP6 and MPK-4), in particular PTP1B (Figure 7 c and d), which has been shown to 
be inhibited allosterically by both covalent58 and non-covalent interactions59. A recent discovery is 
that of an allosteric site on SHP2 which interacts with organic biarsenical compounds to give specific 
SHP2 inhibition60 (Figure 7e).  
 
Figure 9: Bidentate inhibition. Two inhibitor fragments, one binding to the active site of the enzyme 
and another to a nearby allosteric site, are linked to form a more potent and selective inhibitor. The 
active site binding fragment will interact with the catalytic cysteine whilst the allosteric binding 
fragment will interact with residues present in the secondary site, such as arginine in PTP1B (for an 
example of a bidentate interaction see Figure 8b). 
 
Another approach to be considered is that of bidentate inhibitors. These compounds are designed to 
bind both at the enzyme active site and at a secondary binding site adjacent to the first. Through this 
method, several PTP1B specific inhibitors have been designed which target the active site of the 
enzyme and one of two secondary sites in close proximity. The larger, peptide mimetic structures 
have Ki values as low as 2.4 nM against PTP1B (Figure 7a), with at least 10 –fold selectivity over other 
enzymes 9. Bidentate inhibitors have also been used to target a small number of other PTPs (PTP1B, 
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TCPTP, CD45, LAR and SHP2), for example, trifluoromethane sulfonylamine containing compounds 
(for example, Figure 7b) have low micro-molar affinity for SHP29. Although the full extent of 
allosteric inhibition in PTPs is not yet fully understood, this opens up a route to designing more 
selective CBP inhibitors by utilising structural features beyond the catalytic pocket. 
1.4.3 Natural products and analogues 
Natural products have produced a large selection of CBP inhibitors and have provided starting points 
for the development of other synthetic inhibitors. The natural products and their analogues have 
shown a wide range of potency and selectivity towards the CBPs. Some of the natural products, for 
example 4-Isoavenaciolide (Figure 7f), cause non-specific inhibition through irreversible inhibition 
whilst having high potency (IC50 = 1.2 µM against VHR). Others such as the dysidiolide base 
compounds (Figure 7g) are specific for a certain enzyme, in this case Cdc25C (IC50 = 0.8 µM), and act 
via a reversible mechanism. The structures of the active compounds also vary, with some being 
large, long chain or cyclic compounds such as caloporoside (acts on PTP1B) whilst others are small 
molecules such as the cholesterol based compounds (Figure 7h, acts on Cdc25A with an IC50 of  
2.2 µM). Using structure-activity relationships and rational design approaches, phosphatase 
inhibitors could be synthesised based on natural products that show good affinity for the PTPs 
thereby providing the start point for the development of potent inhibitors of a wide range of PTPs7,8. 
At present, however, there are still some issues with enzyme specificity, and with potency not 
reaching the nanomolar range which has been reported for other classes of inhibitors7. 
1.4.4 Metal based inhibitors 
In addition to organic compounds, metal cations (including copper, vanadium and zinc) have been 
utilised as inhibitors of CBPs 49,61,62. Fe3+, Cu2+, Zn2+, and Cd2+ have all been shown to inhibit VHR to 
varying degrees, with the copper(II) ion showing the greatest potency. The authors also found that 
Fe3+, Zn2+, and Cd2+ act via a reversible interaction with residues on the enzyme whilst Cu2+acts to 
oxidise the catalytic cysteine residue to sulfenic acid63 (Figure 5). Tungstate (WO42-)64 and molybdate 
(MoO42-)65 have also been shown to act as anti-diabetic compounds in animal models. Studies on the 
zinc ion have identified it as a very potent inhibitor against various members of the CBP family49 and 
extensive work has been carried out to look at the mechanism of zinc inhibition of PTP1B62,66. The 
zinc ion is an effective PTP1B inhibitor, likely acting to prevent phosphate release in the second step 
of catalysis62. It is also effective against VHR, although evidence suggests that zinc binds away from 
the active site63. Vanadium IV and V ions are also known to inhibit the PTPs via both competitive and 
oxidative mechanisms61 (Section 1.5). 
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Figure 10: Examples of metal complexes shown to inhibit CBPs. (a) disodium aurothiomalate complex, 
(b) example of a carbene gold complex, (c) a bis(maltalol) molybdate complex, and (d) an example of a 
dinuclear copper complex. 
 
Many metals can also act as CBP inhibitors or anti-diabetic drugs within specific complexes. In a 
review67, the authors proposed two mechanisms by which these metal complexes could inhibit the 
CBPS: (1) a reversible interaction with the enzyme active site; or (2) oxidation of the catalytic 
cysteine residue. 
Unlike other metals, complexes of gold and not the free metal cation were shown to inhibit a range 
of PTPs, with the selectivity determined by the structure of the ligand49. Complex (a) in Figure 10 
inhibits both CD45 and PTP1B in the low micromolar range whereas complex (b) shows selectivity for 
PTP-PEST and PTP1B (9 µM) over five other CBPs. The gold complexes (Figure 10a and b) were 
shown to act via a reversible competitive mechanism with the gold interacting with the catalytic 
cysteine68,69. Increasing the steric bulk of the ligands through introduction of phosphine ligands 
introduced selectivity for LYP49. Molybdate complexes have been investigated as antidiabetic agents 
and the maltolato complex (Figure 10c) gave some glucose lowering effects65. 
The two most investigated metals and their complexes are copper(II) and vanadium(IV/V) (Section 
1.5). Varying the structure of the copper complexes affects the potency of the compounds against 
CBPs as well as the selectivity for certain enzymes49. Dinuclear complexes with phosphine ligands 
showed selectivity for TCPTP (30 nM) whilst oxygen ligands (Figure 10d) gave selectivity for PTP1B 
and SHP1 (15-30 nM). In a recent study by Wang et al it was shown that a change in the structure of 
the copper complex affects the ability of the complexes to inhibit PTP-MEG2 and SHP2 and causes a 
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change in selectivity for a selection of other enzymes70. For all of the above inhibitors it should be 
considered that, although all complexes are potent inhibitors of the CBPs, it is likely that the larger 
complexes would not be able to interact with the enzyme active site. This concept is discussed 
further in Chapters 3-5 in relation to the vanadyl complexes. All of the above examples do, however, 
show how small changes to the ligand structure, coordinating atoms and steric bulk can affect the 
potency and selectivity of metal complexes for different CBPs. 
 
1.5 Vanadium complexes as CBP inhibitors 
The most extensively studied metal as an inhibitor of CBPs is vanadium, and both the metal salts and 
complexes of vanadium(IV) and vanadium(V) have been investigated. Vanadium compounds first 
became of interest as metallopharmaceutical agents when the insulin mimetic properties of 
vanadate and vanadyl were discovered71. Early research focused on enhancing the insulin mimetic 
activity of the vanadium complexes, with more recent studies investigating the CBP inhibition 
properties of vanadium salts and a range of vanadium complexes49,72–75. The metal salts of both 
vanadium oxidation states have been found to be very potent inhibitors of CBPs, with vanadate (VV) 
and vanadyl (VIV) inhibiting PTP1B with Ki values of 380 nM and 110 nM respectively61,66. Recent 
reviews have discussed how the species of vanadium present has a significant effect on the mode of 
action, for example whether the vanadium is a salt or complex; the coordination geometry of the 
complex; and the oxidation state of the vanadium centre76,77. In this section, the coordination 
chemistry of vanadium complexes will be discussed in the context of CBP inhibition and insulin 
mimetic activity in order to clearly show how the structure of the complexes and ligands can affect 
the phosphatase-inhibitory properties of the corresponding vanadium complexes. 
Vanadium compounds, due to the coordination geometries available, can act as phosphate 
(substrate or product) or transition state mimetics (Figure 11)76,77 and will therefore interact with the 
catalytic site of CBPs8,61. Phosphate has a tetrahedral structure (Figure 11a) and certain vanadium 
compounds are structurally analogous to the phosphate, having a tetrahedral arrangement of 
ligands (Figure 11a) around the vanadium core. Vanadium compounds can also take on a trigonal 
bipyramidal structure and these compounds will favourably interact with CBPs as they mimic the 
enzyme-phosphate transition state78 (Figure 11b). Shape analysis of vanadium-PTP complexes has 
also suggested that this trigonal bipyramidal structure is favoured when vanadium compounds 
interact with the enzyme active site, although some distorted geometries moving towards a 
tetrahedral structure were also proposed79. The length of the V=O bonds in some complexes is also 
35 
 
complementary to certain enzyme active sites (such as PTP1B) where the longer bond mimics a bond 
breaking step in the enzyme catalytic mechanism77. 
 
Figure 11: Structures of vanadium compounds compared to that of phosphate. (a) Phosphate and 
vanadium compounds with analogous structures; (b) enzyme (Enz)-phosphate transition state and 
representative vanadium compound with analogous structure. 
 
Similar to copper complexes, vanadium complexes can inhibit CBPs via either oxidative or reversible 
mechanisms depending on oxidation state and ligand type. Pervanadates (or peroxovanadates) are 
vanadium(V) compounds that have one or two peroxo ligands. These compounds inhibit the 
enzymes through oxidation of the catalytic cysteine residue, likely involving a single electron transfer 
mechanism80. This irreversible inhibition has been investigated through assays using free 
pervanadate and organo-bisperoxovandium (bpV) complexes61,81 in the presence of either DTT 
(reducing agent) or EDTA (vanadium chelating). On addition of EDTA, enzyme activity was not 
restored suggesting that simply removing the vanadium metal does not affect inhibition. However, 
on addition of DTT, enzyme activity was restored suggesting that oxidation of the catalytic cysteine 
was the mode of inhibition (Figure 12c). This notion is supported by a recent study on the inhibitory 
mechanism of bpV compounds against PTEN, which has shown that these compounds lead to 
disulfide formation through oxidation which is reversible by glutathione and DTT82. Unlike the bpVs, 
vanadate and vanadyl compounds act via a reversible mechanism which is either competitive (Figure 
12a) or mixed (Figure 12b) depending on the complex or enzyme used49,75,83,84. 
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Figure 12: Schematic of different modes of enzyme inhibition. (a) Competitive inhibition: the inhibitor 
competes with the substrate for the active site pocket; (b) Mixed inhibition: The inhibitor binds to the 
enzyme whilst still allowing binding of the substrate at the active site; (c) Irreversible oxidative 
inhibition: the inhibitor causes a reaction to occur at the enzyme active site preventing reaction with 
the substrate. 
 
As with other metal complexes, the potency and selectivity of the vanadium complexes as 
pharmaceutical agents can be tuned by changes to the ligand type or structure. Several organic 
ligands have been utilised such as maltol (Figure 13a), bipyridyl (Figure 13b), chromones (Figure 13c), 
picolinates (Figure 15), and Schiff bases49,61,66,75,84–90 (Figure 14). Investigations into varying the 
structure of the known insulin mimetic complex bis(maltolato)oxovandium (Figure 13a) have 
determined the effects of using isomers of the original ligand and changing the coordinating 
atoms91,92. It was found that using structural isomers of the ligand reduced the insulin mimetic 
activity of the complexes, although some glucose-lowering effects were still observed91. For 
example, a methyl group at the two or six position lowered the effects on blood glucose levels whilst 
linking two ligands removed the glucose lowering activity almost completely. Exchanging the C=O for 
C=S removed all insulin mimetic effects92, showing the importance of the coordination sphere in the 
activity of vanadyl complexes. A review by Thompson and Orvig looks at the effects of varying 
ligands on the insulin-mimetic properties of vanadium complexes, comparing the effects to those 
observed for bis(maltolato)oxovandium. The reviewed data clearly shows that changes to ligands 
and ligand structure affect the properties of the vanadium complexes71. 
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Figure 13: Structures of selection of vanadyl complexes known to inhibit PTPs. (a) bis(maltolato)ox-
vanadium IV, (b) generic bipyridyl complex, and (c) chromone-based complex. 
 
Studies carried out by Lu et al75,84,86,89 have looked at the CBP inhibition properties of Schiff-base and 
glutamate vanadyl complexes, looking into the effects of varying ligand structure on the efficacy and 
specificity of the compounds. The studies showed how increasing the steric bulk of the polypyridyl 
ligand lowered the inhibitory activity of the mixed-ligand Schiff-base complexes against PTP1B75,89, as 
did changing the Schiff-base ligand from salicylidene anthranilic acid (Figure 14a) to naphthaldehyde 
anthranilic acid75. Addition of amino acid groups to the Schiff-base ligands reduced the IC50 values 
against PTP1B by 10-fold, with the exception of tryptophan (Figure 14b)86. Taken together these 
studies show how structural changes to ligands can affect inhibition. A study published in 2012 also 
showed the effects of complex structure on the selectivity for certain PTPs84. A selection of PTPs was 
tested against five Schiff-base complexes with some showing similar affinity for more than one PTP 
(200-600 nM) whilst others were selective for PTP1B. It was also shown how both the enzyme and 
the inhibitor used can affect the mode of inhibition, as some compounds showed competitive 
inhibition for PTP1B75 (Figure 14a and b) whilst others showed non-competitive inhibition for PTP1B 
but competitive inhibition of SHP284 (Figure 14c). 
 
Figure 14: Structures of three key Schiff-base vanadyl complexes. (a) Mixed ligand complex with a 
salicylidene anthranilic acid ligand and a polypyridyl ligand; (b) Mixed ligand complex with salicylic 
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acid-amino acid ligand and a polypyridyl ligand; and (c) Single-ligand complex with a salicylidene 
anthranilic acid ligand. 
 
Picolinic acid complexes of vanadium have been studied for over 50 years72. More recently their 
properties as CBP inhibitors and insulin-mimetic drugs have been investigated in detail66,72,93. Similar 
to the Schiff-base compounds above, varying the structure of the picolinic acid ligands has an effect 
on the selectivity and potency of these vanadyl complexes as CBP inhibitors. It has been shown that 
by adding substituents to the pyridine ring, the insulin mimetic activity of the corresponding vanadyl 
complexes could be affected. Addition of an electron withdrawing group to the 5-position or an 
electron donating group at the 6-position enhances the insulin mimetic activity of the parent 
compound (1.1), whilst adding similar groups at the 3 and 4 positions had the opposite effect94. This 
is likely due to structural changes caused by these substitutions, for example, a substituent at the 6-
position prevents the coordination of a water molecule, thereby favouring a five rather than six-
coordinate geometry. A study within the Woscholski and Vilar groups has identified the selective 
inhibition of PTEN by a 3-hydroxypicolininc acid vanadyl complex (1.2) and its bisperoxo counterpart. 
The ligands bind in a mixed coordination (N,N and N,O) which is not possible for the picolinic 
complex (1.1) and may be responsible for imparting the selectivity and potency which is not seen for 
the picolinic acid complex81,83,95. Within this study95 it was also shown how changing the ligand or the 
oxidation state of the vanadium affected the selectivity for certain CBPs. Bisperoxovanadium 
compounds had a higher affinity for MTM and SAC than the vanadyl complexes whilst the ligand 
used had a greater effect on the affinity of complexes for PTPβ. 
Figure 15: Structures of vanadyl picolinic acid (1.1) and vanadyl 3-hydroxypicolinic acid (1.2) 
complexes. 
 
1.6 Solution speciation and stability of vanadyl complexes 
As discussed in a review by Crans et al.96 vanadium(IV) has a very interesting solution chemistry 
which is highly pH dependant. Due to the sensitivity of vanadium compounds to their environment, 
it is important to consider the conditions under which they are used, including concentrations, 
buffers and solvent polarity77. The species present in solution can be anionic or cationic, and 
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monomeric, dimeric or even polymeric depending on the concentration of vandyl and the pH of the 
solution. Vanadyl complexes can also be present in many forms in aqueous solutions97, and the 
equilibrium between these forms depends on the stability of the complex. When vanadyl forms 
complexes with bidentate ligands one coordination site is left free and this can, therefore, be 
occupied by a solvent molecule in solution. This gives rise to two possible coordination geometries in 
solution: cis or trans (Figure 16). For example, the known insulin mimetic complex 
bis(maltolato)oxovanadium has a square pyramidal geometry in solid state but is predominantly in 
the cis-geometry when dissolved in coordinating solvents98,99. Vanadium-picolinic acid complexes 
and derivatives, as discussed in Section 1.5, have been shown to inhibit the CBPs with good potency 
and selectivity. Due to the ability to tune the properties of these complexes through changes to 
ligand structure, and therefore form highly enzyme-selective compounds, the picolinic ligands were 
used in this project (Section 1.8). The coordination chemistry of these complexes will, therefore, be 
discussed in further detail. 
VO-picolinic acid has been extensively studied with early work establishing both the hydrolytic 
stability and resistance to oxidation of these complexes100. Since then, further studies have been 
carried out using a wider selection of picolinic acid ligands to investigate solution speciation, stability 
and coordination geometry97,101–103. Solution-based studies found that, for picolinic acid and 3-
hydroxypicolinic acid, at low pH only one ligand is bound but once the pH is above 3 the two ligand 
complex is favoured101. However, for 6-methylpicolinic acid the one ligand complex is more 
favourable up to a pH of around 497, which is potentially due to the increased steric interactions 
caused by substitution at the 6-position. Therefore, changing the structure of the ligand would affect 
the equilibrium between one-ligand and two-ligand complexes. As discussed above, the bidentate 
complexes such as the picolinates also have the ability to switch between the cis and trans 
coordination geometries102 (Figure 16) which could affect complex binding to CBPs. The different 
arrangements of coordinating atoms around the vanadyl core could also affect the stability of the 
complexes103. From crystallographic studies, the complexes of picolinic acid103 and 3-hydroxypicolinic 
acid50 have a cis-geometry when crystallised. This has also been reported as the predominant species 
in solution for 3-hydroxypicolinic acid102, and is proposed as the most likely form for picolinic acid 
from EPR data97. However, in the case of 6-substituted picolinic acids, the trans-isomer was shown 
to be the more stable form103 and this is likely due to the steric constraints imposed by the 
substitution97. It should the also be noted that the arrangement of coordinating atoms shown in 
Figure 16 is only one possible arrangement for the cis and trans geometries. Other isomers of these 
coordination modes have been proposed103 and interconversion between these isomers would be 
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possible in solution, for example having one picolinic oxygen opposite the other in the trans 
configuration (Figure 16a). 
Factors such as the coordination mode will also affect the stability of the complex, with certain 
combinations of coordinating atoms (such as N2O2) being more stable than others (such as N4)104. 
Sulfur containing ligands would also be expected to be less stable due to vanadium being a hard 
Lewis acid and sulfur being a soft Lewis base donor, and this was seen to some extent on exchanging 
an oxygen atom for sulfur in a bidentate ligand92. A further feature that affects complex stability is 
the number of coordinating atoms available on the ligand.  It would be expected that tetradentate 
ligands, such as  some Schiff bases, would be more stable than the bidentate ligands such as 
picolinates, malonates and acetonates71,91. 
 
Figure 16: Two possible coordination geometries of VO-picolinic acid complexes: (a) trans geometry 
and (b) cis geometry. 
 
The broad speciation chemistry of vanadium makes it difficult to determine which species is acting at 
any one time to cause the biological effect observed77. Studies carried out on bis(maltolato) and 
picolinic vanadyl complexes indicate that the vanadium complexes are in equilibrium with the free 
metal and ligand in aqueous solution97,98 and that the dominant species present will depend on the 
concentration of the ligand, pH of the solution and the binding constant of the ligand for 
vanadium97. This variation in stability of vanadium complexes in solution has led to the question of 
whether it is the complex that is acting to inhibit CBPs or merely the free vanadium ion. In a recent 
paper by Peters et al, it is proposed that release of vanadium from the complexes may be a 
requirement for the observed CBP inhibition73. If the binding of the ligand to the vanadyl is weak 
then the complex may act as a vanadium delivery system, falling apart in the presence of the enzyme 
to release the vanadyl core. Both vanadium IV and V complexes have been reported to act as 
prodrugs, releasing the vanadium on entering a cellular environment105. The idea that ligands can act 
as vanadium delivery systems was also proposed in a recent review looking at vanadium complexes 
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as enzyme inhibitors. It was noted that the Ki value of a vanadium complex was similar to that of free 
vanadate which likely points to the conclusion that the dipicolinato oxovandium(V) complex was 
delivering vanadate to the phosphatase76. However, there have also been reports that propose that 
coordination of the ligand to vanadium is required and has an effect on CBP inhibition in some 
cases80,83,106. The question of whether CBP inhibition by vanadium compounds is caused by the 
vanadium complexes in some form, or free vanadyl released from the complex in the presence of 
the enzyme is still not fully answered and, therefore, should be considered when looking at 
inhibition data. As will be discussed below, part of the motivation of the work presented in this 
thesis was to elucidate the mode of action of vanadium complexes inhibiting phosphatases (Section 
4). 
Taking into account the current knowledge of the inhibitory mechanisms of vandyl complexes (see 
above), it is possible that any complex could either act as a delivery system of the vanadium or as an 
inhibitor in its own right. It should also be considered that any structural variation to the picolinic 
acid ligands could affect their solution speciation and the presence of two or four coordinating 
atoms under biological conditions. With this in mind, there are three possible forms of the picolinic 
acid-vanadyl complexes which could interact with the CBPs: the full complex (two bound ligands) 
with one water molecule bound (Figure 17a); the ‘half complex’ (one bound ligand) with water filling 
the vacant binding sites (Figure 17b); or free vanadyl (Figure 17c). If the complexes formed are stable 
under the assay conditions used and in the presence of the enzymes then any inhibition seen can be 
attributed to interaction of the full or the one-ligand complex with the enzyme. 
 
Figure 17: Scheme showing three possible states of vanadyl in solution after complexation to picolinic 
acid. (a) Full complex – both ligands remain coordinated to vanadium; (b) ‘half-complex’ – one ligand 
de-coordinates; and (c) uncoordinated vanadyl – both ligands are lost, leaving only the free vanadyl in 
solution. 
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1.7 Current compounds to study CBPs 
As more CBP selective compounds are discovered, possibilities open up for the further elucidation of 
CBP function, but also for the development of novel CBP targeted probes. While the former is 
concerned with the determination of the physiological roles of CBPs and their catalytic activity, the 
latter could prove useful for studying the expression and localisation patterns of phosphatases in the 
context of their catalytic function. Each of these approaches requires chemical probes that are 
selective for the CBP family of phosphatases and preferably are specific for certain members of that 
family. A recent example of a targeted inhibitor based probe is a fluorescently labelled peptide 
based on a known PTP1B inhibitor. This compound provides a tool to look at PTP1B expression, 
activity and subcellular localisation through the attachment of a fluorophore or tag group107. In the 
following section some CBP specific substrates and activity based probes will be discussed in the 
context of current approaches available to study these enzymes both in vivo and in vitro, as well as 
looking at approaches to increase selectivity of these compounds for certain CBPs. 
One area that has been more extensively studied is the measurement of CBP activity using 
fluorescent substrates and activity based probes53. Small molecule fluorescent substrates based on 
coumarin were used, with fluorination of the coumarin ring imparting greater specificity for the CBPs 
and greater sensitivity in the assays108 (Figure 18a). The use of dipeptide analogues allowed for the 
specificity to be further increased for certain PTPs such as PTP1B109. Another method for improving 
selectivity of fluorescent substrates was to look at the structures of the active sites of DSPs versus 
classical PTPs. The DSPs have shallower and sometimes wider active site pockets than the classical 
PTPs which gives improved access of substrates to the catalytic cysteine (Figure 6)15,33. By using a 
wider, less flexible fluorescent head group on the phosphate (for example Figure 18b), the specificity 
for the DSPs was greatly increased yielding optical probes that were selective for these enzymes 
over the classical PTPs110,111. These studies show how the specificity and selectivity of probe 
molecules for certain enzymes can be tuned with consideration of enzyme structure and substrate 
specificity53.  
 
Figure 18: Structures of fluorescent probes for detection of PTPs. (a) 6,8-difluoromethylumbelliferone 
phosphate (DiFMUP), (b) an iminocoumarin derivative with a larger structure to allow selectivity for 
DSPs. 
43 
 
 
Activity based probes (ABPs) are also used to selectively target PTPs by forming a covalent bond with 
the active cysteine residue53. These probes allow investigation of protein expression as well as 
activity and can incorporate an affinity tag such as biotin for pull-down and analysis (Figure 19a) or a 
fluorescent group for in-gel detection112. There are several types of ABPs containing clickable groups, 
pre-attached affinity tags and peptide fragments, but all incorporate the phosphate mimetic head 
group to interact with the enzyme active site53. Some of the probes reported are targeted to the 
whole family of CBPs113 (Figure 19a) whereas others are designed to target specific enzymes by using 
peptide sequences or core structures to interact with different CBPs114 (Figure 19b). Another method 
for targeting CBPs is the incorporation of an inhibitor fragment into the linker between the reactive 
group and the tag (Figure 19c). This approach has been utilised for the detection of oxidised CBPs in 
cells, with the probes also acting as reversible inhibitors of non-oxidised PTPs. These probes showed 
greater detection of two PTPs over previously reported probes and were selective for CBPs over 
other enzyme classes. In the paper by Leonard et al, glyceraldehyde 3-phosphate dehydrogenase 
and the thiol peroxidase Gpx3 were tested to show this selectivity115. This study shows how 
incorporating known inhibitor or substrate fragments into probe compounds can improve both 
specificity and affinity of the compounds for the target enzymes. 
 
Figure 19: Structural features of activity based probes. The structures shown are (a) a CBP-selective 
activity-based probe; (b) an enzyme targeting activity-based probe; and (c) an example of a CBP 
targeting redox-based probe. 
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1.8 Aims, objectives and project rationale 
All of the compounds discussed above act by reacting with the catalytic cysteine of the enzyme to 
either release a fluorescent compound or form a covalent bond. Reversible inhibitors are also 
utilised to look at the physiological roles of enzymes in a targeted manner52, and inhibitor fragments 
have been used for the development of the redox-based probes to help target the probe to the CBP 
family of enzymes115. It should therefore be possible to develop this idea for the design of targeted 
probes for non-oxidised CBPs by attaching a tag to a known, selective inhibitor. As discussed above, 
metal complexes – in particular with vanadium – have been widely investigated as inhibitors of CBPs. 
In Sections 1.4.4 and 1.5, the ability to increase the affinity and specificity of metal complexes for a 
certain CBP by changes to the structure of the ligand was discussed, and this ability to tune the 
properties of the compounds opens up the possibility of utilising metal complexes for the design of 
fluorescent probes targeted to certain CBPs. As discussed above (Section 1.5), vanadium complexes 
have been widely studied and have been shown as promising CBP inhibitors, with high affinity and 
selectivity for CBPs as a whole, and specific enzymes61,66,74,86,87,116. Vanadium has a flexible 
coordination chemistry and can form tetrahedral, pyramidal and octahedral structures depending on 
the ligands71. The range of available ligands allows for selection of properties suitable for both probe 
design and targeting of specific CBPs. In addition, studies have shown that neutral vanadyl 
complexes are cell permeable95,105 whilst still retaining the key structural features to interact with 
the CBPs. The coordination geometry of vanadium complexes means that they can act as phosphate 
or transition state mimetics and there is, therefore, no need for incorporation of phosphate or 
sulfonate groups to target the CBP catalytic pocket53. Both vanadium(IV) and vanadium(V) 
complexes have been studied as CBP inhibitors; however, the vanadyl complexes have the 
advantage over vanadium(V), and some other metal compounds, of acting via a reversible 
mechanism rather than causing the oxidation of the CBP active site61,67,81. The high affinity, tuneable 
selectivity and cell permeability of the vanadyl complexes, as well as the wide range of available 
ligands (Section 1.5), makes these compounds a good starting point for the development of targeted 
CBP optical probes. 
The overall aim of this work is, therefore, the design and synthesis of fluorescently labelled vanadyl 
complexes, which are specific for CBPs and have sufficient affinity to bind strongly to the enzyme 
active site in order to act as a fluorescent probe. Previous work in the Vilar and Woscholski groups 
had identified a vanadyl-based inhibitor for PTEN, complex 1.2, utilising 3-hydroxypicolinic acid as 
the ligand.  PTEN is a tumour suppressor14 and has also been implicated in diabetes95 making this an 
interesting enzyme to study both as a druggable target and to probe its expression and localisation 
in cancerous cells. Complex 1.2 has been shown to inhibit PTEN selectively and in the low nanomolar 
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range95 and therefore has the potential to be developed into a PTEN targeted probe and reversible 
inhibitor. 
Once synthesised, the complexes can be tested against a selection of PTPs to determine if any 
selectivity is observed for PTEN or any other CBP, and whether this can be changed by variations in 
ligand structure. Based on the structures of classical PTPs and DSPs compared to PTEN15, larger 
vanadyl based inhibitors would be likely to show greater selectivity for PTEN as is has a more open 
active site pocket allowing access for bulkier structures. PTEN has a wider and deeper active site 
pocket than VHR (Figure 20) and the pocket is also twice as wide as that of PTP1B15. Docking studies 
carried out in the group (by Dr Agostino Cilibrizzi) suggest that a possible modified structure would 
still be able to interact with the active site pocket of PTEN whilst being too large to enter the far 
narrower pockets of other CBPs, such as VHR shown in Figure 20. 
 Figure 20: Docking study results. The docking structures show the binding of a model modified 
vanadyl complex to (a) PTEN (PDB code 1D5R) and (b) VHR (PDB code 1VHR). Structures were 
produced using Autodock software. Enzyme parameters used were from the original PDB file. Charges 
on the vanadyl complex were corrected to near 0. Docking studies were carried out by Dr Agostino 
Cilibrizzi.   
 
The specific objectives of this project are, therefore: 
1. Design and synthesis of novel, fluorescently labelled ligands starting from hydroxypicolinic 
acids. 
2. Formation of fluorescent vanadyl complexes and other metal complexes from the 
synthesised ligands. 
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3. Determination of the potency and selectivity of the complexes for a selection of CBPs using 
phosphatase assays. 
4. Investigation of complex stability under assay conditions using a selection of assay based 
and fluorescence techniques.  
5. Determination of cell permeability of the novel vanadyl complexes by fluorescence 
microscopy.  
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Chapter 2: Synthesis of modified picolinic acid ligands and their vanadyl 
complexes 
2.1 Synthesis of mono-picolinic ligands: 
2.1.1 Synthesis of biphenyl ligand as a model for picolinic acid modification 
From work carried out during the MRes component of this project, it was discovered that 
modification of 3-hydroxypicolinic acid at the 3-hydroxy position to incorporate a benzyl group did 
not remove the inhibitory properties of the complex against PTEN117. It was therefore decided to 
take the modification further and try to improve the inhibitory properties of the complex by 
introducing a fragment from a known organic PTP inhibitor. For this purpose, 4-phenylbenzyl alcohol 
was selected as this would add a biphenyl fragment which is present in organic inhibitors and has 
been previously used in PTP targeted probes115. This functionality also allowed for attachment to 3-
hydroxypicolinic acid using established chemistry. 
 
Scheme 1: Synthesis of a 4-phenylbenzyl alcohol derivative of 3-hydroxypicolinic acid.  
 
The first step was the protection of the 3-hydroxypicolinic acid at the acid position to give the methyl 
ester 2.1118 which was subsequently reacted with 4-phenylbenzyl alcohol 2.2 via a Mitsunobu 
reaction. Although the reaction was seen to run to completion by TLC, the product was only isolated 
in 39% yield by column chromatography. This is due to the large number of by-products formed in 
the Mitsunobu reaction making purification complicated. As this was a test reaction and enough 
product was isolated to continue with the synthesis, no optimisation was carried out. The carboxylic 
acid from product 2.3 was deprotected by stirring in NaOH and any minor impurities carried through 
from the previous reaction were removed in the workup by extracting with EtOAc before acidifying 
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with HCl to isolate the product. This method only gave product 2.4 in 37% yield which suggests that 
the workup could be optimised, however, the yield was sufficient to attempt vanadyl complex 
formation (see Section 2.4.1). The isolated product was characterised by 1H NMR spectroscopy 
which indicated that the desired compound had formed. A doublet of doublets at 8.3 ppm indicated 
the presence of the picolinic acid and showed the correct integral ratio to a singlet at 5.3 ppm 
corresponding to the CH2 of the 4-phenylbenzyl. The disappearance of a singlet at 4.0 ppm which 
was present in product 2.3 showed that the deprotection had been successful. 
2.1.2 Incorporation of a fluorophore 
As the methyl protection and Mitsunobu chemistry is well established, this was selected as the best 
route to incorporate new functionalities. In order for the vanadyl compounds to be utilised as 
chemical probes, a reporter group such as a fluorophore needed to be incorporated. The selected 
fluorophore would require certain properties in order to be suitable for use as part of the probe 
compound. These are: (1) to have appropriate reactivity and be stable to subsequent synthetic 
steps; (2) to be small enough to not affect the properties of the complex; (3) to not be quenched by 
the paramagnetic V4+ centre; (4) to be stable and retain fluorescence under biological conditions; 
and (5) to not affect assay readouts. For this purpose nitrobenzoxadiazole (NBD) and dansyl were 
selected as both are small molecule fluorophores with amine reactive chloro derivatives, are stable 
to range of synthetic conditions and have emission wavelengths outside the vanadyl absorption 
range (around 500-530 nm, solvent dependent)119–121. The synthesis of the two possible fluorescent 
ligands, including selection of the optimal synthetic pathway, is discussed below. 
A second consideration was the incorporation of a linker to separate the fluorophore from the 
vanadyl binding centre in order to reduce the interaction between the metal and the fluorophore. If 
the fluorophore is in close proximity to the vanadyl, the paramagnetic centre may cause quenching 
and therefore reduce the utility of the complex as a probe. Also, separating the modification from 
the vanadyl centre will reduce interference of the fluorophore in the phosphatase binding properties 
of the metal and reduce steric hindrance that may force the complex into an unfavourable 
conformation.  
Initially, triethylene glycol (compound 2.6) was selected as this would help with the aqueous 
solubility of the complex as well as having the hydroxyl functionality available for Mitsunobu 
reaction. This required mono-protection of the linker with THP to leave one alcohol free for 
Mitsunobu reaction. The protection was successful with the mono-protected product being isolated 
(compound 2.7). The reaction was carried out on large scale as the yield of the desired product is 
very low (2%) allowing a sufficient quantity to be isolated for the following steps. The Mitsunobu 
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reaction to form compound 2.8 did produce the desired product (LCMS: m/z = 370 a.m.u.) however 
the reaction did not run to completion (indicated by the presence of starting material (LCMS: m/z = 
154 a.m.u.)) and the product could not be isolated from the reaction mixture.  
 
Figure 21: Scheme showing the proposed method for attachment of a PEG linker to 3-OHpic (2.1). 
 
An alternative option was the use of a dual functionality linker such as propanolamine, as the amine 
could be selectively protected, the alcohol reacted with picolinic acid via a Mitsunobu reaction and 
then the amine protection removed to react with an appropriate, amine reactive fluorophore. For 
this purpose, propanolamine was selected as this could be purchased as the boc-protected material 
thereby removing the need for the protection step. 
 
Scheme 2: Two routes investigated for the attachment of NBD fluorophore to 3-OHpic via a 
propanolamine linker.  
50 
 
 
Two possible routes were envisaged to attach NBD to the modified picolinic acid as shown in Scheme 
2. The first step in each case was the attachment of the boc-propanolamine linker to the protected 
picolinic acid using the Mitsunobu reaction. Unlike the biphenyl complex, the ratio of 1:1.5 picolinic 
acid:alcohol gave poor yield, so a 1:2 ratio was used. This improved the yield and was therefore used 
for subsequent reactions. As with the previous Mitsunobu reactions, TLC indicated that the starting 
material had been consumed, but the product could not be identified by TLC. LCMS (m/z = 311 
a.m.u.) indicated that the product was present but ran close to the side product triphenylphosphine 
oxide (OPPh3, m/z = 279 a.m.u) thereby making its separation difficult by column chromatography. A 
slow gradient column was trialled but this took a long time and an excess of solvent after which the 
product was still not completely separated from OPPh3. In order to overcome the issues with a 
manual slow gradient column, the purification was attempted using automated column 
chromatography. Although this reduced the ratio of OPPh3 to product 2.10 there was still some of 
the by-product present which could not be removed. Precipitation with hexane reduced the ratio 
still more but 2.10 could not be isolated clean.  
Looking at the following steps in either route (2.10-2.14 or 2.10-2.12) it was considered that the 
triphenyphosphine oxide could be removed in the workup or purification of the deprotected acid or 
amine. The first route attempted was via intermediates 2.13 and 2.14 as this did not involve the 
handling of a zwitterionic species. TFA was used to remove the boc-group quantitatively to give a 
mix of the free amine 2.13 and OPPh3. The removal of the boc-group could be monitored by the 
disappearance of the resonance at 1.44 ppm (assigned to the methyl protons) in the 1H NMR 
spectrum. Using a silica plug, the impurity was eluted with EtOAc before adding TEA to elute the free 
amine and isolate the desired compound giving the overall yield for these two steps as 16%. The 
product was taken forward for reaction with NBD-Cl to form the fluorescent compound 2.14 but this 
reaction gave many side products. This meant that only a small amount of the desired product could 
be formed which then decomposed in the final methyl deprotection step (2.14-2.15). Attachment of 
NBD to give 2.14 was indicated by LCMS (m/z = 374 a.m.u.). However the acid deprotection proved 
challenging and the alternative route via 2.11 and 2.12 was therefore attempted (see Scheme 2). 
The first step was the methyl removal to give the free carboxylic acid. Once the reaction was 
complete, the OPPh3 could be removed in the workup step by first washing with EtOAc which took 
up the impurity and left the product in the water layer. Acidification and further extraction gave the 
desired product, in the absence of by-products, in 89% yield. This was shown by the disappearance 
of the OPPh3 peaks in the aromatic region of the 1H NMR spectrum and the loss of the signal at 4.01 
ppm assigned to the methyl group of the ester. This was followed by boc removal to give compound 
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2.12 which was confirmed by NMR and the disappearance of the signal at 1.36 ppm corresponding 
to the methyl groups of boc. A singlet at 76.9 ppm in the 19F NMR spectrum indicated that the 
product was present as the TFA salt. In order to remove the TFA from the previous step prior to the 
NBD-coupling reaction taking place, the reaction was run in the presence of excess TEA. The reaction 
was monitored by NBD consumption, as neither the starting amine nor the product could be moved 
from the baseline on TLC. As with the previous NBD coupling, by-product formation occurred 
including a brown residue. Careful workup and filtration removed the brown residue and allowed 
characterisation by LCMS. This indicated that compound 2.15 had formed and column 
chromatography allowed the fluorescent ligand to be isolated clean by LCMS (m/z = 360) but the 
mass of product isolated was not sufficient to attempt vanadyl complex formation. 
Having tried two different routes and a range of conditions to attach the NBD group to the ligand, it 
became apparent that, although the incorporation of the fluorophore was possible, the large 
number of side products formed and low yields posed a problem. The presence of the fluorophore 
also affected work-up and purification steps, leading to lower yields. To make the modified ligand in 
sufficient yield and purity to be reacted with the vanadyl would be synthetically challenging and it 
was decided that a more synthetically tractable fluorophore should be found.  
2.1.2.2 Incorporation of Dansyl 
Scheme 3: Two possible routes for attachment of a dansyl fluorophore to 3-OHpic via a 
propanolamine linker. 
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For the incorporation of the dansyl it was decided to first to try the route with the carboxylic acid 
deprotected at the second step via intermediate 2.11, as this had been successful for the NBD 
reactions. The same conditions were used to synthesise compound 2.12 as for NBD attachment, but 
the conditions were changed for incorporation of the fluorophore. The attachment of dansyl via this 
route, however, also gave a number of side products and the desired product could not be isolated 
in sufficient purity. 
It was therefore decided to try the route via the protected acid. Formation of 2.10 and 2.13 were 
carried out as for NBD attachment, giving the free amine in the presence of TEA:TFA salt identified 
by the disappearance of the signal at around 1.5 ppm in the 1H NMR spectrum as well as a shifted 
triplet and quartet corresponding to a TEA salt (1.25 and 2.90 ppm). Attachment of the dansyl group 
was carried out based on literature procedures120,122,123, using anhydrous acetonitrile and TEA to limit 
the hydrolysis of the sulfonyl chloride to sulfonic acid. As the dansyl chloride is non-fluorescent, the 
reaction was monitored by the appearance of a fluorescent spot and the disappearance of the 
starting material. The reaction ran well with minimal side reaction and was isolated pure (single spot 
on TLC) by column chromatography and characterised by 1H NMR spectroscopy. Incorporation of the 
dansyl could be confirmed by the presence of additional aromatic proton signals and a singlet at 2.8 
ppm (integrating to six protons) associated with the N-methyl groups. In order to deprotect the 
carboxylic acid the established conditions using 6M NaOH were used, however, this gave a relatively 
low yield which was thought to be due to the strongly basic conditions. Milder conditions were 
therefore trialled, using LiOH and leaving the reaction for longer124. At first the yield was not 
improved, but this was likely due to the workup and not breakdown of the product in the reaction. 
Extraction with EtOAc did not isolate all of the product from the aqueous layer and this could be 
clearly seen by TLC. Further extraction of the aqueous layer with DCM collected more of the desired 
product (2.17) to raise the yield from 20-40% to 80-85%. In each case the product was first identified 
by the disappearance of a methyl signal at 3.75 ppm in the 1H NMR spectrum, with the identity 
confirmed by LCMS (m/z = 430 a.m.u.). Sufficient quantity of ligand 2.17 was isolated to take 
forward for vanadyl complex formation.  
2.1.2.3 Incorporation of dansyl on 5-hydroxypicolinic acid 
In order to determine whether the position of the hydroxyl group affects the properties of the ligand 
and subsequent vanadyl complex the above synthesis was repeated starting with 5-hydroxypicolinic 
acid. 
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Scheme 4: Synthesis of dansyl labelled 5-hydroxypicolinic acid. 
 
As can be seen from Scheme 3 and Scheme 4, the conditions used for the synthesis of the 
fluorescently labelled 5-hydroxypicolinic acid ligand are the same as for 3-hydroxypicolinic acid, and 
very similar reactivities and physical properties were observed for the intermediates. The Mitsunobu 
reaction was purified by manual column chromatography as OPPh3 and the product 2.19 showed 
better separation on TLC than the equivalent 3-hydroxy isomer (2.10); therefore, a faster gradient 
could be used to remove some of the by-product. Success of the reaction and the identity of the 
by=product were confirmed by mass spectrometry (OPPh3 = 279, m/z = 311 a.m.u.). The residual 
OPPh3 was removed after the boc deprotection, using the plug column conditions optimised for 
2.13, to give 2.20 as confirmed by 1H NMR spectroscopy and mass spectrometry, which no longer 
showed signals for the OPPh3. The addition of the dansyl and removal of the methyl protection ran 
as expected from the 3-hydroxypicolinic acid work and the ligand 2.22 was isolated in good yield 
(81%). The compound was characterised by 1H and 13C NMR spectroscopy, which showed the 
presence of the N-methyl signal at 2.79 ppm and 38.9 ppm respectively and loss of the O-methyl 
signal. Identity of the ligand was further confirmed by elemental analysis (see experimental, Section 
6.2) and mass spectrometry (m/z = 430 a.m.u.). 
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2.2 Synthesis of mixed-ligand complexes 
In order to attach two different functionalities to the complex, or block one side of the complex to 
only incorporate one fluorophore and reduce the size of the final compound, a method for the 
formation of an asymmetric or mixed-ligand complex needs to be developed. As part of work carried 
out in the MRes year, this idea was developed to try and synthesise one of the complexes shown in 
Figure 22. 
 
 
Figure 22: Structures of asymmetric vanadyl complexes using picolinic acid derivatives and salicylic 
acid as ligands. 
 
Using different orders of addition of reagents, varying the pH of the reaction, and changing reaction 
solvent (ethanol, methanol or water) and vanadyl starting material (vanadyl sulfate of vanadium 
acetylacetanoate) gave some of the desired mixed-ligand products but, not surprisingly, as a mixture 
of complexes with the symmetrical products as shown by mass spectrometry. An example mass 
spectrum with identification of products formed is shown in Figure 23. 
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Figure 23: Example mass spectrum for mixed-ligand complex formation. Mass spectrum showing the 
products formed in the reaction to give complex 2.23. The spectrum also shows the presence of 
ligands at m/z = 132 and 230. 
 
It was clear that this approach would not yield pure samples of the desired compounds, so a new 
route was designed using a Schiff base as one side of the asymmetric complex. This route was 
selected as there was literature precedence for the synthesis of mixed-ligand complexes where the 
Schiff base provided one of the ligands. There are also reports of the synthesis of these complexes 
and their subsequent use as PTP inhibitors and therefore this approach could potentially be used 
without impacting on the inhibition properties of the compounds75,84,86,89,125. The complexes are also 
reported to have been obtained pure whereas for the formation of asymmetric complexes using two 
bidentate ligands this is not reported. The proposed structure of the complex (2.25) is shown in 
Figure 24. 
m/z = 344 
m/z = 434 
m/z = 524 
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Figure 24: Products of Schiff-base mixed-ligand reaction. Structure of an asymmetric vanadyl complex 
using a Schiff base and picolinic acid (2.25) and the product formed on reacting vanadyl with the Schiff 
base ligand (2.26). 
 
The Schiff base was synthesised according to a literature procedure125 in good yield and purity as 
confirmed by 1H NMR spectroscopy (in DMSO-d6) with key peaks seen at 13.79, 9.74 and 8.96 ppm 
for the two OH groups and NH respectively. The ligand was then reacted with vanadyl 
acetylacetanoate in the presence of picolinic acid or 3-hydroxypicolinic acid. Precipitation of reaction 
products was induced by pouring the cooled reaction into an excess of diethyl ether. Analysis of the 
precipitate by mass spectrometry showed that, as for the previous mixed ligand reactions, a mixture 
of the desired product (2.25) and the symmetrical picolinic acid complex (1.1) were formed. Inducing 
further precipitation of the reaction mixture yielded a dark solid which was identified as compound 
2.26 by mass spectrometry (m/z = 474 a.m.u.) and IR spectroscopy, which did not show the 
distinctive V=O peak at 930-960 cm-1. The identity of the complex was further confirmed by 
elemental analysis. 
From the preliminary work on mixed-ligand complexes it was determined that the formation of 
mixed-ligand vanadyl complexes would be synthetically challenging due to the difficulties in 
producing only the desired product. The vanadyl complexes formed are also difficult to separate; 
therefore, formation and isolation of a pure mixed-ligand product is difficult to achieve. An 
alternative method for incorporation of one functionalised picolinic acid or multiple functional 
groups was required. 
 
2.3 Synthesis of bridged picolinic acid ligands 
2.3.1 Model bridged ligands 
One method of removing the problem of asymmetric complex formation is to bridge two picolinic 
acids together using a linker with a reactive group to allow incorporation of different functionalities. 
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This would provide a ligand that kept the two picolinic acid core whilst allowing for the incorporation 
of one or more functional groups required for the probe without the need for asymmetric complex 
formation. Figure 25 shows the proposed structures for the bridged and functionalised 
intermediates. 
 
Figure 25: Proposed structure of a di-picolinic acid ligand with an amine handle for functionalisation.  
 
Before developing the functionalised ligands it was decided that optimal conditions for picolinic acid 
bridging should be established using simple diols. For the synthesis of the linked picolinic acid ligand, 
5-hydroxypicolinic acid was used as this provided a better conformation than the 3-isomer because 
the position of the carboxylic acid para to the hydroxyl provides a more accessible site for 
tetradentate vanadyl coordination without steric interactions with the linker or functional group.  An 
example is shown in the scheme below.  
 
Scheme 5: Synthesis of a pentanediol-bridged picolinic acid ligand. 
 
The first conditions to be determined were for the Mitsunobu reaction in order to favour the di-
substitution of the diol whilst still adding sufficient linker that the yield is not affected. For this, 
propanediol and pentanediol were used as linkers. The Mitsunobu reaction of propanediol with 
picolinic acid using a 1:1 ratio of acid to alcohol gave the majority of the di-substituted product, but 
this was probably too short a linker to use for formation of a vanadyl complex. For the reaction with 
pentanediol, the disubstitued product 2.27 was identified as the minor product by LCMS. The 
conditions were changed to a 1:0.5 ratio of picolinic acid to alcohol and this yielded only the 
disubstituted product 2.27, indicated by LCMS of the crude product (m/z = 375 a.m.u.). Product 
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identity was confirmed by 1H NMR spectroscopy, after column chromatography, by the presence of 
aliphatic signals at 4.12, 1.93 and 1.73 ppm which showed the correct integral ratios to the picolinic 
acid signals at 8.39 and 8.11 ppm. These conditions were taken forward for the synthesis of the 
amine-containing bridged compounds. The established conditions (6M NaOH, 3 hours, rt) for 
removal of the methyl protection on picolinic acid were used on the pentanediol product. The 
reaction ran as expected but the product 2.28 precipitated out in the workup and was collected by 
filtration, indicating the lower solubility of the bridged product relative to a single modified picolinic 
acid. The product could be identified by 1H NMR spectroscopy by the presence of the signals 
described above and the loss of the methyl signal at 3.98 ppm. 
 
2.3.2 Synthesis of functionalised bridged ligands 
In order to incorporate the desired functionalities, the first option was to bridge two different or 
differently functionalised groups together, but this could potentially have given the same issues of 
multiple products and low yields as seen for the asymmetric vanadyl complexes (Section 2.2). The 
alternative was to have a synthetic handle within the linker for attachment of the required 
functional groups, such as an amine, for which reaction conditions with the dansyl fluorophore were 
already established. The synthetic route is shown in Scheme 6. 
 
Scheme 6: Synthesis of a bridged picolinic acid ligand with incorporation of a dansyl group.  
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2.3.2.1 Diethanolamine bridge and dansyl attachment 
In order to form the functionalised bridged ligand a linker of suitable length containing a 
synthetically available group would need to be used. Diethanolamine was selected as the amine 
group provided a suitable synthetic handle with literature precedence for boc-protection126 and 
reaction of dansyl chloride with similar secondary amines122,123. 
Boc-protection of the amine proceeded as expected, and a good yield was obtained as reported in 
the literature126. For the Mitsunobu reaction, the conditions used were those determined from the 
pentanediol linker. Although this reaction gave only the desired disubstituted product, the reaction 
did not go to completion, with some starting material remaining as evidenced by TLC after 72 hours. 
The reaction also had the same problem as the boc-propanolamine attachment (Scheme 4) where 
the product could not be easily separated from OPPh3 using column chromatography and could only 
be isolated with the side-product. The column conditions were optimised to minimise the amount of 
impurities eluting with the desired product 2.31a.  The best purity obtained was around 1:0.25 
product:OPPh3 as evidenced by 1H NMR spectroscopy comparing the picolinic acid signal at 8.39 ppm 
to the aromatic multiplet at 7.5-7.75 ppm corresponding to peaks for OPPh3. 
On first running the boc deprotection, the yield was lower than expected when compared to the 
corresponding reaction with the terminal amine and TLC analysis revealed that the reaction did not 
run to completion in the time given. Increasing the reaction time from 30 min to 2 hours led to all of 
the starting material being consumed and the yield was improved. The silica plug (as for compound 
2.13) was employed to remove the excess OPPh3 at this step and 2.32a was isolated with some 
TEA:TFA salt impurity. The identity of the product and the removal of OPPh3 were confirmed by 
LCMS, which showed a clear signal corresponding to the product at m/z = 377 a.m.u. but no OPPh3 
signal at m/z = 279 a.m.u.. Attachment of a dansyl group to a secondary amine has been reported in 
the literature122 and is synthetically viable; therefore, the previously identified conditions optimised 
for the primary amine (Section 2.1.2.3) were replicated, except for a slightly larger excess of 
trimethylamine. However, side products formed in the reaction which ran close to the product on 
TLC. By optimisation of column chromatography conditions, 2.33a could be collected free of side 
products with yields of 50-75%. The identity of the product was shown by mass spectrometry (m/z = 
609 a.m.u.) and was confirmed by the presence of signals corresponding to the linker (e.g. 4.21 
ppm), picolinic acid (7.2 ppm) and the dansyl group (e.g. 8.5 ppm) all with correct integral ratios for 
the desired product. The final step was the methyl removal to give the free carboxylic acids in 2.34a. 
As expected from the trial reactions, the compound had low solubility and precipitated out during 
the reaction. Doubling the amount of solvent allowed the reaction to be stirred for the required 
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time. During the workup, sonication was used to help take up the product into EtOAc as after 
acidification some of the precipitated product could not be re-dissolved. After workup the product 
was isolated and its 1H NMR spectrum (no methyl peak at 3.91 ppm) and MS (m/z = 581 a.m.u.) 
showed the desired product had formed. 
 
2.3.2.2 Dipropanolamine bridge and dansyl attachment 
Dipropanolamine is not commercially available and so was synthesised according to a literature 
procedure127. The protocol for separating the desired product from an excess of the starting amine 
was distillation however, when this method was attempted only the 3-chloropropanol starting 
material was collected and the desired product 2.29b was not isolated. It was therefore decided to 
take the mixture of amines through to the boc-protection step where the products could be 
separated by column chromatography. 
Scheme 7: Synthesis of a di-propanolamine linker for formation of a bridged picolininc acid ligand. 
 
As boc-propanolamine was available as a reference, the purification at the amine protection step 
was relatively simple and the desired product 2.30b was isolated. The product was characterised by 
1H and 13C NMR spectroscopy with the key signals being a clear triplet at 3.15 ppm corresponding to 
the CH2 adjacent to the central nitrogen and the boc carbon peak at 155 ppm. The following steps 
proceeded as previously described for the diethanolmine bridged ligand (Section 2.3.2.1) and the 
final compound 2.34b was isolated in good yield. The identity of the product was confirmed by 1H 
NMR spectroscopy, with signals at 8-8.5 ppm for the dansyl and picolinic acid showing the correct 
integral ratios to signals for the linker at 3.5-4 ppm, and MS (m/z = 609 a.m.u.). 
In summary, two new bridged ligands have been synthesised and functionalised with a dansyl 
fluorophore (2.34a and b). Although these compounds can be synthesised in sufficient yield and 
purity to form the vanadyl complexes the solubility is poor, especially in water. Therefore, it would 
be of interest to synthesise a modified version of the compounds with a group in place of the dansyl 
to increase solubility. This would make it easier to study the physicochemical properties of the 
complexes such as stability, as well as providing a wider range of solvents to use for attempting 
crystal growth for X-ray crystallographic studies. 
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2.3.2.3 Incorporation of solubilising functionalities 
The main requirements of the new functionality are that there is a derivative that will react with the 
secondary amine on the linker and that it increases solubility of the compound. For this reason 1-(2-
chloroethyl)piperidine was selected as this could be attached using standard alkylation conditions 
onto compound 2.32 to give compound 2.35. However, after trying a range of solvents, bases and 
temperatures the reaction never ran to completion and a number of side products formed meaning 
the isolated yield was <20%. One alternative was to attach the piperidine to the diethanolamine 
linker (2.36) before reaction with the picolinic acid. This reaction ran well and once the workup had 
been optimised the linker could be isolated in good yield. However, in the Mitsunobu reaction no 
product (2.35) was formed so the piperidyl attachment was left at this stage. 
 
 
Figure 26: Desired piperdyl functionalised compound 2.35 and the intermediate linker 2.36. 
 
Another functional group that could impart more solubility than dansyl was tosyl, due to the 
reduced size of the aromatic ring system. It was expected that the sufonyl chloride would have 
similar reactivity to the dansyl analogue towards the secondary amine and could therefore be more 
easily incorporated than 1-(2-chloroethyl)piperidine, whilst imparting some solubility as an aromatic 
sulfonyl group. 
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Scheme 8: Synthesis of a tosylated derivative of the bridged picolinic acid ligand.  
 
A small amount of the free amine with the longer linker (2.32b) was used to run a trial reaction for 
attachment of the tosyl. The same conditions were used as for attachment of the dansyl group 
(Section 2.3.2) and the reaction ran well to give 2.37b in 63% yield after column chromatography as 
confirmed by 1H NMR spectroscopy with signals corresponding to the tosyl group at 7.68 and 2.38 
ppm. This was taken forward for removal of the methyl protecting groups, at which point it 
appeared the solubility had been improved as there was no precipitation during the reaction. The 
free ligand 2.38b was collected after workup in 42% yield and the identity of the product was 
confirmed by 1H NMR spectroscopy.  
As only a small amount of this compound was isolated it was decided to try this synthesis with the 
shorter linked ligand as the starting materials for this synthesis were more readily available and the 
route was, therefore, easier to scale up. Once the free amine (2.32a) had been formed this was 
reacted with tosyl under the established conditions however in this case a significant side product 
formed. The desired product and the side product ran with similar Rf values on TLC, and initial 
attempts at purification by column chromatography (methanol in DCM) gave almost entirely mixed 
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fractions. As the side-product could not be identified, it was not known whether this could be 
removed in the workup after methyl deprotection, so further purification at this stage was required. 
Suitable chromatography conditions were found and the desired product was isolated as confirmed 
by the presence of tosyl signals in 1H NMR spectrum, but in poor yield. LiOH was used instead of 
NaOH for the removal of the methyl protecting groups to try and improve the yield from that 
observed for 2.38b, and this was successful with 59% isolated yield of 2.38a. However, in this case, 
the ligand started to precipitate out of the reaction and could not subsequently be dissolved in 
organic solvents after workup, meaning the improved solubility seen for 2.38b had been lost. Clear 
signals for picolinic acid (8.18 ppm), tosyl (7.77 ppm) and the linker (3.78 ppm) with correct integral 
ratios in the 1H NMR spectrum, and mass spectrometry (m/z = 502 a.m.u.) confirmed the desired 
product had been isolated. 
In summary, although initially it seemed that the tosyl group was both synthetically available and 
gave increased solubility, this was only seen for the dipropanolamine bridged ligand 2.38b. 
Therefore, it would seem that functionalisation of the longer linker provides the best route to 
ligands and complexes with improved solubility. 
 
2.4 Synthesis of vanadyl complexes 
2.4.1 Synthesis of non-bridged vanadyl complexes 
In order to test whether the new modified compounds still inhibited the CBPs (see Chapter 1.5 and 
1.8), and how the fluorophore properties changed on proximity to vanadium, the symmetric 
complexes of the new ligands were synthesised. Although the ligands were designed as modified 
versions of 3-hydroxypicolinic acid, the coordination mode available for vanadyl after modification is 
more similar to picolinic acid (2N and 2O) as the hydroxyl group is no longer available for 
coordination. The conditions for the formation of the picolinic acid complex (Figure 27a(i)) were, 
therefore, initially used72. 
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Figure 27: Vanadyl complex formation. (a) General scheme for the formation of vanadyl complexes 
with modified picolinic acid ligands. (b) Structures of two vanadyl complexes formed using 
synthesised ligands. 
 
For the synthesis of the biphenyl complex 2.39, the ligand was first stirred in the presence of base to 
ensure that all was dissolved before addition of the vanadyl sulfate as a solid; the reaction was left 
stirring overnight. This was a change from the picolinic acid conditions in which the ligand and 
vanadyl were mixed and on addition of base the complex immediately precipitated out. Initial 
analysis on the collected green solid by mass spectrometry (m/z = 676 a.m.u.) and IR spectroscopy 
(V=O = 966 cm-1) indicated that the desired complex had formed, and this was confirmed by 
elemental analysis (Table 3). Subsequent UV-visible spectroscopic analysis showed similar spectral 
properties to the parent complex50 (1.2) with a strong absorbance peak (ε = 1.12×104 M-1cm-1) at 
around 300 nm which can be assigned to π-π* transitions (as reported for 3-hydroxypicolinic acid128) 
and a weaker peak (ε = 1.90×101 M-1cm-1) at 750 nm which can be assigned to the d-d transitions of 
the VO2+ core (Figure 28a). The d-d transitions occur due to the crystal field splitting of the d-orbitals 
on the metal when a complex is formed. If light of the correct wavelength is absorbed, the d-
electron can be promoted to a higher energy d-orbital giving rise to the lower energy absorbance 
peak. 
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As the NBD-functionalised ligand had not been synthesised in sufficient yield to attempt complex 
formation, only the dansyl ligands could be used for the synthesis of the corresponding complexes. 
In order to optimise the formation of complex 2.40 two different sets of conditions were trialled: the 
first used the conditions of picolinic acid complex formation, the second used the conditions for the 
3-hydroxy isomer. First a suspension of ligand and vanadyl was formed followed by dropwise 
addition of 2M NaOH. The solid that was formed appeared to contain the desired complex by mass 
spectrometry and IR spectroscopy but the elemental analysis was very poor and suggested the 
presence of some unreacted vanadyl sulfate. A second complex formation was attempted, this time 
using a set molar amount of 10% NaHCO3 to help dissolve the ligand and vanadyl sulfate. Mass 
spectrometry (m/z = 924 a.m.u.) again indicated the presence of the desired complex but, although 
the elemental analysis was improved from the previous attempt, it still indicated the presence of a 
large amount of water (see experimental, Section 6.3) also suggested by the presence of a broad 
peak at 3,372 cm-1 in the IR spectrum. 
 
 
Scheme 9: Formation of a vanadyl complex from a danasyl modified 5-hydroxypicolinic acid ligand. 
 
Since using NaHCO3 as a base gave better complex purity for complex 2.40 these conditions were 
used for the formation of complex 2.41. For this reaction, a solution of the ligand with base was first 
formed and then the vanadyl added at which point the complex started to precipitate as a green 
powder. As before, mass spectrometry (m/z = 924 a.m.u.) and IR (V=O = 964 cm-1) indicated that the 
desired complex was present; elemental analysis confirmed the formation of 2.41. UV-visible 
spectroscopic analysis showed a shift in the main absorbance peak from 300 nm to 340 nm 
compared to complex 2.39 (Figure 28) and this is likely due to the presence of the dansyl group 
which has a strong absorbance around 340 nm. 
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Figure 28: UV-visible spectra of vanadyl complexes. (a) 60 µM complex 2.39, insert run at 300 µM; (b) 
60 µM complex 2.41 taken in DMSO. 
 
In each of the above reactions a relatively low yield was obtained and this could be due either to 
some of the complex not coming out of solution, or slow reaction of the metal with the ligand. 
However, enough of each complex was obtained to carry out biological studies (see Chapter 3). 
 
2.4.2 Synthesis of bridged vanadyl complexes 
 
Scheme 10: Synthesis of dansyl-labelled vanadyl complexes using linkjed picolinic acid ligands.  
 
In order to carry out the complex formation, conditions similar to those for mono-picolinic ligands 
were used. A lower concentration (0.03 M) of reagents was used to limit potential polymerisation 
products, and the reagents were dissolved before mixing to give better rate of reaction. The 
complexation was first carried out on the 5-atom bridged ligand 2.34a. Although the low 
concentration of reagents meant that precipitation of the complex did not occur during the reaction, 
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allowing the mixture to stand for 5 days gave some green precipitate (although on repeating the 
reaction some precipitation was seen immediately after addition of vanadyl, possibly due to a 
change in the scale of the reaction as this has been seen to affect precipitation in earlier reactions). 
UV-visible spectroscopic analysis showed the expected peaks with a strong absorbance band (ε = 
1.12×104 M-1cm-1) at 340 nm and two weaker d-d bands (ε = 1.53×102 M-1cm-1, 1.44×102 M-1cm-1) at 560 
and 670 nm respectively. IR spectroscopy (V=O = 965 cm-1), mass spectrometry (m/z = 668 a.m.u. for 
mass + Na) and elemental analysis all indicated that the desired complex had formed, (Table 3) 
although it should be considered that the analysis shown could also be associated with the 
formation of a polymeric complex. The conditions described above were repeated for the formation 
of complex 2.43b. This behaved similarly to the previous reaction, with a vanadium complex 
precipitating out of solution after two days (see Table 3). One issue discovered for these complexes 
compared to the non-linked forms was that they had very poor solubility and were found to only 
dissolve in hot DMSO or hot DMF. This could be explained by some or all of the complex present 
being in the polymerised form, however poor solubility of the ligand could also be a factor.  
Table 3: Analytical data for vanadyl and platinum complexes. IR data was recorded using solid samples 
while UV-vis data was collected using solutions in DMSO, unless otherwise indicated. 
Compound V=O IR 
peak/cm-1 
Mass 
Spectrometry 
(a.m.u.) 
Elemental analysis UV-vis: λmax/nm 
(ε/M-1cm-1) 
2.39 966 676 [M+H]+ C38H28O7N2V·2H2O: 
Calc.: C 64.14, H 4.50, N 3.93  
Found: C 63.91, H 4.52, N 4.28. 
300 (1.12×104)  
2.41 964 924 [M+H]+ C42H44N6O11S2Vˑ4H2O:  
Calc.: C 50.65, H 5.26, N 8.44. 
Found: C 50.73, H 4.89, N 8.28 
340 (7.42×103) 
2.43a 965 668 [M+Na]+ C28H26O9N4SV·3H2O:  
Calc.: C 48.07, H 4.61, N 8.01 
Found: C 48.07, H 4.39, N 7.72 
340 (5.96×103) 
2.43b 961 696 [M+Na]+ C30H30O9N4SV·3.5H2O:  
Calc.: C 48.92, H 5.06, N 7.61 
Found: C 48.62, H 4.71, N 7.39 
262 (7.37×104)* 
2.44 n/a 774 [M+Na]+ C28H26O9N4SPt·3.5H2O: 
Calc.: C 40.19, H 3.98, N 6.70; 
Found: C 39.80, H 3.72, N 6.65. 
320 (3.16×104) 
*sample run in MeOH/DMF 
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2.4.3 Further characterisation of fluorescent complexes 
Two questions that needed to be answered were: whether the fluorescence properties of the dansyl 
ligand were affected once the vanadyl complex was formed; and if the fluorescence was affected on 
dissolution in solvents required for biological testing. For the first point, the fluorescence intensity of 
the ligands and the corresponding complexes at 30 µM (in DMSO) were compared. As shown below 
(Figure 29), for both bridged and open complexes the fluorescence intensity of the dansyl group is 
reduced in the complex compared to the ligand, however, for the open complex 2.41 this difference 
is less pronounced which could be due to the presence of two fluorescent ligands in the complex. 
This reduction in fluorescence is likely due to an interaction between the fluorophore and the metal 
centre leading to quenching due to an energy or electron transfer effect129,130. To assess the 
potential effect of solvents on the fluorophore emission, the complexes were diluted in buffer to 30 
µM and fluorescence recorded using a 96-well plate format. Under these conditions the 
fluorescence output of both the ligand and the complex, and the difference in intensity between 
them, were reduced (Figure 30) suggesting that the dansyl fluorophore is significantly affected by 
the solvent, an effect that has been previously reported131. 
  
Figure 29: Fluorescence spectra of vanadyl complexes. Spectra are comparing fluorescence intensity 
of a 30 µM solution in DMSO of (a) ligand 2.22 and complex 2.41 and (b) ligand 2.34b and complex 
2.43b. 
0
50
100
150
200
250
300
350
400
450
400 500 600
Fl
u
o
re
sc
e
n
ce
 in
te
n
si
ty
/a
.u
.
Wavelength/nm
a
2.22 2.41
0
50
100
150
200
250
300
350
400
450
400 500 600
Fl
u
o
re
sc
e
n
ce
 In
te
n
si
ty
/a
.u
.
Wavelength/nm
b
2.34b 2.43b
69 
 
 
Figure 30: Fluorescence spectrum of a vanadyl complex and ligand. The spectrum is comparing 
fluorescence intensity of 30 µM solutions of ligand 2.34b and complex 2.43b in aqueous buffer (100 
mM Tris, 1 mM DTT). 
 
2.5 Synthesis of alternative metal complexes 
In order to investigate the necessity of the vanadyl centre for inhibition of PTPs it was decided to 
look at the effects of using a different metal. For this purpose, platinum(II) was chosen as it should 
still form a complex with the picolinic acid ligand whilst the nature of the metal would mean the 
structure of the complex would be different to that seen for vanadyl. Platinum(II) is also diamagnetic 
and so would allow NMR spectroscopy to be used for characterisation. 
 
Scheme 11: Synthesis of dansyl-labelled platinum II complexes using linked picolinic acid ligands. 
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The route to form the platinum complex was modified from two literature procedures132,133. The 
ligand was first solubilised in water with 2M NaOH before slow addition of a solution of the metal 
salt. The reaction was then heated to 40 ᵒC for three hours and monitored for colour change or 
formation of a precipitate. When neither was observed the temperature of the reaction was 
increased to 60 ᵒC and after two hours a yellow precipitate was seen to have formed. Analysis by 
mass spectrometry (m/z = 774 a.m.u.) indicated the desired complex was present with the spectrum 
having an isotopic pattern consistent with that of a platinum complex; unfortunately, 
characterisation of the complex by 1H NMR spectroscopy was inconclusive due to the insolubility of 
the complex leading to solutions of too low concentration to give a clear spectrum. Elemental 
analysis, however, was consistent with formation of the complex and therefore the platinum 
complex could be taken forward for biological characterisation. The main issue with the complex 
was its very poor solubility, however, dissolution was possible in hot DMSO up to a concentration of 
500 µM which is sufficient for the required enzymatic testing. 
2.6 Synthesis Summary 
A selection of novel picolinic acid based ligands have been synthesised and the corresponding 
vanadyl complexes formed. Although it was not possible to synthesise asymmetric complexes (i.e. 
mixed-ligand complexes) an alternative strategy was designed to incorporate the desired 
functionalities without having too much effect on the size of the vanadium-picolinic core. This 
involved the incorporation of a bridging linker with a synthetically versatile group for the 
incorporation of desired fluorescent functionalities. One drawback of this method is the potential for 
polymeric complexes to form due to the availability of two distinct vanadyl coordinating sites on the 
ligand, which would affect the species present in biochemical studies. Non-bridged picolinic acid 
based complexes were also synthesised, incorporating both fluorescent and non-fluorescent 
functionalities. In addition, a platinum(II) complex of ligand 2.34a has been synthesised to 
investigate the effects of varying the metal centre on the properties of the complex. All metal 
complexes have been analysed by various techniques (Table 3) and have been isolated in sufficient 
yield and purity to take forward for biological characterisation. 
71 
 
Chapter 3: Study of inhibitory properties of complexes against a 
selection of CBPs. 
In order to test the utility of the vanadyl complexes as potential CBP probes, the affinity of these 
complexes for CBPs and the selectivity of the complexes for certain enzymes needs to be tested. This 
was carried out through investigating the potency of the vanadyl complexes against a selection of 
CBPs, allowing for the affinity for the CBPs as a whole and any specificity for a certain enzyme or 
class of enzymes to be determined. As the structure of the new complexes is based on a known 
PTEN inhibitor, all of the compounds were tested against PTEN to determine the effects of structural 
changes on the affinity of the complexes for the enzyme. PTEN is also an enzyme of interest as it has 
been implicated as a tumour suppressor and has a role in the insulin pathway14,95. Muscle-specific 
PTEN deletion and PTEN inhibition by reactive oxygen species led to an increase in insulin 
sensitivity134,135, however, inhibition or removal of PTEN can also lead to cell proliferation and loss of 
response to apoptotic signals which is a factor in tumour formation14,136. PTEN is therefore of 
interest to study from both an inhibitory and investigative perspective. In order to determine the 
selectivity of the probes for PTEN and the potency against different CBPs, a small selection of 
enzymes was required. For this, four enzymes were chosen: PTP1B (protein-tyrosine phosphatase 
1B), SHP2 (src homology region 2 domain-containing phosphatase-2), LMW-PTP (low molecular 
weight protein tyrosine phosphatase) and VHR (dual specificity protein phosphatase 3). These 
enzymes were selected as they covered different types of CBPs (classical, low molecular weight and 
dual specificity) as well as having interesting therapeutic applications (see Section 1.1). 
PTP1B is a classical PTP that has gained interest due to the role it plays in the insulin response. It has 
been identified as having a role in insulin-dependent signalling pathways and PTP1B has therefore 
been implicated in type II diabetes and obesity24. For this reason, considerable effort has been put 
into the development of targeted inhibitors for this enzyme137,138. PTP1B is a key regulator of the 
insulin receptor, acting to dephosphorylate a tyrosine residue that is required for downstream 
signalling, as well as seeming to act at points further along the signalling pathway137. In vivo and in 
vitro data from various sources have shown the significance of PTP1B in insulin signalling138. Metal 
complexes have been shown to inhibit PTP1B and have antidiabetic activity which makes this a 
suitable enzyme for studying the new vanadium-based inhibitors67. 
SHP2 and LMW-PTP are also classical PTPs and have been implicated in cancer progression. SHP2 has 
been reported as one of the common causes of juvenile myelomonocytic leukaemia, with gain of 
function mutations being implicated in the disease139. It has also been shown that mutations in this 
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enzyme occur in several human cancers such as lung and colon cancer, as well as adult leukaemia20. 
Because of this, SHP2 has been investigated as a possible drug target and work has been carried out 
to find enzyme targeted inhibitors60. LMW-PTP has also been shown to be a positive regulator of 
tumour progression and high levels of LMW-PTP have been detected in certain human cancers. The 
oncogenic effects of LMW-PTP have been linked to its effects on the function of a receptor tyrosine 
kinase ephrin A212,140. LMW-PTP overexpression has also been noted in certain tumour types, with 
the highest expression being in neuroblastoma140. Therefore, as with SHP2, it is it is relevant to study 
this enzyme in the context of inhibition for treatment of cancers85. 
VHR is a dual specificity phosphatase and has many roles in cell signalling such as angiogenesis and 
cell cycle regulation10. VHR is also thought to play a regulatory role in various cancers and is found to 
be upregulated in cancer cells as compared to normal healthy cells, for example in cervical cancer141. 
In prostate cancer cells, VHR is upregulated and has been shown to play a role in preventing 
apoptosis through the JNK-pathway142. It has also been found that a lack of VHR in cells leads to cell 
cycle arrest, and cells often exhibited senescence phenotypes143. Due to the involvement of VHR in 
disease and cell cycle progression, it is of interest to study this enzyme. It also provides a second 
example of a dual specificity phosphatase for comparison with PTEN and to look at the effects of the 
new compounds on DSPs versus classical PTPs. The enzymes selected for this work are all implicated 
in at least one disease state and are, therefore, of significance to study in the context of inhibitor 
and probe development to investigate activity, function and localisation. These enzymes also cover 
the three main CBP classes of interest so the effects of the vanadyl complexes on these structurally 
diverse enzymes can be fully determined. 
Evaluation of inhibitor potency and therefore binding affinity of small molecules requires the 
determination of either an IC50 or Ki value. In both cases, the smaller the value the better the 
inhibitor; however, there is a difference between the Ki and the IC50 value. Ki is an inhibition 
constant, providing information about the affinity of an inhibitor for the enzyme, and, therefore, the 
rate of dissociation of the enzyme-inhibitor complex. The IC50 is the concentration of inhibitor 
required to halve the rate of an enzyme catalysed reaction. As the Ki value is a constant, its value is 
not dependent on the substrate or its concentration for a given enzyme and inhibitor compound. On 
the other hand, the IC50 is a relative value, and will be dependent on the substrate and its 
concentration144. The concentration of substrate used for IC50 determination should, therefore, be 
carefully considered. In this work, concentrations close to the Km values of the substrate for each 
enzyme were used. The Km is the concentration of substrate at which the enzyme is working at half 
of its maximum rate; therefore, this represents the rate of enzyme turnover which is not so slow 
that inhibition cannot be observed, but it is still within the linear portion of the rate curve145 (Figure 
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31). This allows for a more accurate determination of the rate of enzyme reaction. The use of the Km 
value of the substrate for IC50 determination has also been established for PTEN assays in the past95. 
The use of Km values means that the IC50 values for all complexes against a specific enzyme will be 
comparable as the concentration of substrate will be constant for each inhibitor, although the 
concentration of substrate used will vary between enzymes. The Km and Vmax (maximum rate of 
enzyme reaction) values at different concentrations of inhibitor have also been investigated as this 
provides information on the mechanism of inhibition, i.e. whether it is competitive, mixed or non-
competitive (Figure 12). 
Figure 31:  Michaelis-Menten graph showing the Km determination for an un-inhibited enzyme and 
Vmax for no inhibition and competitive inhibition. 
 
As mentioned above, IC50 values are affected by the substrate used; therefore, this needs to be kept 
the same across all the enzymes studied. In order to achieve this, a substrate should be selected that 
is compatible with each of the enzymes used in this study. The assay readout also shouldn’t be 
affected by the presence of highly coloured and fluorescent vanadyl complexes present in the 
inhibition assays. Previous studies of CBPs from literature and in the group have established that o-
methylflourescein phosphate (OMFP, Figure 32a) acts as a substrate for a selection of CBPs, with Km 
values ranging from 10-200 µM81,146,147. OMFP also allows for online readout of enzyme activity as a 
fluorescent compound is released on removal of the phosphate, and this is useful because the 
progress of the reaction can be monitored so any change in the rate of enzyme reaction can be 
easily obsereved145. An alternative substrate is pNPP (para-nitrophenylphosphate, Figure 32b) which 
is also readily available and gives an online readout (enzyme activity against assay time) for an 
increase in absorbance (405 nm) on phosphate cleavage. With the exception of PTEN, Km values have 
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been reported for this substrate for the PTPs of interest148–151 and this, therefore, provides a viable 
alternative to OMFP. 
Figure 32: Structure of artificial CBP substrates: (a) OMFP and (b) pNPP are shown with cleavable 
bond marked. 
 
Before any inhibition assays were run, control assays in the absence if inhibitor were carried out to 
confirm that, at the concentrations of enzyme and substrate used, the activity observed was 
sufficient to be able to clearly see inhibition. This ensured that any variation in enzyme activity not 
due to inhibitors was minimised thereby lowering the error associated with the variability of the 
enzyme. 
One further consideration when interpreting activity data is the effects of solution pH on enzyme 
activity. In all assays discussed here the pH is buffered to pH 7.4, around physiological pH, which falls 
within the pH range that the PTPs are known to be active. All enzymes, including the PTPs, have an 
optimal pH and if the pH of the assay deviates from this significantly then the activity of the enzyme 
will be affected. Factors such as contaminated buffer or non-aqueous additives to the assay (in this 
case DMSO) could affect the pH and the enzyme activity recorded, and hence this should be 
considered when interpreting assay data.  
 
3.1: Do the modified vanadyl complexes still inhibit PTEN? 
As the parent complex (1.2) has been previously characterised as a potent PTEN inhibitor (30-40 
nM)83,95, compounds were initially tested against PTEN to determine the effects of the modifications 
on potency. As can be seen from Figure 33, the complex formed from the modified 3-
hydroxypicolinic acid ligand (2.39) has an approximate IC50 of almost one order of magnitude lower 
than the fluorescent complexes based on 5-hydroxypicolinic acid (2.43a, 2.43b and 2.41). The IC50 for 
compound 2.39 (around 50 nM) is similar to that reported for the parent complex (around 40 nM95) 
suggesting that the addition of the biphenyl group, a PTP inhibitor fragment115, neither reduced nor 
enhanced the inhibitory properties of the complex. 
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Figure 33: Inhibition data for PTEN. The charts show the effects on PTEN (3.5 µM) activity of 2.39; 
2.43a; 2.43b; 2.41 at a range of concentrations. Compounds were incubated with the enzyme for 10 
minutes before addition of OMFP (200 µM, Km= 216 µM) to initiate the reaction. Data is shown as a 
percentage of uninhibited enzyme activity. Error bars are the standard deviation of 6 data points over 
two independent experiments. Assays were run in Tris buffer at pH 7.4. 
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The observed decrease in potency for the fluorescent complexes (2.43a, 2.43b and 2.41) (IC50 of 300-
400 nM) is likely due to the change in the structure of the vanadyl complex on first shifting the 
position of the hydroxyl group and second linking the picolinic acid groups. When the modified 
hydroxyl is moved from the 3 to the 5 position there is a decrease in potency seen without 
significant change in the steric bulk of the substituent. This is likely due to an interaction between 
the hydroxyl group at the 3-position and a component of the active site of PTEN which can no longer 
occur when the group is shifted to the 5-position. This is supported by previously published data95, 
as well as other work carried out by the group117 which showed a 4-fold increased IC50 (around  
160 nM) when using picolinic acid as a ligand (complex 1.1) compared to 3-hydroxypicolinic acid 
(complex 1.2). Therefore, although the activity of the dansyl-labelled complexes (2.43a and 2.43b) 
remains within the nanomolar range, there is an order of magnitude drop from the 3-
hydroxypicolinic acid parent compound. When the linker is present the ligand is constrained, and so 
the complex (2.43a and b) may not be able to obtain the conformation which caused greater activity 
against PTEN. It is possible that the linker at the 5-position will mean that the complex favours trans 
rather than cis geometry (Section 1.6) which would again interact differently with the enzyme active 
site. It can be concluded, therefore, that the modified complexes do still inhibit PTEN, with complex 
2.39 showing an inhibition potency similar to that of 1.2. The fluorescent complexes also still inhibit 
PTEN in the nanomolar range and, therefore, can still be utilised as fluorescent probes. 
 
3.2: Enzyme selectivity of Biphenyl complex 2.39 
Having established the effects of structural modifications on PTEN inhibition, the complexes were 
next tested against other CBPs to determine the effects on enzyme specificity. For this purpose, four 
enzymes were selected: PTP1B, SHP2, LMW-PTP, and VHR. As discussed above (see Section 3), these 
enzymes all play key roles in a range of diseases and have also been shown to accept OMFP as a 
substrate. Firstly, complex 2.39 was tested against these enzymes to determine if the structural 
modifications had affected the selectivity of the complex for PTEN. 2.39 is a non-fluorescent 
compound, and, therefore, will not be utilised as a fluorescent probe, although it is important to 
determine the effects of adding the biphenyl group on enzyme selectivity for future work on 
targeted inhibitors. Comparison of Figure 33a and Figure 34 indicates that some specificity for PTEN 
(50 nM) was observed over PTP1B and SHP2 (around 200 nM and 150 nM respectively). This is not as 
great as for the parent complex (1.2, IC50 = 40 nM )95, where IC50 values for a selection of 
phosphatases (PTPβ, SAC, MTM and SopB) ranged from 580 nM to 58 µM. LMW-PTP showed a 
similar inhibition profile to PTEN with an IC50 of around 75 nM (Figure 34a), whereas VHR seemed to 
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be inhibited to a greater extent with an IC50 of less than 50 nM (Figure 34d). Excluding LMW-PTP, this 
suggests a 3-5 fold specificity for DSPs over the classical PTPs, although where small differences are 
seen, sources of error such as laboratory conditions or dilution of compounds should be considered 
when interpreting results. This loss of PTEN specificity could be due to either the change in the 
overall structure of the complex, as the hydroxyl is no longer available to coordinate vanadium or 
interact with the enzyme; or due to the addition of the biphenyl group, a known PTP inhibitor 
fragment, which enhances activity against tyrosine phosphatases. Incorporation of the biphenyl 
group has been shown to enhance affinity and selectivity of probe compounds for PTPs (such as 
PTP1B)115, and is likely to have caused the observed increase in affinity of complex 2.39 for the 
classical PTPs. 
Figure 34: Inhibition of PTPs by 2.39. Effects of a range of concentrations of 2.39 on the activity of (a) 
LMW-PTP (6 nM); (b) PTP1B (21 nM); (c) SHP2 (145 nM); (d) VHR (12 nM). Compounds were 
incubated with the enzyme (concentration indicated in brackets above) for 10 minutes before 
addition of OMFP at concentrations matching the Km values for each enzyme respectively (LMW-PTP: 
40 µM, PTP1B: 150 µM, SHP2: 80 µM and VHR: 15 µM) to initiate the reaction. Data is shown as a 
percentage of the uninhibited enzyme activity. Error bars are the standard deviation of 6 data points 
over two independent experiments. Assays were run in Tris buffer at pH 7.4. 
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3.3 Potency and enzyme selectivity of dansyl labelled complexes 
Compounds 2.43a and b were next tested against the four CBPs. OMFP inhibition assays were run to 
determine IC50 values against each enzyme. As mentioned in Chapter 2, these complexes were 
poorly soluble and initially solutions were made up by heating a suspension of the complexes in 
DMF. However, large discrepancies in inhibition properties were observed between different stock 
solution batches of the complexes, which was likely due to inconsistent dissolution and subsequent 
decomposition of the complex over time. This was documented by fluorescence data (Figure 35) 
which shows that the two DMF solutions of supposedly identical concentrations have different 
fluorescence intensities, suggesting different concentrations of complex present. For solutions made 
up in heated DMSO this variation was not seen. However, the solutions in DMSO had lower 
fluorescence intensity, which suggests that the solutions in DMF had started to decompose as when 
the complex breaks down and the ligand is released fluorescence intensity increases (see Section 
2.4.3). Therefore, stock solutions in DMSO were used for all subsequent assays. 
Figure 35: Fluorescence spectra comparing stock solutions. Fluorescence spectra of two solutions of 
complex 2.43a (30 µM) in DMF and two in DMSO. Spectra were run using a Varian fluorescence 
spectrometer with an excitation wavelength of 340 nm and an emission range of 400-650 nm. 
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The data in Table 4 show that the complexes are more potent inhibitors of the four CBPs compared 
to PTEN (Figure 33). However, between the four CBPs shown in the table, no clear specificity for one 
particular enzyme is observed, with the complexes broadly inhibiting these CBPs in the range of  
70-200 nM. Despite this apparent lack of specificity, some variation in inhibition is observed 
between the enzymes. The IC50 value for 2.43a against LMW-PTP is almost two-fold higher than the 
other enzymes, which does suggest that the complexes show some selectivity towards certain CBPs 
compared to others. There also seems to be an effect on the inhibitory properties of the complex by 
increasing the length of the linker from diethanolamine (2.43a) to dipropanolamine (2.43b) for VHR, 
SHP2, and LMW-PTP. No significant effect is observed for PTP1B inhibition on increasing linker 
length, giving a lower IC50 value for 2.43b (below 100 nM) as compared to the other enzymes (120-
160 nM) again indicating some enzyme preference. This suggests that varying the linker length could 
be used as a method to tune selectivity of the complexes as the effect differs across the CBPs. It 
should, however, be considered that the observed variation in IC50 may be due to other factors 
affecting the assay. Errors in serial dilution of the complexes or variation in timings and 
temperatures of the assays could introduce errors not considered in the presented data, affecting 
the way the results could be interpreted. 
Table 4: IC50 values (nM) of vanadyl complexes 2.43a, 2.43b and 2.41, and VOSO4. Ten concentrations 
(1.5-30,000 nM) of each compound were incubated with each enzyme for 10 minutes prior to OMFP 
addition to initiate the reaction. Enzymes tested were LMW-PTP (6 nM); PTP1B (21 nM); SHP2 (145 
nM); VHR (12 nM). IC50 values were fitted using GraFit software (Figures A14-A17) and are shown as 
the average of three independent assays ± standard deviation. Assays were run in Tris buffer at pH 
7.4. 
 
 
 
 
 
 
 
 
Compound PTP1B VHR SHP2 LMW-PTP 
2.43a 
(5-atom linker) 
94±43 72±10 77±27 177±7 
2.43b 
(7-atom linker) 
84±24 130±14 162±20 120±12 
2.41 64±34 106±39 109±31 296±2 
VOSO4 151±16 120±6 71±8 117±4 
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In order to better understand the mechanism by which the complexes are acting, the inhibitory 
properties observed needed to be compared to that of the ligand and free vanadyl to check that the 
complex was not decomposing in situ with either the free ligand or vanadyl acting as the inhibitor. 
Figure 36 shows the inhibition profile of ligands 2.34a and 2.34b against two of the enzymes and the 
data clearly show that, at the concentrations (50-200 nM) at which the complexes were seen to 
inhibit these enzymes, no reduction in enzyme activity is observed on incubation with the ligands 
(Figure 36). At 50 µM there is a drop in enzyme activity but this could be due to the ligand 
precipitating out in the assay and affecting the readout as the ligand has poor water solubility. 
However, even with the observed drop in activity at the highest concentration, it can be concluded 
that the ligands do not inhibit the enzymes in the absence of vanadium at the concentrations 
present in the assays. 
IC50 values for VOSO4 against PTP1B, VHR, SHP2 and LMW-PTP were determined to represent the 
effects of free vanadyl on the enzymes and the results are shown in Table 4. The free vanadyl does 
show an inhibitory effect against the CBPs in the nanomolar range, a result that has also been 
previously reported for PTP1B66. The observed values are very similar to those of the complexes (70-
150 nM) and this therefore opens up the question of how the complexes are acting to inhibit the 
enzymes. As discussed in Section 1.6, it has been suggested that vanadyl complexes may act by 
delivering vanadyl to the CBPs rather than inhibiting the enzymes as a whole complex73,105. In this 
case, the complexes would break down in solution forming an equilibrium between the complex and 
the free vanadyl, allowing the metal to interact with the enzyme. This possibility was investigated 
(Chapter 4) and the results taken into account when interpreting the inhibition data 
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Figure 36: Effects of a range of concentrations of ligands on the activity of PTP1B (21 nM) and VHR (12 
nM). (a) PTP1B with ligand 2.34a; (b) PTP1B with ligand 2.34b; (c) VHR with ligand 2.34a; (d) VHR with 
ligand 2.34b. Compounds were incubated with the enzyme for 10 minutes before addition of OMFP 
((a) and (b) 150 µM, (c) and (d) 15 µM) to initiate the reaction. Data is shown as a percentage of 
uninhibited enzyme activity. Error bars are the standard deviation of 6 data points over two 
independent experiments. Assays were run in Tris buffer at pH 7.4. 
 
Although some of the IC50 values for VOSO4 are similar to those of the complexes, in some cases 
there is variation which could suggest that the complexes and not the free vanadyl are causing the 
inhibition. This variation is seen for SHP2, for which the IC50 value for 2.43b is around two-fold higher 
than that of VOSO4 (162±20 nM and 71±8 respectively), and for the inhibition of LMW-PTP by 
complex 2.41 (296±2 nM for 2.41 and 117±4 nM for VOSO4). Low errors in these values suggest the 
results are significant but, as for previous results, other causes of variation not shown in this analysis 
must be considered, such as the use of water instead of DMSO to make up stock solutions of VOSO4. 
This points to the conclusion that the ligand-vanadyl complex is intact when interacting with the 
enzyme, although further physical evidence to support this is required (Chapter 4). 
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Some of the variation in inhibition potency could be explained by the overall shape of the catalytic 
domain of the CBPs (for example VHR and LMW-PTP, Figure 37). The active site pocket is much 
deeper and narrower, with the catalytic domain less exposed for LMW-PTP than VHR, which could 
lead to a reduced interaction between the inhibitor and the catalytic domain; therefore, a higher IC50 
as observed. These variations in CBP structure affecting small molecule binding have been previously 
seen for studies with a selection of fluorescent substrates53. The smaller oxovanadium compound 
VO4 has been shown to bind to the active site of PTP1B by X-ray crystallography73 and it may, 
therefore, be possible for hydrated VO2+ to similarly enter the active site pocket of the CBPs. This 
could explain the lack of variation seen for the IC50 values of VOSO4 as the vanayl could interact with 
the active site of all the CBPs studied in a similar way. However, the variation in activity is also not 
seen for inhibition by 2.43b and so it is possible that this complex is interacting with these enzymes 
in a different way, for example as a partial complex (Section 1.6). 
Figure 37: Crystal structures of PTPs. (a) LMW-PTP (PDB code 4z99)152, and (b) VHR (PDB code 1VHR)33 
highlighting the CX5R domain (pink) and catalytic cysteine (yellow) with complex 2.43a superimposed 
onto the structures. Enzyme structures were created using Pymol software. Complex structures were 
drawn using ChemDraw and were superimposed on the enzyme structures based on computational 
data obtained in the group (Figure 20). 
 
IC50 values for complex 2.41 were also obtained (Table 4) and a similar range and pattern of results 
to 2.43a was observed. Within the margins of error, PTP1B, SHP2 and VHR had similar values for 
inhibition, but LMW-PTP is inhibited to a lesser extent with an IC50 of 296 nM compared to the 70-
130 nM for the other CBPs. Within the margins of error, SHP2 is the only enzyme to show a 
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difference in the effects of the bridged complexes and 2.41. Figure 33 also shows that the inhibition 
of PTEN is similar to that of LMW-PTP (Table 4) with both having an IC50 of around 300 nM.  
Taken together, the inhibition data (Figure 33 and Table 4) indicate that the fluorescent complexes 
are in general less potent inhibitors of PTEN compared to the other four CBPs investigated, and two 
of the three complexes (2.43a and 2.41) are also worse inhibitors of LMW-PTP than the other 
enzymes. This variation in enzyme selectivity and inhibition potency would support the notion that it 
is the full complexes inhibiting the enzymes, however, as discussed above and in Section 1.6, it is 
important to consider the mode of action of these vanadyl complexes and in what form the vanadyl 
interacts with the enzymes (Figure 17).  
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3.4 Studies to determine the mode of inhibition of 2.43a and VOSO4 against LMW-PTP 
In order to investigate the mode of inhibition of the complexes against the CBPs, LMW-PTP was 
selected as a model enzyme as it showed the greatest differences between the inhibition potency of 
the complexes and VOSO4 for complexes 2.43a and 2.41. The effects of adding vanadyl complexes on 
the kinetics of the enzyme activity were then investigated (i.e. the apparent Km and Vmax values). For 
this, complex 2.43a was selected as this had showed a greater variation from VOSO4 than 2.43b and 
had a better inhibition potency than 2.41. 
 
 
Figure 38: Michalis-Menten and Lineweaver-Burke plots of kinetic data (rates vs substrate 
concentration) for LMW-PTP (6 nM). Vanadyl compounds were preincubated for 10 minutes with the 
enzyme before addition of OMFP (0-80 µM). The concentrations of inhibitor studied are 0, 25, 50 and 
100 nM. (a) Michalis-Menten plots of kinetic data for 2.43a; (b) Lineweaver-Burke plots of the kinetics 
data in a. (c) Michalis-Menten plots of kinetic data for VOSO4; (d) Lineweaver-Burke plots of the 
kinetic data in c. Turnover rate was calculated using a calibration curve of OMF concentration against 
fluorescence readout (see Section 7.2.3, Figure 58). Assays were run in Tris buffer at pH 7.4. 
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Table 5: Km and Vmax values for LMW-PTP (6 nM) with increasing concentrations of 2.43a and VOSO4. 
The data is an average of three independent repeats ± the standard deviation. Values were calculated 
using GraFit 7.0 and are taken from the data shown in Figure 38. Assays were run in Tris buffer at pH 
7.4. 
 2.43a VOSO4 
Concentration  Km/µM Vmax/pmolmin-1 Km/µM Vmax/pmolmin-1 
0nM 100±27 15±0.25 72±3 9±0.2 
25nM 73±18 11±2 95±8 6±0.3 
50nM 70±25 7±1 93±14 3±0.3 
100nM 112±22 5±2 119±38 2±0.5 
 
The Km and Vmax values were determined for LMW-PTP with OMFP as a substrate in the presence or 
absence of inhibitor. The data in Figure 38 and Table 5 indicate that over an inhibitor concentration 
range of 0-100 nM the Km value for OMFP is unaffected within the margins of error whilst the Vmax 
values show a reduction as the inhibitor concentration is increased for both 2.43a and VOSO4. At the 
lower concentrations of both compounds the Vmax is clearly being reduced suggesting that the 
mechanism is non-competitive due to the reduction in enzyme turnover with no observed effect on 
the Km. However, at 100 nM of 2.43a the change in Vmax (7-5 pmol min-1) is less and the values have a 
higher error. This effect is likely due to the large variation in the results at 100 nM of inhibitor as can 
be seen, for example, from the error bars in Figure 38a and c. It is also interesting to note that within 
the margins of error the values for the Km are very similar for the two inhibitors whilst the Vmax is 
higher for 2.43a. 
The data suggest that vanadyl sulfate and complex 2.43a act via a non-competitive mechanism 
against LMW-PTP. It is of interest to note that although the IC50 values for 2.43a and VOSO4 were 
different, the effects of both compounds on the Vmax were similar. This data indicate that, for 
inhibition of LMW-PTP, the complexation of vanadyl to the fluorescent ligand does not have an 
effect on the mode of inhibition which implies that the compounds interact with the enzyme in a 
similar way. This may suggest at least partial loss of ligand coordination as it is possible that both the 
vanadyl and the complex interact at the enzyme active site. Alternatively, the compounds could 
interact with the enzyme at an allosteric site that accommodates both the complex and the free 
vanadyl. The integrity of the fluorescent compounds and their interaction with the enzyme will be 
discussed in more detail in Chapter 4. 
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3.5 Inhibition properties of platinum complex 2.44 
As discussed in Section 1.4.4, vanadium is not the only metal to act as a CBP inhibitor. Other metal 
cation complexes of picolinic acid have been reported to have insulin mimetic effects comparable to 
that of vanadyl49,70; therefore, it is relevant to determine whether changing the metal in the bridged 
complexes will affect the inhibitory properties. In order to determine the importance of the vanadyl 
core for inhibition, a platinum complex using the bridged fluorescent ligand 2.34a was synthesised 
and tested against the four CBPs of interest. Platinum was selected as it is reported to form 
complexes with picolinic acids and is diamagnetic, so can be characterised by NMR spectroscopy. It is 
also widely used in metallopharmaceuticals49,133 and it is therefore of interest to determine its effect 
on CBPs as little has been reported in this area153. In addition, platinum(II) forms square planar 
complexes and therefore would yield a compound with a different geometry as compared to the 
vanadyl complexes. It would therefore be expected that the platinum complexes would have a lower 
potency for the CBPs than the vanadyl complexes. 
The first point to consider for the assays was the selection of a suitable inhibitor concentration 
range. As the complex was poorly soluble, even in hot solvents, the highest stock concentration in 
DMSO that could be made up was 500 µM. This poor solubility, as with the vanadyl complexes, could 
be indicative of a polymeric species having formed. The maximum concentration was, therefore, 
limited to 5 µM, as too high a concentration of DMSO could affect the outcome of the assays.  
Preliminary data (Figure A18) for this complex indicated that there was an effect on the readout in 
the OMFP assay; therefore, a different substrate was required where this effect was not observed. 
For this reason, pNPP (para-nitrophenyl phosphate) was selected148–151. The substrate pNPP is 
employed in much higher concentrations compared to OMFP and detected by absorbance at 405nm, 
which works well with the relatively low absorbance of the platinum complex at this wavelength 
(0.05 OD at 10 µM). Using the same assay format as for OMFP (see Chapter 7) the potency of 
inhibition against CBPs was investigated. 
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Figure 39: Inhibition properties of complex 2.44. Effects on the activity of (a) LMW-PTP (6 nM, IC50 = 
3715 nM); (b) PTP1B (21 nM, IC50 = 783 nM); (c) VHR (12 nM, IC50 = 1575 nM); and (d) SHP2 (145 nM, 
IC50 = 1193 nM) on incubation with a range of concentrations of complex 2.44. The compound was 
incubated with the enzyme for 10 minutes before addition of pNPP ((a) and (d) 5 mM, (b) 2 mM, (c) 
10 mM) to initiate the reaction. Data is shown as a percentage of uninhibited enzyme activity. Error 
bars are the standard deviation of 6 data points over two independent experiments. Assays were run 
in Tris buffer at pH 7.4. 
 
The results shown in Figure 39 indicate that the platinum complex inhibits all of the enzymes with 
comparable IC50 values in the low micromolar/high nanomolar region (Figure 39). It is also 
interesting to note that using different substrate concentrations when looking at different enzymes 
does not have a significant effect on the inhibition data suggesting that there is little or no effect on 
the assay readout by the platinum complex. 
The data show that the platinum(II) complex is around 10 times less active against the CBPs 
compared to vanadyl (Table 4) which suggests that the metal used has an impact on the CBP 
inhibition properties of picolinic acid-metal complexes. This could be due to the change in structure 
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of the metal centre which would affect the interactions of the complex with the enzyme. Here, the 
geometry of the platinum(II) complex will be square planar133 whilst the vanadyl will give an 
octahedral structure with coordination of a water molecule95,102. The vanadyl complex structure will 
mimic the phosphate of the substrate (Section 1.5) and will therefore interact favourably with the 
enzyme whilst the platinum complex may not have the phosphate-mimetic properties and this will 
be seen as the reduction in inhibition. As discussed at the start of this section, inhibition of CBPs by 
platinum complexes is relatively unexplored and further work will be needed to determine if 
platinum is a suitable metal for use in phosphatase inhibition. 
In summary, the novel vanadyl-based fluorescent compounds have been analysed as PTEN and CBP 
inhibitors. Although the fluorescent complexes do still inhibit PTEN (Figure 33) they are not as 
effective as the parent 3-hydroxypicolinic acid complex and no longer have the selectivity for PTEN 
over other CBPs (Table 4). Further characterisation of the bridged complex 2.43a suggested that it 
was acting as a non-competitive inhibitor against LMW-PTP (Table 5). A platinum(II) complex was 
also tested against the CBPs and the results show that, although the complex still inhibited enzyme 
activity, there was a ten-fold decrease in efficacy, indicating the importance of the vanadyl core for 
CBP inhibition by picolinic acid based complexes (Figure 39). This suggests that the vanadyl 
complexes interacting with the enzyme relies either on the structure of the complex or the presence 
of the vanadyl centre which corresponds with an interaction of the vanadyl at the enzyme active 
site. Comparison of the data for the fluorescent complexes (2.43a, 2.43b and 2.41) to that of VOSO4 
showed some similarities between the inhibition profile and the mechanism of inhibition, although 
for some enzymes a difference was seen between the values for the complexes and the vanadyl salt 
(Table 4). As discussed in Section 1.6, the similarities observed between the inhibition profiles of the 
vanadyl salt and the fluorescent complexes could be down to the complexes releasing vanadyl in the 
presence of the enzyme which would therefore mean that the vanadyl salt is acting as the inhibitor 
in this case. The idea that vanadyl complexes merely act to deliver the vanadyl ion to the site where 
it is needed is still under debate73,105; therefore, it is necessary to determine whether this is 
occurring for the complexes studied in this chapter. As these complexes will potentially be used as 
CBP probes, a requirement will be that the fluorescent ligand remains attached to the vanadyl core, 
as it has been shown by inhibition studies that the ligands themselves do not interact with the 
enzymes. 
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Chapter 4: Determination of stability of fluorescent vanadyl complexes 
in the presence of enzymes. 
In the previous chapter inhibition data for the fluorescent vanadyl and platinum complexes were 
analysed. Considering the data presented here and by others in previous investigations,73,105 one 
could not exclude the possibility that the complexes might be merely a delivery mechanism for 
vanadyl to the enzyme active site106, a notion that would be in agreement with the similar inhibition 
potencies observed for vanadyl complexes and free vanadyl (see Section 3.3). In this section, the aim 
is to find clear evidence for the mode of action of these complexes, which will be achieved by 
studying whether the vanadyl complexes are stable in the presence of CBPs. 
It has been previously shown that the inhibition of CBPs by free vanadium and complexes is 
reversible by addition of ethylenediaminetetraacetic acid (EDTA)61,81; therefore, the rate of 
reversibility and concentration of EDTA required to see an effect was investigated. It would be 
expected that if the complexes remained whole in the presence of the CBPs they would behave 
differently to VOSO4, as it is likely that the free vanadyl will interact differently with the enzyme to 
the full complex. This would mean that the time taken for the EDTA to chelate the vanadyl from the 
complexes compared to free vanadyl, and the concentration of EDTA required in each case, will be 
different. Therefore, if a significant difference in the effect of EDTA between free and complexed 
vanadyl is seen, this would indicate that the complex is not releasing vanadyl in the presence of the 
enzyme. The fluorescence properties of the complex such as the quenching on binding vanadyl 
(Section 4.2.2) or fluorescence anisotropy changes on interacting with the enzyme (Section 4.2.3) 
can also be utilised. For the former, changes in fluorescence intensity were used to determine 
whether the complex is present in the assay solution or it breaks down releasing the free ligand 
(which should lead to an increased fluorescence). Fluorescence anisotropy was also employed to 
study the complex-protein interactions and the results obtained are discussed in Section 4.2.3.  
 
4.1 Effects of EDTA on ability of vanadyl complexes to inhibit PTPs. 
As discussed above, it is likely that adding EDTA to the inhibition assays would reverse the observed 
inhibition caused by vanadyl sulfate and the fluorescent complexes as the mechanism has been 
shown to be reversible. In order to test this, inhibition assays were run in the presence and absence 
of EDTA to see if the enzyme activity could be restored on addition of EDTA. If this is the case, EDTA 
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can be used to investigate whether the complexes are interacting with the enzyme, as discussed 
above, or they simply act to ‘deliver’ free vanadyl to the enzyme. 
Figure 40: Effects of EDTA on the inhibition potency of vanadyl compounds. 300 nM VOSO4, 2.43a and 
2.43b were incubated with LMW-PTP (6 nM) and EDTA (1 mM) was added to the assay prior to the 
vanadyl compounds. Compounds were incubated with the enzyme for 10 minutes before addition of 
OMFP (40 µM) to initiate the enzymatic reaction. Data is shown as a percentage of uninhibited 
enzyme activity. Data shown is the mean ±standard deviation of triplicate repeats. Assays were run in 
Tris buffer at pH 7.4. 
 
Inhibition assays with VOSO4 and complexes 2.43a and b were run in the presence and absence of 
EDTA. The data (Figure 40) show that, in the absence of EDTA, enzyme activity is reduced to 20% on 
addition of 300 nM of the vanadyl compounds. When 1mM EDTA is added prior to the addition of 
inhibitors, enzyme activity is restored to around 80-90% of the maximum. As it has been shown that 
the ligand has no effect on enzyme activity at the concentration used (Section 3.3, Figure 36) it can 
be inferred that the EDTA removes vanadyl from the assay both for the free vanadyl and the 
complexes thereby removing the inhibitory component and restoring enzyme activity. However, 
there is residual inhibition seen for all compounds in the presence of EDTA. This can be explained by 
some of the vanadyl not being chelated by the EDTA during the incubation time which could be due 
to protection by the enzyme or strong ligand chelation in the case of the complexes. The reversibility 
of the inhibition by vanadyl compounds was also confirmed by a control experiment where EDTA is 
added during the assay, and the activity of the enzyme can be seen to return to close to that of the 
uninhibited enzyme. 
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4.2 Using EDTA chelation to investigate bridged complex stability 
4.2.1 Activity based assays 
The properties of EDTA described above can be used to determine whether the vanadyl complexes 
are stable under the enzyme assay conditions (Chapter 7). There are two parameters for the effect 
of EDTA that could vary between free and complexed vanadyl which are: (1) the rate of vanadyl 
uptake as shown by the time of EDTA incubation needed to restore enzyme activity; and (2) the 
concentration of EDTA required to reach a certain level of enzyme activity recovery. Therefore, two 
approaches were required in order to investigate the effects of kinetics and concentration on the 
ability of EDTA to restore enzyme activity. 
The first experiment was carried out by pre-incubating the inhibitor-enzyme mixture with EDTA  
(1 mM at each time point) for a range of different times and looking at how much enzyme activity 
was restored at each time point. If the complex is inhibiting the enzyme and not releasing vanadyl 
(as discussed above) it would be expected that the ‘off rate’ for the vanadyl complex-enzyme 
binding interaction would be different to that of free vanadyl, seen as a difference in enzyme activity 
restoration at a given time. It should also be considered that, for the complex, the EDTA is 
competing with the ligands as well as the enzyme for vanadyl. The rate at which the EDTA captures 
the vanadyl will therefore be affected by the relative Kds of EDTA and the ligand for vanadyl. The Kd 
is a dissociation constant which gives a measure of binding affinity between two molecules, such as a 
metal and ligand. The vanadyl-EDTA complex has a very high reported stability constant (18.77)154 
whereas that of vanadyl-picolinic acid is lower (around 12.11)102, suggesting that EDTA is likely to 
have a greater affinity for the vanadyl than the ligands. As can be seen from Figure 41, both the 
complex and vanadyl sulfate inhibit the enzyme to 20% activity when EDTA is added just before 
addition of OMFP to the assay. However, with increasing time the ability of EDTA to restore enzyme 
activity appears to be less for vanadyl sulfate as compared to the complex. A clear difference is seen 
between the activity of the enzyme with VOSO4 and 2.43b from around 35 minutes’ incubation with 
EDTA, although the initial slope for each appears to be similar. This was not expected as, in the case 
of the complex, EDTA is competing with the ligand and enzyme for the vanadyl whereas the ligand 
interaction is not a factor in chelation of VOSO4. One explanation for this could be that the smaller 
free vanadyl is able to enter the active site or other pockets on the enzyme and is therefore 
protected from the EDTA whereas the complex is more sterically hindered and, therefore, may be 
more exposed to EDTA. The similarity in the slopes for the first 30 minutes could be due to more free 
vanadyl in solution, but as the concentration available decreases the residual vanadyl is protected 
whilst the complex remains exposed. 
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One other observation from the data is that the enzyme activity does not return to near 100% on 
incubation with EDTA. Although these data appear to be inconsistent with that in Figure 40, where 
more enzyme recovery is observed, this can be explained by the order of addition of the EDTA and 
vanadyl. The data shown in Figure 41 was obtained from an experiment where vanadyl is already 
present in the assay before addition of EDTA (1 mM), allowing time for interaction with the enzyme 
before chelation by EDTA can occur. In the previous assay (Figure 40) the EDTA was added prior to 
the vanadyl and therefore had time to chelate the vanadyl before interaction with the enzyme (for 
further discussion see Section 4.4). Despite this, there is a difference between the activities of the 
enzyme at 45 minutes for the VOSO4 and 2.43b. Although this observation suggests that the vanadyl 
sulfate is interacting differently with the enzyme to the complex, errors in the assay setup should be 
taken into account when assessing the data. The results could be indicative of complex stability but 
alone they are not sufficient to conclude that the complex is stable under the assay conditions, 
especially above 45 minutes incubation. 
Figure 41: Effects on inhibition properties of 300 nM (a) 2.43b and (b) VOSO4 against LMW-PTP (6 nM) 
on incubation with EDTA (1 mM) for 0-45 minutes before addition of OMFP (40 µM). Compounds 
were incubated with the enzyme for 10 minutes prior to EDTA addition. Control assays were run with 
identical EDTA incubation times in the absence of inhibitor and data is shown as a percentage of 
uninhibited enzyme activity in the presence of EDTA. Data shown is the mean ±standard deviation of 
triplicate repeats. Assays were run in Tris buffer at pH 7.4. 
 
The second assay run was to determine the effect of EDTA concentration on enzyme activity 
restoration. Seven different EDTA concentrations were added to the assay and allowed ten minutes 
to react before enzyme activity was measured. The data in Figure 42 show a similar pattern to that 
seen for the kinetics data, with the vanadyl sulfate requiring a higher concentration of EDTA to be 
added before enzyme activity started to be restored. A roughly four-fold higher concentration of 
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EDTA is required to start restoring enzyme activity with vanadyl sulfate as compared to the vanadyl 
complex. Also, the maximum activity restored for VOSO4 (40%) was less than for the full complex 
(70%) which reinforces the conclusion from the kinetics assay that the vanadyl sulfate is behaving 
differently to the vanadyl complexes. This could again be explained by the enzyme active site limiting 
access of the EDTA to the vanadyl. At higher concentrations of EDTA the vanadyl is taken up faster 
when it is released from the enzyme, as the vanadyl-enzyme binding is a reversible process. The fact 
that high activity restoration was not seen for 1mM EDTA can again be explained by that fact that 
here the complex and VOSO4 were allowed time to interact with the enzyme before addition of 
EDTA. 
Figure 42: Effects of inhibition properties of 300 nM (a) VOSO4, and (b) 2.43b against LMW-PTP (6 nM) 
on incubation with a range of EDTA concentrations (0-1000 µM) for 10 mins before addition of OMFP 
(40 µM).  Compounds were incubated with the enzyme for 10 minutes prior to EDTA addition. Data is 
shown as a percentage of uninhibited enzyme activity in the presence of EDTA. Data shown is the 
mean ±standard deviation of triplicate repeats. Assays were run in Tris buffer at pH 7.4. 
 
It has been shown that both the kinetics of EDTA-vanadyl binding and the concentration of EDTA 
required to remove vanadyl are different for free vanadyl and complex 2.34a, as can be seen from 
Figure 41 and Figure 42. In both cases, reversing the effects of the free vanadyl on the enzyme 
appears to be more difficult than for the complex with longer times and higher concentrations of 
EDTA required to restore enzyme activity. As the vanadyl compounds are pre-incubated with the 
enzyme, the experiments (Figure 41 and Figure 42) are designed to probe the removal of the vanadyl 
after protein-metal interaction and not the chelation of vanadyl from prior to enzyme exposure 
(seen in Figure 40). Taking this into consideration, if the complexes were merely acting as a vanadyl 
delivery mechanism it would be expected that the rate of chelation of the vanadyl by EDTA, shown 
by the increase in enzyme activity, would be the same for the complex and the free vanadyl. A 
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similarity would also be expected for the concentration of EDTA required to reverse the inhibition, as 
in both cases it would be the uncoordinated vanadyl that interacts with the enzyme. This, however, 
is not seen and the data would therefore suggest that the free vanadyl, once bound to the enzyme, 
is better protected from EDTA than the complex. Taken together, the data from Figure 41 and Figure 
42 would seem to suggest that the interaction of the complex and the free vanadyl with the enzyme 
are different. Although these data could suggest that the complex is stable in the presence of CBPs, 
other factors such as dissolution and dilution of the compounds and variability in enzyme activity 
could contribute to the difference seen. Further evidence will be required in order state conclusively 
whether the complexes are stable under the assay conditions.   
 
4.2.2 Fluorescence assays 
As discussed in Chapter 2, on binding of vanadyl to the dansyl labelled ligands, the fluorescence 
intensity of the ligands is reduced due to a quenching effect of the vanadyl. This effect would also be 
expected in the opposite direction, such that when the vanadyl is removed from the ligand the 
original fluorescence is restored. It can therefore be assumed that if the vanadyl is removed from 
the ligand, for example by EDTA, there would be an observed increase in fluorescence intensity, 
which could be used to determine whether the complex is stable under the conditions used for 
enzyme assays. For this, the positive control would be EDTA in the absence of enzyme as this should 
fully destroy the complex, and the negative control would be assay buffer as this should have no 
effect on the complex. In each case the ligand was also tested as a comparison. 
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Figure 43: Effects of conditions on fluorescence of complex 2.43a. Fluorescence intensity at 560 nm of 
a 30 µM solution of ligand 2.34a and complex 2.43a in the presence or absence of LMW-PTP (Enz, 10 
µM) and 1 mM EDTA in Tris buffer containing 1 mM DTT. Reading was taken after 5 minutes’ 
incubation at room temperature. Intensity is mean ±standard deviation of triplicate repeats. Readings 
were taken in Tris buffer at pH 7.4. 
 
The first readings were taken five minutes after addition of the complex or ligand to the buffer 
solution and it can be seen that in this time the EDTA had almost completely released the ligand in 
the absence of enzyme, as shown by the fluorescence returning to almost that of the ligand. In the 
buffer control the fluorescence intensity remains at the level expected for the complex from 
previous data (Figure 29 and Figure 30), and in the presence of enzyme the fluorescence was of a 
similar intensity, suggesting the complex is stable for a short period under assay conditions (Figure 
43). When both EDTA and the enzyme were present, although some increase in fluorescence 
intensity was observed when compared to the enzyme alone, the fluorescence intensity did not 
return to that of the ligand, suggesting that some of the ligand is still coordinated to the vanadyl. 
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Figure 44: Effects of EDTA on the fluorescence intensity of complexes 2.43a and 2.43b. Fluorescence 
intensities (excitation 485 nm, emission 560 nm) of 2.34a (a) and 2.34b (b), complexed to vanadyl or 
as a free ligand (30 µM each) in the presence or absence of LMW-PTP (Enz, 10 µM) and/or 1 mM 
EDTA were taken after 2 hours’ incubation at room temperature. The solution of complex 2.43a was 
that used for the reading in Figure 43. Intensity is mean ± standard deviation of triplicate repeats. A 
statistical analysis has been performed showing that the difference between the fluorescence 
intensity of 2.34a/b and 2.43a/b incubated with enzyme in the absence of EDTA, are statistically 
significant (*p < 0.05), which is not seen in the presence of EDTA with no enzyme (**p > 0.05) (Figure 
A20). Readings were taken in Tris buffer at pH 7.4. 
 
After two hours’ incubation, the fluorescence of the solution of complex in the presence of EDTA 
and enzyme together had also returned to that of the ligand suggesting that the enzyme was initially 
providing some protection against the effects of EDTA for the reading at 5 minutes, but not over two 
hours. However, where only enzyme (enz-no EDTA) is present, no such rise in fluorescence is 
observed, with the fluorescence remaining at the intensity seen in buffer alone. This would suggest 
that the ligand is still coordinated to the vanadyl in the presence of the enzyme over a period of two 
hours. This effect is significant and is seen for both of the bridged complexes (Figure 44a and b), 
which implies that the linker length does not affect the stability of the complex or the ability to bind 
the enzyme. Together these data suggest that the enzyme is able to interact with the vanadyl 
complex and ‘protect’ it from the effects of EDTA for a short time, which is consistent with evidence 
from previous assays (Figure 41 and Figure 42). However, on comparison of the fluorescence 
intensity with the ligand and complex in buffer only, the increase in fluorescence appears more 
significant and so this effect may not be as pronounced as the enzyme-EDTA results suggest. The 
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data also suggest that the vanadyl is still coordinated to the ligand, either as the whole original 
complex or a partially coordinated ligand – see below for further discussion – in the presence of the 
enzyme for at least two hours, due to the fluorescence not returning to that of the ligand solution in 
contrast to the solutions containing EDTA. This effect is clearly significant (Figure 44) within the 
margins of error of the assay which would indicate that the complexes are stable under assay 
conditions. Variation in the fluorescence intensity of the ligand under different conditions could 
suggest that errors other than those associated with the assay setup could have an effect on the 
results. More data will, therefore, be required in order to confirm the stability of the complexes and 
their interaction with the CBPs.  
 
4.2.3 Fluorescence anisotropy or fluorescence polarisation 
Although the fluorescence assays indicate that the complex is stable in the presence of the enzyme, 
this does not clearly show complex-enzyme binding and it is, therefore, important to investigate this 
further using a different technique. As the fluorescence studies of the complexes provided the 
strongest evidence for the complex remaining intact, it was decided that this property should be 
utilised in further experiments to investigate complex-enzyme binding interactions. Fluorescence 
anisotropy is a technique that allows investigation of binding of a fluorescent molecule to a second, 
larger molecule155,156, such as a protein or receptor. This interaction slows the ‘tumbling’ of the 
fluorophore in solution, which can be seen by an increase in recorded fluorescence anisotropy as the 
smaller free fluorophore will ‘tumble’ faster than the fluorophore bound to a larger molecule. This 
technique could, therefore, be utilised to show whether the fluorescent vanadyl complexes bind to 
the CBPs with the fluorophore still attached to the vanadyl, as a change in fluorescence anisotropy 
will only be observed if the complex binds the enzyme. If it can be shown that the vanadyl is 
required for the fluorophore to bind to the enzyme then this would confirm the hypothesis that a 
vanadyl-ligand complex is interacting with the enzyme to cause the observed inhibition. As it was 
shown that the ligands do not cause inhibition, it would seem unlikely that they would bind to the 
CBPs in the absence of vanadium; therefore, any binding of a fluorescent molecule to a CBP, shown 
by increases in fluorescence anisotropy, can be attributed to a ligand-vanadyl complex interacting 
with the enzyme. 
In order to determine if the enzyme-complex binding can be seen by fluorescence anisotropy, 
readings were taken for complex 2.43a in the presence of increasing concentrations of enzyme. This 
would also give an indication of the binding ratio of the complex to the enzyme. In order to 
determine this, LMW-PTP was titrated into a cuvette containing the complex 2.43a and the 
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fluorescence anisotropy measured after each addition (Figure 45). As a control, the fluorescence 
anisotropy was measured at three glycerol concentrations and no effect due to increased viscosity 
was observed (Figure A19). This ensures that any effect seen is due to the complex interacting with 
LMW-PTP. 
 
Figure 45: Fluorescence anisotropy of 2.43a (10 µM) in the presence of increasing concentrations of 
LMW-PTP (0-36 µM). Readings were taken in 100 mM Tris buffer solution in a 200 µL fluorescence 
cuvette. Excitation wavelength is 340 nm, emission recorded at 560 nm. The error is shown as the 
standard deviation of three independent experiments. Readings were taken in Tris buffer at pH 7.4. 
 
The data show that the complex is interacting with the enzyme as, with increasing concentrations of 
enzyme, the fluorescence anisotropy reading increases (to a maximum around 2 equivalents). This is 
expected, because at very low concentrations of enzyme some of the complex would still be free to 
rotate in solution, whereas, at higher enzyme concentrations more of the complex is bound at any 
one time, so the number of fluorescent molecules free in solution is reduced. At one equivalent of 
enzyme the complex is around 80% bound (Figure 45) which suggests a close to 1:1 binding 
relationship under the conditions used. Having established the enzyme-fluorophore interaction, it 
was then necessary to confirm that it is the vanadyl-ligand complex that is causing the observed 
fluorescence anisotropy. The preliminary readings were taken using 2.43b in the presence of VHR 
(Figure 46). 
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Figure 46: Fluorescence anisotropy of 2.43b. Readings were taken using 10 µM of complex in the 
absence (buffer + compound) or presence of VHR (72 µM) and over 105 minutes of incubation with 
the enzyme and 1 mM EDTA. Readings were taken in 100 mM Tris buffer solution in a 200 µL 
fluorescence cuvette. Excitation wavelength is 340 nm, emission recorded at 560 nm. The error is 
shown as the standard deviation of three readings.  Significant differences to the “buffer + 
compound” data are indicated (* p < 0.05). Statistical analysis also showed a significant difference 
between the fluorescence anisotropy at 0 and 105 minutes (**p < 0.05) (Figure A21). Readings were 
taken in Tris buffer at pH 7.4. 
 
As can be seen from Figure 46, when the complex is dissolved in assay buffer (with a small amount 
of glycerol as would be present when the enzyme is added) the fluorescence anisotropy is relatively 
low (around 0.25 a.u.). However, when VHR is present in the solution, the fluorescence anisotropy is 
roughly doubled to around 0.55 a.u. suggesting that the enzyme has bound a fluorescent species, 
slowing the rotation of the fluorophore in solution.  
One way to demonstrate that the observed effect is due to the whole complex binding to VHR is to 
look at the effect of EDTA addition. As shown in Figure 41, prolonged exposure to EDTA removes 
vanadyl from the assay through chelation, shown by an increase in enzyme activity. If the whole 
complex is binding to the enzyme, on incubation with EDTA the complex should be broken down and 
the observed increase in fluorescence anisotropy reversed. As can be seen in Figure 46, this is indeed 
the case, with a large initial drop in fluorescence anisotropy after 15 minutes and a gradual decrease 
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back to the baseline value (buffer + compound) observed over 105 minutes. This would strongly 
suggest that the vanadyl is key to the interaction with the enzyme as once it is chelated by EDTA and 
no longer bound to the ligand the interaction of the fluorophore with the enzyme is lost. 
Table 6: Comparison of fluorescence anisotropy data for ligands and complexes. Fluorescence 
anisotropy readings for the bridged complexes (2.43a and 2.43b) and ligand 2.34a in the presence and 
absence of enzyme. Readings were taken in 100 mM Tris buffer solution in a 200 µL fluorescence 
cuvette. Excitation wavelength is 340 nm, emission recorded at 560 nm. Values are an average of 6 
readings ± standard deviation. Readings were taken in Tris buffer at pH 7.4. 
Compound Fluorescence anisotropy no 
enzyme / a.u. 
Fluorescence anisotropy with 
enzyme / a.u. 
2.34a (with LMW-PTP) 0.20±0.01 0.21±0.01 
2.43a (with LMW-PTP) 0.26±0.02 0.36±0.02 
2.43b (with VHR) 0.25±0.06 0.54±0.01 
 
In order to investigate whether this effect is seen for both complexes and with a different CBP the 
assay was repeated, this time using LMW-PTP as the enzyme and 2.43a as the fluorescent complex. 
First, a comparison was made between the fluorescence anisotropy values for the complex (2.43a) 
and the ligand (2.34a) in the presence of the enzyme to show that no non-specific binding was 
occurring. The values obtained for the fluorescence anisotropy were 0.36±0.02 a.u. for the complex 
and 0.21±0.01 a.u. for the ligand (Table 6), which suggests that no non-specific binding is occurring 
as the fluorescence anisotropy of the ligand is below the baseline value for the complex. This 
indicates that the presence of the enzyme has no effect on the fluorescence anisotropy of the free 
ligand. 
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Figure 47: Fluorescence anisotropy of 2.43a. Readings were taken using 10 µM of complex in the 
absence (buffer + compound) or presence of LMW-PTP (36 µM) and over 100 minutes of incubation 
with the enzyme and 1 mM EDTA. Readings were taken in 100 mM Tris buffer solution in a 200 µL 
fluorescence cuvette. Excitation wavelength is 340 nm, emission recorded at 560 nm. The error is 
shown as the standard deviation of 6 readings from two independent experiments. Significant 
differences to the “buffer + compound” data are indicated (* p < 0.05). Statistical analysis also 
showed a significant difference between the fluorescence anisotropy at 0 and 100 minutes (**p < 
0.05) (Figure A21). Readings were taken in Tris buffer at pH 7.4. 
 
Figure 47 shows that the increase in anisotropy on addition of LMW-PTP to the complex is not as 
pronounced as for VHR (Figure 46); however, the increase is still significant within the margins of 
error, and the gradual drop back to the baseline value (buffer + compound) on incubation of EDTA 
can be clearly seen. These results, together with the previous data (Figure 46), indicate that both 
bridged complexes bind to the CBPs examined here as a ligand-vanadyl complex and when the 
vanadyl is removed the binding no longer occurs. This shows that the vanadyl is essential for CBP 
binding, which is consistent with the lack of enzyme inhibition observed for the free ligands. As 
discussed in Section 1.6, there are two possible species which could be interacting with the enzyme: 
the full complex with tetradentate ligand coordination or the bidentate complex (see Section 4.3, 
Figure 50a) where one of the picolinic groups is no longer coordinated to the vanadium centre. This 
is possible due to the solution speciation of the complexes under different conditions101 giving an 
equilibrium between the vanadyl species present that can interact with the enzymes. 
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4.3 Stability of complex 2.41 under assay conditions 
As for the bridged fluorescent complex, it is important to determine whether the non-bridged 
complex is stable under the assay conditions. Therefore the EDTA assays carried out on the bridged 
ligands (Figure 41, Figure 42 and Figure 44 ) were repeated for 2.41 to see if the same effects on 
enzyme inhibition and fluorescence were observed in the presence of EDTA.  
 
Figure 48: Complex stability data for 2.41 with LMW-PTP (6 nM). (a) Effects of inhibition properties of 
300 nM 2.41 against LMW-PTP on incubation with 1 mM EDTA for 0-45 minutes before addition of 
OMFP (40 µM). Data is shown as a percentage of uninhibited enzyme activity in the presence of EDTA. 
(b) Fluorescence intensity at 560 nm of a 60 µM solution of ligand 2.22 and a 30 µM solution of 
complex 2.41 in the presence or absence of LMW-PTP (Enz, 12 µM), and 1 mM EDTA in Tris buffer 
containing 1 mM DTT. For wells containing enzyme and EDTA the enzyme was first incubated with 
compound or EDTA for 5 minutes before addition of EDTA or compound respectively. Readings were 
taken at 5 minute intervals over 35 minutes. Assays were run in Tris buffer at pH 7.4. 
 
Firstly, the kinetics of enzyme activity restoration on incubation with EDTA were investigated (Figure 
48). In contrast to the bridged complex (Figure 41a), the enzyme activity is only restored to around 
50% of maximum (Figure 48a), which is closer to the value seen for vanadyl sulfate. This data 
therefore show that the slope of the graph and the activity at 45 minutes are similar to that of 
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vanadyl sulfate (Figure 41b) within the margins of error. As discussed previously (Section 1.6), the 
vanadyl can be present in one of three forms in solution: the full complex, a complex with one ligand 
coordinated to the vanadium centre or free vanadyl. There are, therefore, two interpretations for 
this data (Figure 48a). The first is that the complex loses one ligand and the smaller complex is able 
to interact with the enzyme active site thereby providing protection from EDTA. The second is that 
the complex is releasing vanadyl which would give similar data to the VOSO4 assay. In order to try 
and determine by which route the complex is acting, the breakdown of the complex was monitored 
by fluorescence spectroscopy. As for the bridged complexes, the fluorescence is fully restored to 
that of the ligand in the presence of EDTA (Figure 48b). However, when EDTA is added in the 
presence of the enzyme, the fluorescence is not restored to that of the ligand but instead reaches a 
plateau after an initial increase over 5 minutes. It is of interest to note that the fluorescence has an 
initial increase in the presence of the enzyme whether or not EDTA is added to the assay. The 
increase observed with both EDTA and enzyme present is, however, greater than for the enzyme 
alone although it never fully reaches the level of the ligand. This could be due to the fact that the 
complex is not fully broken down and, therefore, a fragment of the complex is being protected by 
the enzyme. The data could also be explained by the ligand interacting with the enzyme and causing 
a quenching effect although this is unlikely as the same effect was not seen for the bridged ligands. 
 
Figure 49: Fluorescence anisotropy of 2.41. Readings were taken using 10 µM of complex in the 
absence (buffer + compound) or presence of LMW-PTP (36 µM) and over 105 minutes of incubation 1 
mM EDTA. Readings were taken in 100 mM Tris buffer solution in a 200 µL fluorescence cuvette. 
Excitation wavelength is 340 nm, emission recorded at 560 nm. The error is shown as the standard 
deviation of 6 readings from two independent experiments. Results were normalised by taking the 
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anisotropy reading in the presence of enzyme and before addition of EDTA (initial anisotropy value) as 
1, with all other readings taken as new anisotropy value/initial anisotropy value. Readings were taken 
in Tris buffer at pH 7.4. 
 
In order to investigate this further the fluorescence anisotropy assay was carried out on complex 
2.41. As for the bridged complex, the anisotropy is highest after addition of the enzyme (Figure 49, 0 
mins) indicating that the complex binds to the enzyme. On addition of EDTA the anisotropy initially 
falls to around 60% of the maximum value after 15 minutes’ incubation. However, as seen in the 
fluorescence assay data in Figure 48b, after the initial drop the fluorescence anisotropy remains at 
roughly the same level and does not return to the baseline level (Figure 49, buffer + compound 
(complex)). This result suggests that a fluorescent species is still interacting with the enzyme after 
105 minutes’ incubation, given that if all interaction was lost, the reading would have returned to 
the baseline. There are two possible explanations for this observation: (1) that the complex is fully 
broken down by the EDTA, but the ligand is still able to interact with the enzyme to cause the 
observed reading; or (2) the complex is broken down into a smaller species, with the vanadyl bound 
to a fluorescent group, that can bind tightly to the enzyme, and therefore, not be fully broken down 
by EDTA in the timeframe of the assays. This is an interesting result as it could lead to the conclusion 
that it is a ‘single ligand’ bidentate complex that is interacting with the enzyme to cause the 
inhibition (Figure 50b) as the initial drop in anisotropy could be explained by the release of one 
ligand leaving the exposed vanadyl to bind more tightly to the enzyme active site. This result also fits 
with the data in Figure 48 which shows that the EDTA only has a significant effect on the complex 
after longer incubation or in the absence of the enzyme. The decomposition of the vanadyl complex 
into a smaller species would also explain how a bulky complex is able to interact so strongly with the 
classical PTPs, which have small active site regions. 
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Figure 50: Schematic representation of the possible binding mode of partially broken down (a) 
complex 2.43b and (b) complex 2.41 to the active site of a generic CBP. 
 
An alternative conclusion could be that the vandyl complexes, whether fully or partially coordinated, 
are interacting with the CBPs at a site distinct from the enzyme active site. This would explain how 
the large complexes are able to interact with and inhibit the CBPs whilst still showing non-
competitive inhibition (Section 3.4).  
 
4.4 Does the enzyme protect against EDTA? 
One question that has arisen from the EDTA effects data for both the bridged and non-bridged 
complexes is whether the enzyme has the ability to protect the vanadyl complexes against EDTA 
when bound. This could explain why enzyme activity is not fully restored even with a large excess of 
EDTA. One way to test this would be to vary the order of addition of EDTA and the complex to the 
assay, to see if this has an effect on the restoration of enzyme activity (for previous discussion see 
Section 4.2.1). If the enzyme has a protecting effect, less activity should be restored when the 
complex is added first (Figure 52b) than if EDTA is added before the complex, as EDTA already 
present in the assay would have a chance to chelate the vanadyl before it can interact with the 
enzyme (Figure 52c). Although this effect was suggested by the results of the previous EDTA assays 
(Figure 40, Figure 41 and Figure 42), it was decided that a direct comparison of results for EDTA 
added before and after the inhibitor would clearly show whether the effect was real or just a factor 
of the different assay setups. 
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Figure 51: Effects of order of addition of vanadyl and EDTA on inhibition. Activity of LMW-PTP (6 nM) 
in the presence or absence of 300 nM (a) 2.41; (b) 2.43a and with: i) no EDTA added; ii) EDTA (1 mM) 
added after the inhibitor or iii) EDTA (1 mM) added before the inhibitor. Each incubation is for 10 
minutes before addition of OMFP (40 µM). Data is shown as a percentage of uninhibited enzyme 
activity. Error bars are the standard deviation of 6 data points over two independent experiments. 
Assays were run in Tris buffer at pH 7.4 
Figure 52: Cartoon to show how order of addition of EDTA and vanadyl to an assay affects vanadyl 
chelation. S represents substrate, P represents product. (a) With no inhibitor or EDTA the enzyme 
activity is at maximum as the enzyme can bind the substrate. (b) Vanadyl is added first and allowed to 
incubate with the enzyme. The enzyme has a protecting effect against EDTA meaning little activity is 
restored and less product is produced. (c) EDTA is added first allowing chelation of vanadyl to occur 
before enzyme interaction. The enzyme cannot protect the vanadyl so near full activity is restored. 
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The data in Figure 51 clearly show that for both the open and bridged complexes, when the EDTA is 
added first the enzyme activity remains at 80-100% whereas when the complex is given time to 
interact with the enzyme before the addition of EDTA only 40-50% activity restoration is seen. This 
would suggest an enzyme-complex interaction which slows the effects of EDTA is occurring if they 
are given time to interact (Figure 52b), whereas when EDTA is added first a mechanism like that 
shown in Figure 52c would occur with the EDTA chelating the vanadyl before it reaches the enzyme. 
This would suggest that the enzyme is ‘shielding’ the vanadyl complexes from the effects of EDTA. 
When allowed time to interact as over the 10-minute incubation period, only around a third of the 
inhibited activity is restored (Figure 51). This fits with the previous data seen for these compounds 
(Figure 41, Figure 42 and Figure 48), as after 10 minutes’ incubation with EDTA in the kinetics studies 
around 30% activity was restored which is consistent with the results seen in Figure 51. This is also 
consistent with the fact that in all of the previous EDTA assays, when the inhibitor was added before 
EDTA the enzyme activity did not return to 100% in the timescale of the experiments, suggesting 
some protection of the complex on interacting with the enzyme. 
 
4.5 Conclusions on complex stability 
The aim of the work presented in this section was to determine the stability of the metal complexes 
under assay conditions, therefore showing whether the inhibition of the CBPs observed was due to 
the complexes interacting with the enzyme or merely releasing vanadyl. Through the evidence of 
enzyme activity and fluorescence based assays it can be concluded that the bridged complexes 2.43a 
and 2.43b do not break down to release vanadyl when interacting with the enzyme. The data 
comparing the effects of EDTA on free vanadyl and the complexes showed differences between the 
two vanadyl species (Figure 41, Figure 42), although other factors such as external error should be 
considered when assessing the data. The observation that the EDTA affected the fluorescence 
intensity of the complexes whereas the enzyme showed a minimal effect (Figure 44) could also 
indicate that the complex is stable. In addition, fluorescence anisotropy data confirmed the 
interaction of the fluorescent complex with the enzyme, shown by an increase in anisotropy reading 
when enzyme was present and a decrease back to the enzyme free control on incubation with EDTA 
(Figure 46 and Figure 47), strongly supporting the hypothesis that the complexes are interacting with 
the CBPs. A summary of the results of the fluorescence-based experiments is given in Table 7. 
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Table 7: Summary of results from fluorescence assays to investigate the stability of vanadyl complexes 
in the presence of PTPs.  
Compound 
Technique 
Fluorescence 
effects with 
enzyme 
Fluorescence 
effects with 
EDTA 
Fluorescence 
anisotropy 
Fluorescence 
anisotropy +EDTA 
2.43a 
 
 
 
In absence of 
EDTA 
fluorescence 
remained below 
that of the 
ligand. 
(Figure 44a) 
EDTA returned 
fluorescence 
to that of free 
ligand. 
(Figure 44a) 
Increased on addition 
of enzyme. 
(Figure 47) 
Decreased back to 
baseline (complex in 
buffer) on incubation 
with EDTA for 100 
min. 
(Figure 47) 
2.43b 
 
In absence of 
EDTA 
fluorescence 
remained below 
that of the 
ligand. 
(Figure 44b) 
EDTA returned 
fluorescence 
to that of 
ligand. 
(Figure 44b) 
Increased on addition 
of enzyme. 
(Figure 46) 
Decreased back to 
baseline on incubation 
with EDTA for 105 
min. 
(Figure 46) 
2.41 
 
In absence and 
presence of 
EDTA 
fluorescence 
remained below 
that of the 
ligand. 
(Figure 48b) 
EDTA returned 
fluorescence 
to that of 
ligand. 
(Figure 48b) 
Increased on addition 
of enzyme. 
(Figure 49) 
Decreased slightly on 
incubation with EDTA 
but never reached 
baseline. 
(Figure 49) 
 
The data summarised in Table 7 confirm the utility of these compounds, not only as CBP inhibitors, 
but also as potential fluorescent probes for CBPs as the fluorescent functionality has been shown to 
interact strongly with the enzymes. It should, however, be considered that, although the data imply 
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that the complexes are acting as a whole to inhibit the enzymes, it is unlikely that they can do so by 
entering the enzyme active site due to the narrow openings of the active site pockets of LMW-PTP, 
VHR (Figure 20), SHP2 and PTP1B. One possible conclusion is that there are larger allosteric sites 
available for binding the complexes on the CBPs, as discussed in Section 1.4.2. There is previous 
evidence to suggest that secondary binding sites are available on CBPs which, in some cases, are able 
to accommodate larger molecules than those that could fit in the active site9,60,157. There may, 
therefore, be allosteric sites on the enzymes studied that are able to accommodate either the whole 
or partially coordinated complexes. More extensive studies of the interactions of the complexes with 
the CBPs would need to be carried out in order to investigate this hypothesis. A second possibility is 
that the complexes are partially broken down under the assay conditions leaving a complex where 
only one of the two picolinate groups is coordinated to vanadyl when interacting with the enzyme 
(Figure 50). In the case of complexes 2.43a and 2.43b this would mean that the ligand is acting as a 
bidentate rather than a tetradentate ligand, whereas for 2.41 only a single ligand would be attached 
to the vanadyl core. Speciation of vanadyl complexes in aqueous solutions has been reported, with 
the free vanadyl, single ligand complex (VOL) or two ligand complex (VOL2) all being available in 
solution depending on pH and conditions101 (Section 1.6). This speciation has also been reported 
when investigating the effects of biologically relevant compounds such as citric acid and lactic acid97. 
Considering the effects of conditions and available coordinating species in solution, the speciation 
and stability of these complexes inside cells should be investigated when looking at cell based 
studies.  
 
4.6 Cell uptake studies 
Having shown that the fluorescent vanadyl complexes act as inhibitors of the CBPs, the next step 
was to determine their utility as chemical probes for cellular imaging. Preliminary work was carried 
out by Dr Agostino Cilibrizzi and Marina Fedorova in which the ability of the bridged complex 2.43a 
to enter live cells was investigated. Cells were incubated with increasing amounts of 2.43a and 
fluorescence microscopy was carried out to establish cellular uptake and localisation (Figure 53). 
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Figure 53: Fluorescence microscopy images showing uptake of 2.43a (green) by NIH3T3. Cells were 
incubated for 24 hours in media containing 1 μM, 5 μM or 10 μM of complex 2.43a and fixed with PFA 
prior to imaging. To provide a better perception of the nuclear and perinuclear localisation of 2.43a, 
three representative images, along with the merge channel images, are shown for each concentration 
of compound. 
 
The images show that, at all concentrations, the fluorescent complex is taken up into cells. Under 
the conditions used, the complex is localised throughout the cell. The probe does, however, seem to 
be more concentrated in perinuclear regions in some cell images. This could be explained by the fact 
that certain CBPs such as PTEN and VHR are known to localise in these regions158,159, and therefore, it 
is possible that the complex is interacting with these CBPs. Although the data does suggest that the 
complex is interacting with the desired enzymes, it must also be considered that the cellular 
localisation could be due to interaction with other proteins in the cell. From these images it can 
therefore be concluded that the complex 2.43a can be taken up into cells and visualised using 
fluorescence microscopy. These data, along with the evidence that it is a fluorescent vanadyl 
complex that interacts with the enzymes, show that these complexes have the potential to be used 
as intracellular probes for CBPs. 
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Chapter 5: Summary, Conclusions and Further Work 
5.1 Summary and conclusions 
The aim of this PhD research was the design and synthesis of a novel CBP targeted probe based on a 
known inhibitor of PTEN, a 3-hydroxypicolinic acid vanadyl complex. The ligand would be modified to 
incorporate a fluorescent tag before vanadyl complex formation to allow detection of the inhibitor 
bound to CBPs. 
In this work, the synthesis, characterisation and biological testing of a selection of vanadyl 
complexes has been carried out. Each of the complexes made has been fully characterised by 
spectroscopic and analytical methods, although in the case of the bridged complexes the possibility 
of polymeric species being present could not be excluded. All complexes were tested against a 
selection of CBPs to investigate the effects of varying structure and functional groups on the efficacy 
and selectivity of the compounds. It has been shown that the complexes act via a non-competitive 
mechanism to inhibit the CBPs and that they are stable under the conditions used for the assays 
(Table 8). 
 
Table 8: Summary of results obtained for complexes of interest. 
Complex Characterisation 
(Section 2.4, Table 3) 
Biological Data 
(Section 3) 
Stability Experiments  
(Section 4) 
2.39 EA, ES-MS, IR (Figure 
A9), UV-vis 
IC50: 40-200 nM (Figure 
33, Figure 34) 
No data  
2.41 EA, ES-MS, IR (Figure 
A10), UV-vis 
IC50: 60-300 nM (Figure 
33, Table 4) 
Non-competitive (Figure 
38, Table 5) 
EDTA effects (Figure 48) 
Fluorescence Intensity (Figure 48) 
Fluorescence Anisotropy (Figure 
49) 
2.43a EA, MALDI-MS, IR 
(Figure A11), UV-vis 
IC50: 60-400 nM (Figure 
33, Table 4) 
EDTA effects (Figure 41 and 
Figure 42) 
Fluorescence Intensity (Figure 44) 
Fluorescence Anisotropy (Figure 
47) 
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Complex Characterisation 
(Section 2.4, Table 3) 
Biological Data 
(Section 3) 
Stability Experiments  
(Section 4) 
2.43b EA, MALDI-MS, IR 
(Figure A12), UV-vis 
IC50: 80-400 nM (Figure 
33, Table 4) 
Fluorescence Intensity (Figure 44) 
Fluorescence Anisotropy (Figure 
46) 
VOSO4 No characterisation. IC50: 70-150 nM (Table 
4) 
Non-competitive (Figure 
38, Table 5) 
EDTA – comparison to whole 
complexes (Figure 41 and Figure 
42) 
2.44 EA, MALDI-MS, IR 
(Figure A13), UV-vis  
IC50: 700-2000 nM 
(Figure 39) 
No data 
 
 
All of the complexes have been shown to inhibit PTEN to varying degrees, with complex 2.39 being 
more active than the fluorescent complexes (Figure 33). This suggests that the position of the 
hydroxy group on the picolinic ring is important for interaction with this enzyme as the 3-hydroxy 
complex is more effective than the 5-hydroxy complex. The complexes have also been shown to 
inhibit a selection of CBPs in the nanomolar range (Table 8). No clear enzyme specificity was shown 
by the complexes and although variation was seen in the IC50 results between certain enzymes, this 
could be due to small differences in assay conditions as well as enzyme preference (Section 3, Table 
4). The incorporation of the inhibitor fragment (2.39) has also shown that greater affinity for the 
CBPs can be obtained by the introduction of targeted motifs (Figure 34) as this compound inhibited 
the PTPs in the nanomolar range whereas the parent compound (1.2) was selective for certain 
enzymes95. 
The mechanism of inhibition of complex 2.43a against LMW-PTP has also been determined (Table 8, 
Figure 38) and the complex was shown to inhibit non-competitively, which is unexpected as 
vanadium compounds normally show a mixed or competitive mode of inhibition75,83,89. This could be 
due to the structure of the complex or the mode of interaction with the enzyme as if the complex 
does not interact with the enzyme active site to cause inhibition then it would be expected that the 
inhibition would be non-competitive with the substrate. It is also possible that there is a mixed-
mode of inhibition but due to the low range of inhibitor concentrations used and inconsistent results 
at higher concentrations (Section 3, Table 5) this could not be clearly seen. 
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Comparison of the IC50 values obtained for the complexes and vanadyl sulfate showed that the 
values are similar for some enzymes. This led to the question of whether these complexes are acting 
as a whole to inhibit the CBPs or merely to deliver vanadium to the enzyme active site. The latter 
mechanism has been proposed in literature73,105, and biochemical studies of vanadium compounds in 
biological media have indicated that ligand-free vanadium interacts with the CBPs to cause 
inhibition96 rather than the complexes. On comparing the effects of EDTA on the inhibition of CBPs 
by the fluorescent complexes and vanadyl sulfate, differences in the results could be seen, especially 
for the bridged complexes 2.43a and b (Figure 41 and Figure 42). This suggested that the enzymes 
were interacting differently with the complexes compared to the free vanadyl but the results did not 
clearly show stability of the complex. Fluorescence assays suggested that the complexes were stable 
in the presence of the enzyme. When the fluorescent complexes were incubated with EDTA the 
fluorescence of the solutions was seen to increase back to that of the ligand showing breakdown of 
the complex. This effect was not, however, seen in the presence of LMW-PTP (Figure 44 and Table 
8), suggesting that the vanadyl remains at least partially coordinated to the ligand in the presence of 
CBPs. This conclusion was confirmed by the fluorescence anisotropy results which showed clearly 
that the fluorophore only bound to the enzymes in the presence of vanadyl, seen as a significant 
increase in the anisotropy reading for the fluorescent complexes on addition of the enzyme (Figure 
46 and Figure 47) which was not seen for the ligand alone. Also, on addition of EDTA, the 
fluorescence anisotropy reading dropped back to that recorded in the absence of enzyme which was 
likely due to chelation of the vanadyl preventing binding of the fluorophore to the enzyme (Figure 46 
and Figure 47). Figure 54 shows how binding of the complexes to the enzyme and addition of EDTA 
to the solution affect the fluorescence anisotropy readings. 
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Figure 54: Cartoon to demonstrate the fluorescence anisotropy experiments. Effects of the presence of 
enzyme and EDTA (shown in blue) on the fluorescence anisotropy of vanadyl complexes (green circle = 
ligand). (a) In the absence of enzyme, the complex rotates rapidly in solution so fluorescence 
anisotropy is low; (b) on binding to the enzyme, rotation is slowed and the fluorescence anisotropy is 
increased; (c) EDTA chelates vanadyl and prevents binding to the enzyme. Ligand is free in solution 
increasing rotation speed and lowering fluorescence anisotropy. Enzyme structure is of PTEN created 
in PyMol from pdb file 10.2210/pdb1d5r/pdb  
 
In addition to the vanadyl complexes, a platinum(II) complex using the fluorescent ligand 2.34a was 
synthesised and preliminary tests carried out against a selection of CBPs. Due to the low solubility 
and strong colour of the complex, the concentrations that could be used in the assays were limited. 
The results showed that the platinum(II) complex had a ten-fold lower affinity for the CBPs 
compared to the equivalent vanadyl complex (Figure 39). As discussed in Section 3.5, this could be 
due to the difference in coordination geometry of the vanadyl complexes and the platinum complex. 
In Chapter 4, the possibility was also discussed that the vanadyl complexes could be acting as ‘half’ 
complexes. If the platinum(II) complexes could not similarly lose a ligand, the full complex could be 
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unable to interact with the enzyme in the same way as the vanadyl complexes and would therefore 
show the change in inhibition properties. 
For all of the dansyl complexes synthesised, two effects on the fluorescence intensity of the dansyl 
group have been noted: (1) on forming either a vanadyl or a platinum complex the fluorescence 
intensity of the ligand is decreased (Figure 29); and (2) in aqueous solution the emission intensity of 
the ligands and complexes is decreased (Figure 30). The first observation is likely due to the 
interaction of the metal centres with the fluorophore leading to quenching. It is known that 
quenching of the dansyl fluorophore by transition metals can occur by either energy or electron 
transfer processes depending on the nature of the metal and the complex129,130. Platinum(II) has also 
been shown to quench the fluorescence of dansyl but this was to a much lesser extent than in the 
corresponding platinum(IV) complex160. It is also known that the dansyl fluorophore is sensitive to 
pH and solvent polarity with, for example, a much lower quantum yield being observed in water 
than in hydrocarbon solvents which would likely explain the second observation131. 
Preliminary cell uptake studies carried out on the 2.43a (Figure 53) showed that the complex could 
be taken up into cells and was localised at the perinuclear regions of the cell. These results also 
confirmed that the complexes could be visualised by fluorescence microscopy in the cellular 
environment at concentrations down to 1 µM, showing their utility as intracellular probes for the 
CBPs. 
 
5.2 Further work 
One interesting observation from this work is the loss of PTEN selectivity and potency on modifying 
the hydroxypicolinic acid complex. For complex 2.39, the potency of the compound is unaffected but 
the selectivity appears to be lost, whereas, for the fluorescent complexes based on 5-
hydroxypicolinic acid, both the potency and the selectivity are lost. As discussed in Section 3.1, this 
could be due to a change in the structure of the complex affecting its ability to effectively interact 
with the PTEN active site, such as a change in the shape of the vanadyl centre or the loss of 
availability of the OH group on attachment of a new functionality. One way to solve this would be to 
find a route to forming the mixed complexes and thereby have two different ligands coordinated to 
the vanadyl centre. This would allow for the attachment of a functionality on one side of the 
complex whilst maintaining the core structure, and potentially keeping the OH available for 
interaction with the enzyme (Figure 55). 
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In order to achieve this, either conditions would need to be established such that only the desired 
product was isolated, or a reliable method to separate a mixture of complexes would need to be 
developed. One synthetic approach could be to preform one complex and, by changing the pH or 
other conditions, induce a ligand exchange for one of the two bound ligands to form the mixed 
complex. By lowering the pH on addition of the second ligand the equilibrium would be shifted 
towards the single-ligand complex, therefore allowing for coordination of a new ligand. This would 
require careful control of the equivalents of the different ligands as an excess of either could shift 
the equilibrium towards a non-mixed complex. This may need to be adjusted depending on the 
relative binding constants of each ligand for vanadyl. Potential methods for purification of vanadyl 
complexes were also researched, but none of the reported methods used complexes similar in 
structure to the picolinic acid complexes161–163, and under all chromatography conditions trialled the 
complexes were found to be unstable. 
Figure 55: Structure of a mixed ligand fluorescent complex as a proposed structure for a more 
selective PTEN probe. 
 
Another interesting result was the selectivity of complex 2.39 for the DSPs (PTEN and VHR) over the 
classical PTPs (PTP1B, SHP2 and LMW-PTP), a selectivity that is not seen for the fluorescent 
complexes. This could be explained by the fact that the OH group has not been moved, and this 
allows for interactions that can take place between residues in certain enzymes and the oxygen at 
the three position of the pyridine ring. In order to determine if it is the fluorescent functionality or 
the position of the OH group that is affecting the inhibition, a fluorescent 3-hydroxypicolinic acid 
complex would need to be synthesised. Synthesis of the ligand was reported in this work, but the 
yield and purity of the complex were not sufficient to attempt biological characterisation (Section 
2.4.1). Since the initial attempts to form this complex, conditions have been optimised to remove 
impurities caused by undissolved starting materials. Both the ligand and the vanadyl are in solution 
before mixing such that any precipitate present in the reaction should be the desired complex. More 
thorough drying of the complex before characterisation would also provide more accurate analysis 
of the product formed. Successful synthesis of the fluorescent complex 2.40 (Section 2.4.1) would 
allow comparison of the patterns of selectivity between this complex (2.40, Section 2.4.1) and the 5-
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hydroxy complex 2.41 to see if the position of the hydroxyl group on the picolinic ring affects the 
inhibition properties of the vanadyl complexes. The compounds could also be tested against a larger 
selection of DSPs to determine if the affinity is for this whole class of phosphatases or merely a small 
selection. 
Chapter 4 discussed a selection of methods that was used to investigate the stability of the vanadyl 
complexes in the presence of the CBPs and under assay conditions. The methods used are 
summarised in Table 7 and Table 8 for each complex. One way to look directly at the affinity of the 
ligand for vanadyl in aqueous solution would be to determine the binding constant of the new 
ligands for vanadium. There is literature discussing pH potentiometric methods for looking at 
stability and speciation of picolinic complexes 1.1 and 1.2 (see Section 1.6) using VOSO4 as the 
vanadyl source97,101. However, the ligands for this experiment were commercially available, 
therefore, large quantities were available for protocol optimisation and Kd determination which is 
not the case for the ligands synthesised in this work. There is also the problem of solubility, with the 
ligands being poorly soluble in aqueous solvents and the complexes readily precipitating out of 
solution under reaction conditions, making it harder to obtain the data. Determination of Kd for the 
bridged complexes would therefore require more extensive studies in order to find the optimal 
conditions to carry this out. Other analytical techniques such as EPR and crystal structure 
determination could also be used to characterise the vanadyl complexes however the problems of 
poor solubility and low amounts of complex formed have meant that these could not be utilised in 
this work. 
In relation to the structural studies, it would also be of interest to investigate how the vanadyl 
complexes bind to the phosphatases and if they interact with the active site or elsewhere. X-ray 
crystallographic studies of the enzyme bound to the vanadyl complexes could be used to determine 
the exact mode of binding and would also show whether the complex binds as a whole, is partially 
coordinated or releases the vanadyl to the enzyme. Such studies have been carried out with the 
bis(maltolato)oxovanadium complex and the resulting crystal structure indicated that vanadium 
released from the complex was interacting with the enzyme active site73.   
As mentioned above, the change in metallic centre from vanadyl to platinum had a pronounced 
effect on the ability of the complex to inhibit CBPs. It would therefore be of interest to synthesise 
complexes with a range of different metallic centres that would show a variety of structural features. 
A number of 3-hydroxypicolinic acid-metal complexes have been reported with different 
coordination geometries (Figure 56). Unlike vanadyl, none of the reported metals have a 
coordinated oxygen and so all octahedral metal complexes have water filling two coordination sites 
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(Co2+, Fe2+, Zn2+ and Mn2+). The Cu2+ complex has only the picolinate ligands coordinated128 giving a 
structure closer to that of the platinum complex (Figure 56b). As these metals are known to 
coordinate picolinate ligands, a small selection of fluorescent metal complexes could be synthesised 
to investigate further the effects of changing the metal on physical properties such as complex 
fluorescence and stability. For each of the metals mentioned the protocol for complex formation is 
similar to that of vanadyl and so initially similar conditions would be trialled as reported in Chapter 
6, although optimisation of pH and order of reagent addition may be needed. These complexes 
could also be tested against the CBPs to look at the effects of changing the properties of the metal 
centre and the structure of the complexes on the inhibition properties. This would provide a picture 
of which metals impart good potency and selectivity as CBP inhibitors when bound to the picolinate 
ligands. 
Figure 56: Structures of picolinic acid complexes of (a) Co2+ (distorted octahedral), (b) Cu2+ (square 
planar), and (c) Zn2+ (octahedral). 
 
It would also be of interest to look at the effects of changing from a vanadyl complex to 
bisperoxovandium. There are literature protocols available for the synthesis of bisperoxovanadium 
picolinic acid complexes164, and therefore, these conditions could be replicated for formation of 
fluorescent bpV compounds. Being a vanadium(V) compound, the bisperoxo complex would likely 
behave differently to the vanadyl complexes, and could give an indication of the importance of 
vanadium oxidation state on CBP inhibition properties, as well as simply the presence of a vanadium 
core. The bisperoxo complexes would also resemble the bis-coordinated complexes proposed to be 
inhibiting the enzymes (Figure 50 and Figure 57) and could therefore be useful for structure-activity 
analysis, looking at the effects of having only one ligand coordinated to vanadium. It should also be 
noted that the inhibition by the bisperoxovanadium complex is unaffected by EDTA, unlike the effect 
seen for the vanadyl complexes81. These complexes could be used to gain positive controls for the 
experiments such as effects of EDTA on inhibition of enzymes as, unlike for vanadyl, no effect on CBP 
inhibition should be observed when adding EDTA to bisperoxovandium compounds. It should, 
however, be considered that the potency of the inhibition by these compounds and the lack of EDTA 
susceptibility could be due to oxidation of the enzyme, as discussed in Section 1.5. It has been shown 
119 
 
that, on oxidation of the catalytic cysteine, these complexes break down into ligand, water and 
orthovanadate80,82, meaning the ligands would no longer be associated with the vanadium and 
therefore the enzyme. This potential mechanism could be investigated using fluorescence 
anisotropy as if the complex is broken down on oxidising the enzyme then the fluorophore would 
not be interacting with the enzyme and no increase in anisotropy reading would be seen. This could 
give some insight into the different mechanisms of inhibition on changing the oxidation state of 
vanadium. 
 
Figure 57: Structure of dansyl labelled bisperoxovanadium picolinic acid complex. 
 
In addition to the assay based work, it was also shown that the complexes could be taken up into 
cells using cell uptake and fluorescence microscopy. To further develop these cell-uptake studies 
there are three key developments that could be made. The first would be to look at comparing the 
uptake of the complex to the free ligand. It would be expected that, under the assay conditions, the 
carboxylic acids in the ligand would be deprotonated giving a doubly-charged molecule which would 
not be able to cross the cell membrane, unlike the complex which is neutral due to coordination of 
vanadyl. If this is the case, images to compare uptake of ligand and complex could be used to show 
that the complex is taken into the cell as a whole. The second development would be to look at co-
localisation studies to determine whether the complex binds to CBPs in a cellular environment. 
Changing the fluorophore could also help with these studies as the intracellular fluorescence of the 
dansyl is relatively weak and therefore hard to detect by fluorescence microscopy. The localisation 
information would be important when considering the utility of these compounds as targeted and 
potentially selective probes of CBPs at an intracellular level. Once this has been established, the 
effects on the cells could be investigated to find out if any cellular pathways are affected and if the 
compounds have any cytotoxic effects.  
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Chapter 6: Synthesis Experimental Section 
 
6.1 General Experimental and Materials 
Chemicals were sourced from Sigma Aldrich, Apollo Scientific, VWR, Fischer Scientific and Acros 
Organics. Anhydrous solvents were sourced from Acros Organic. NMR, IR and UV-vis was run on site. 
IR spectra were recorded on a Perkin Elmer FT–IR1720 Research Series spectrometer in the range 
4000-600 cm-1. Electrospray (ESI+) mass spectrometry was run at on a Waters Aquity UPLC I-CLASS 
coupled with Waters LCT Premier (operating in ES+ or ES- mode). MALDI analyses were performed 
using MicroMass MALDI microMX TOF operating in reflectron mode using a 337nm nitrogen laser. 
NMR spectra were recorded on a Bruker spectrometer with d6-DMSO (δH = 2.50 ppm, δC = 39.5 
ppm), CD3OD (δH = 3.31 ppm, δC = 49.2 ppm) and CDCl3 (δH = 7.26 ppm, δC = 77.2 ppm) as internal 
references. Fluorescence data was collected using a Varian fluorescence spectrometer. MS was 
kindly run by Dr Lisa Haigh at Imperial College. Elemental analysis was run at University of 
Cambridge.  
3-hydroxypicolinic acid methyl ester (2.1) and 5-hydroxypicolinic acid methyl ester (2.18) were 
synthesised according to a literature procedure118. N-(2-hydroxyphenyl)salicylaldimine was 
synthesised according to a literature procedure125.  
 
6.2 Synthesis of organic ligands 
Synthesis of 3-(4-phenylphenol)oxy-2-pyridine carboxylic acid methyl ester 2.3. In an oven-dried 
round bottom flask under nitrogen, to a solution of 3-hydroxy-2-pyridine carboxylic acid methyl 
ester (400 mg, 2.61 mmol), triphenylphosphine (1.371 g, 5.23 mmol) and 4-phenylphenol (772.3 mg, 
3.92 mmol) in anhydrous THF (19 mL) was added dropwise a solution of diethyl azodicarboxylate 
(0.82 mL, 5.23 mmol) in anhydrous THF (2 mL). The reaction was stirred over night at room 
temperature. The reaction was monitored by TLC (60% EtOAc/Hexane, Rf = 0.32) and upon full 
conversion of the starting material the solvent was removed under reduced pressure to yield the 
crude product as an orange oil. The product was purified by column chromatography (60% 
EtOAc/Hexane) to yield the desired compound as a pale yellow oil (325 mg, 1.02 mmol, 39%). 1H 
NMR (400 MHz, CDCl3): δ(ppm) 8.23 (dd, 3J = 4.2 Hz, 4J = 1.5 Hz, 1H, ArH), 7.24-7.58 (m, 11H, ArH), 
5.19 (s, 2H, CH2), 4.01 (s, 3H, CH3). 
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Synthesis of 3-(4-phenylphenol)oxy-2-pyridine carboxylic acid 2.4. A solution of 3-(4-
phenylphenol)oxy-2-pyridine carboxylic acid methyl ester 2.3 (325 mg, 1.02 mmol) in THF/MeOH 
(3:8, 3.7 mL:1.4 mL) was cooled to 0 °C and 6M NaOH (1.42 mL, 1.4 mmol) was added dropwise over 
5 minutes. The reaction was warmed to room temperature and stirred for 3 hours after which the 
solvent was removed under reduced pressure and the resulting residue diluted with H2O (10 mL). 
The aqueous layer was extracted with EtOAc (2 × 10 mL) and the organic layer set aside. The 
aqueous layer was cooled on ice and acidified to pH 3 with 6M HCl. After warming to room 
temperature the aqueous layer was further extracted with EtOAc (3 × 15 mL). The second organic 
extracts were dried over Na2SO4 and the solvent removed by rotary evaporation to yield the product 
as a yellow oil. Dissolving in CH2Cl2 and evaporating the solvent in air overnight yielded the desired 
product 2.4 as a white solid. (115.4 mg, 0.38 mmol, 37%). 1H NMR (400 MHz, d6-DMSO): δ(ppm) 
12.04 (bs, 1H, OH), 8.17 (dd, 3J = 4.6 Hz, 4J = 1.2 Hz, 1H, ArH), 7.69 (m, 5H, ArH), 7.43-7.58 (m, 5H, 
ArH), 7.38, (m, 1H, ArH), 5.29 (s, 2H, CH2). 
Synthesis of 1-THP triethylene glycol 2.7. To a mixture of triethylene glycol (0.96 mL, 7.2 mmol) and 
3,4-dihydropyran (0.16 mL, 1.8 mmol) was added conc. HCl (1 drop) and the reaction stirred at room 
temperature for 15 hours. The reaction was quenched with 20% saturated NaHCO3 (4 mL) and 
extracted with EtOAc (2 mL per extraction) until all di-THP impurity was removed (monitored by TLC, 
60% EtOAC/Hexane, KMnO4 visualisation). The aqueous layer was then saturated with NaCl and 
extracted with CH2Cl2 (4 × 2 mL). The combined CH2Cl2 layers were extracted with H2O (5 × 8 mL), 
dried over anhydrous Na2SO4 and the solvent removed in vacuo to yield the desired compound 2.7 
as a clear oil (28.1 mg, 0.12 mmol, 2%). 1H NMR (400 MHz, CDCl3): δ(ppm) 4.63 (m, 1H, CH) 3.87 (m, 
2H, CH2), 3.74 (m, 2H, CH2), 3.68, (m, 6H, CH2), 3.62 (m, 4H, CH2), 3.50 (m, 1H, OH), 1.63 (m, 6H, 
cyclohexyl-H). 
Attempted synthesis of 1-THP-10-(3-hydroxypyridine-2-carboxylic acid methyl ester)-triethylene 
glycol 2.8. In an oven-dried round bottom flask under nitrogen, to a solution of 3-hydroxypyridine-2-
carboxylic acid methyl ester (300 mg, 1.96 mmol), triphenylphosphine (1027 mg, 3.9 mmol) and 1-
THP triethylene glycol 2.7 (688 mg, 2.94 mmol)  in anhydrous THF (14 mL) (on ice) was added 
dropwise a solution of diethyl azodicarboxylate (0.6 mL, 3.9 mmol) in anhydrous THF (1.5 mL). The 
reaction was stirred over night at room temperature. The reaction was monitored by TLC (70% 
EtOAc/Hexane) and upon full conversion of the starting material the solvent was removed under 
reduced pressure to yield the crude product as an orange oil. LCMS indicated the desired compound 
2.8 was present. LCMS (ES+) 154 ([SM+H]+), 370 ([M+H]+). Column chromatography was carried out 
(60% EtOAc/Hexane) but due to the large number of by-products none of the desired product was 
isolated. 
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Synthesis of 3-(N-boc propanolamine)-2-pyridine carboxylic acid methyl ester 2.10. In an oven-
dried round bottom flask under nitrogen, a solution of 3-hydroxypyridine-2-carboxylic acid methyl 
ester (1.3 g, 8.5 mmol), triphenylphosphine (4.45 g, 17 mmol) and N-Boc-propanolamine (2.94 g mL, 
17 mmol) in anhydrous THF (65 mL) was cooled on ice. To the resulting solution was added dropwise 
a solution of diethyl azodicarboxylate (2.7 mL, 17 mmol) in anhydrous THF (3 mL). The reaction was 
stirred over night at room temperature and the reaction was monitored by TLC (65% 
EtOAc/Hexane). After 24 hours the solvent was removed under reduced pressure to yield the crude 
product 2.10 as a pale orange oil. Isolera column chromatography (100% Hexane-100% EtOAc) gave 
the desired product 2.10 as a mixed sample with OPPh3. NMR integration was used to calculate the 
amount of product isolated. (1.03 g, 3.33 mmol, 40%). 1H NMR (400 MHz, CDCl3) The following 
spectroscopic data corresponds to the signals associated to 2.10: δ(ppm) 8.30 (dd, 3J = 4.5 Hz, 4J = 
1.3 Hz, 1H, ArH), 7.32-7.42 (m, 2H, ArH), 4.14 (t, 3J = 5.67 Hz, 2H, CH2), 3.99 (s, 3H, CH3), 3.39 (t, 3J = 
Hz, 2H, CH2), 2.06 (m, 2H, CH2), 1.44 (s, 9H, (CH3)3). Signals corresponding to triphenylphosphine 
oxide are found as a multiplet between 7.40 and 7.75 ppm. 
Synthesis of 3-(N-boc propanolamine)-2-pyridine carboxylic acid 2.11. To a solution of 3-(N-boc 
propanolamine)-2-pyridine carboxylic acid methyl ester 2.10 (403 mg, 1.3 mmol) in THF:MeOH 
(1.4:0.6 mL) cooled on ice was added 6M NaOH (0.3 mL, 1.82 mmol). The reaction was warmed to 
room temperature and stirred for 3 hours. The solvent was removed by rotary evaporation to give a 
yellow oil and white solid which was diluted with water (2 mL) and extracted with EtOAc (2 × 5 mL). 
The organic layer was set aside and the aqueous layer acidified to pH 6 with 2M HCl. This was then 
extracted with EtOAc (3 × 6 mL). The aqueous layer was further acidified to pH 3 with 2M HCl and re-
extracted with EtOAc (3 × 6 mL). The second and third organic layers were combined, dried over 
MgSO4 and the solvent removed by rotary evaporation to give the desired product 2.11 as a pale 
yellow oil. 1H NMR (400 MHz, d6-DMSO): δ(ppm) 8.14 (dd, 3J = 4.5 Hz, 4J = 1.1 Hz, 1H, ArH), 7.58 (dd, 
3J = 8.5 Hz, 4J = 1.2 Hz,  1H, ArH), 7.47 (dd, 3J = 8.5 Hz, 4.6 Hz, 1H, ArH), 4.02 (t, 3J = 6.2 Hz, 2H, CH2), 
3.08 (q, 3J = 6.6 Hz, 2H, CH2), 1.82 (m, 2H, CH2), 1.36 (s, 1H, C(CH3)3). 
Synthesis of 3-(propanolamine)-2-pyridine carboxylic acid 2.12. To a solution of 3-(N-boc 
propanolamine)-2-pyridine carboxylic acid 2.11 (363 mg) in CH2Cl2 (1 mL) was added TFA (1 mL) and 
the reaction stirred at room temperature for 40 minutes. The reaction was diluted with CH2Cl2 and 
the solvent removed by rotary evaporation to give the TFA salt of product 2.12 as an orange oil 
which was at a sufficient purity for the next synthetic step as indicated by 1H NMR spectroscopy. 1H 
NMR (400 MHz, d6-DMSO): δ(ppm) 8.20 (dd, 3J = 4.6 Hz, 4J = 1.2 Hz, 1H, ArH), 7.65 (dd, 3J = 8.7 Hz, 4J 
= 1.2 Hz,  1H, ArH), 7.56 (dd, 3J = 8.6 Hz, 4.5 Hz, 1H, ArH), 4.20 (t, 3J =  5.7 Hz, 2H, CH2), 3.01 (q, 3J = 
6.2 Hz, 2H, CH2), 2.03 (m, 2H, CH2). 
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Synthesis of 3-(propanolamine)-2-pyridine carboxylic acid methyl ester 2.13. To a solution of 3-(N-
boc propanolamine)-2-pyridine carboxylic acid methyl ester 2.10 (105.5 mg, 0.34 mmol) in CH2Cl2 
(0.5 mL) was added TFA (0.5 mL) and the reaction stirred at room temperature for 40 minutes. The 
reaction was allowed to dry in air to give a yellow oil. The reaction was purified by column 
chromatography (80% EtOAc/Hexane then MeOH: CH2Cl2:triethylamine 10:85:5) to give the desired 
product 2.13 as an orange oil. (57 mg, 0.27 mmol, 78% yield). 1H NMR (400 MHz, MeOD): δ(ppm) 
8.24 (dd, 3J = 4.5 Hz, 4J = 1.5 Hz, 1H, ArH), 7.72 (dd, 3J = 8.7 Hz, 4J = 1.3 Hz,  1H, ArH), 7.63 (dd, 3J = 8.6 
Hz, 4.5 Hz, 1H, ArH), 4.32 (t, 3J =  5.6 Hz, 2H, CH2), 3.95 (s, 1H, CH3), 3.19 (t, 3J = 5.6 Hz, 2H, CH2), 2.19 
(m, 2H, CH2). 13C NMR (100 MHz, MeOD): δ(ppm) 166.2 (C), 160.2 (C), 140.7 (CH), 128.3 (C), 121.9 
(CH), 67.7 (CH2), 51.8 (CH3), 38.3 (CH2), 27.0 (CH2). 
Attempted synthesis of 2.15 To a solution of triethylamine (0.07 mL, 0.5 mmol) in MeOH (0.5 mL) 
was added the TFA salt of 3-(propanolamine)-2-pyridine carboxylic acid 2.12 (30 mg, 0.1 mmol) in 
MeOH (0.7 mL) and the solution left to stir for 15 minutes. To the resulting solution was added 
dropwise a solution of NBD-Cl (19 mg, 0.1 mmol) in MeOH (0.8 mL) and the resulting solution stirred 
for 24 hours, monitoring for consumption of NBD-Cl by TLC (20% EtOAc/Hexane). The volume of the 
reaction was then reduced to 0.5 mL, followed by dilution with H2O (0.3 mL) and extraction with 
Et2O. The aqueous layer was then re-extracted with EtOAc (2-3 mL) and the two organic layers set 
aside. The aqueous layer was then acidified (pH 3-4) and extracted with EtOAc (2 × 2 mL). A couple 
of drops of acid were added and the aqueous layer re-extracted with EtOAc. All organic fractions 
were kept separate. TLC analysis (50% EtOAc/Hexane) indicated that fractions 3-5 contained a 
fluorescent compound which was confirmed by LCMS to be the desired product 2.15. The fractions 
were then purified by column chromatography (10 g pre-packed column). The compound was dry-
loaded onto the column and eluted sequentially with 20% MeOH in CHCl3, 30% MeOH in CHCl3 and 
then flushed with Aqueous 1% formic acid: MeOH: CHCl3 10:40:50 to elute the target molecule 2.15. 
(20 mg, 0.05 mmol, 50%).  LC-MS (+) 360 ([M+H)]+. Further characterisation could not be carried out 
as the small quantity of product with a large amount of residual solvent meant NMR signals could 
not be assigned.  
Synthesis of 2.16. To a solution of 3-propanolamine-2-pyridine carboxylic acid methyl ester 2.13 
(338 mg, 1.8 mmol) and dansyl chloride (597 mg, 2.2 mmol) in anhydrous CH3CN (57 mL) was added 
anhydrous triethylamine (0.51 mL, 3.6 mmol) and the reaction stirred at room temperature 
overnight. Solvent was removed by rotary evaporation to give the crude product which was purified 
by column chromatography (80% EtOAc/Hexane-100% EtOAc) to give the desired product 2.16 as a 
yellow/green solid. (333 mg, 0.75 mmol, 41%).  ). 1H NMR (400 MHz, DMSO): δ(ppm) 8.4 (dt, 3J = 8.4 
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Hz, 4J = 1.2 Hz, 1H, ArH), 8.27 (dd, 3J = 8.6 Hz, 4J = 1 Hz, 1H, ArH), 8.11 (dd, 3J = 7.3 Hz, 4J = 1.3 Hz, 2H, 
ArH),  7.96 (t, 3J = 5.6 Hz, 1H), 7.56 (dd, 3J = 8.6 Hz, 7.4 Hz,  2H, ArH), 7.44 (dd, 3J = 8.5 Hz, 4.5 Hz,  2H, 
ArH), 7.34 (dd, 3J = 8.6 Hz, 4J = 1.3 Hz,  2H, ArH), 7.22 (m, 1H, ArH), 3.85 (s, 1H, CH3),  3.85 (t, 3J =  5.8 
Hz, 2H, CH2), 3.71 (s, 3H, CH3), 2.96 (t, 3J = 6.4 Hz, 2H, CH2), 2.81 (6H, s, NCH3), 1.74 (m, 2H, CH2). 
Synthesis of 2.17-methyl protected route. To a solution of dansylated 3-propanolamine-2-pyridine 
carboxylic acid methyl ester 2.16 (333 mg, 0.75 mmol) in THF:MeOH:H2O (6:2.1:2.1 mL) under N2 
was added LiOH (72 mg, 3 mmol) and the reaction stirred overnight. The solvent was removed by 
rotary evaporation and the yellow residue was diluted with H2O and then the pH was lowered to 
approximately 3.5 with 1M HCl. The aqueous layer was extracted with twice CH2Cl2, acidified further 
to pH 2.5 and extracted a further two times with CH2Cl2. The organic layer was dried over Na2SO4 
and the solvent removed by rotary evaporation to give the desired product as a yellow solid (268 
mg, 0.62 mmol, 83%). 1H NMR (400 MHz, MeOD): δ(ppm) 8.40 (d, 3J = 8.5 Hz, 1H, ArH), 8.28 (d, 3J = 
8.6 Hz, 1H, ArH), 8.16-8.06 (m, 2H, ArH),  7.97 (t, 3J = 5.8 Hz, 1H, ArH), 7.56 (dd, 3J = 8.6 Hz, 7.4 Hz, 
2H, ArH), 7.40 (dd, 3J = 8.5 Hz, 4.5 Hz, 1H, ArH), 7.30 (dd, 3J = 8.6 Hz, 4J = 1.3 Hz,  1H, ArH), 7.23 (d, 3J = 
7.5 Hz, 1H, ArH), 3.90 (t, 3J = 6.0 Hz, 2H, CH2), 2.98 (q, 3J = 6.5 Hz, 2H, CH2),  2.81 (6H, s, CH3), 1.74 (p, 
3J = 6.4 Hz, 2H, CH2). ES-MS (+) 430 ([M+H]+). LC-MS (+) 430 ([M+H]+) 452 ([M+Na]+).  Calc. for 
C21H23O5N3S.0.5H2O: C 57.52, H 5.52, N 9.58 Found: C 57.69, H 5.35, N 9.09. (Calc with 0.25 EtOAc : C 
57.38, H 5.69, N 9.12). 
Attempted synthesis of 2.17 via the zwitterion route. To a solution of dansyl chloride (428 mg, 1.38 
mmol) in CH2Cl2 (16 mL) under nitrogen was added a solution of 3-(propanolamine)-2-pyridine 
carboxylic acid 2.12 (447 mg, 1.66 mmol) and triethylamine (1.2 mL, 8.3 mmol) in CH3CN (10.7 mL). 
The solution was stirred for 3 hours after which TLC indicated that a fluorescent compound was 
forming. The reaction was left for a further 1.5 hours, stopped and left under N2. The solvent was 
removed by rotary evaporation and the resulting residue redissolved in MeOH : H2O mix (2 mL: 6 
mL). The aqueous solution was extracted with diethyl ether (3 × 5 mL) then washed with EtOAc (2 × 
2 mL). The aqueous layer was acidified with 2 M HCl to pH 4 and extracted with EtOAc (1 × 6 mL), 
then further acidified to pH 2.5 and extracted with EtOAc (3 × 6 mL). The organic extracts from pH 4 
and pH 2.5 washes were dried separately over Na2SO4 and the solvent removed by rotary 
evaporation to give yellow oils. NMR indicated that both extracts contained product and so they 
were combined. The compound was dissolved in CH2Cl2 and washed with H2O. The CH2Cl2 layer was 
set aside and the aqueous layer extracted with EtOAc (3 times). The EtOAc layers were dried over 
Na2SO4 and the solvent removed by rotary evaporation to give the desired product with a reduced 
amount of triethylamine as a yellow oily solid. The compound was redissolved in H2O, acidified to pH 
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2.5 and extracted with EtOAc (4 x 6 mL) whilst maintaining pH at 2.5 with 2M HCl. The organic 
fractions were dried to give a yellow oil from which the desired product could not be isolated.  
Synthesis of 5-(N-boc propanolamine)-2-pyridine carboxylic acid methyl ester 2.19. In an oven-
dried round bottom flask under nitrogen, to a solution of 5-hydroxypyridine-2-carboxylic acid methyl 
ester (500 mg, 3.3 mmol), triphenylphosphine (1713 mg, 6.5 mmol) and N-Boc-propanolamine (1131 
mg, 6.5 mmol) in anhydrous THF (25.5 mL), cooled on ice, was added dropwise a solution of diethyl 
azodicarboxylate (1.02 mL, 6.5 mmol) in anhydrous THF (1 mL). The reaction was stirred over night 
at room temperature and the reaction was monitored by TLC (100% EtOAc). After 16 hours the 
solvent was removed under reduced pressure to yield the crude product 2.19 as a dark orange oil. 
Column chromatography (70% EtOAc/Hexane-100% EtOAc) gave the desired product as a mixed 
sample with O=PPh3. The following spectroscopic data corresponds to the signals associated to 2.19. 
1H NMR (400 MHz, CDCl3): δ(ppm) 8.36 (d, 4J = 2.9 Hz, 1H, NArH), 8.07 (d, 3J = 8.7 Hz, 2H, ArH), 7.23 
(dd, 3J = 8.8 Hz, 4J = 2.9 Hz,  1H, ArH), 3.95 (s, 3H, CH3), 3.31 (m, 2H, CH2), two of the propanolamine 
signals are obscured by EtOAc. Signals corresponding to triphenylphosphine oxide are found as a 
multiplet between 7.40 and 7.75 ppm. ES-MS (+) 311 ([M+H]+) (50%) ([OPPh3+H]+) (100%). 
Synthesis of 5-(propanolamine)-2-pyridine carboxylic acid methyl ester 2.20. To a solution of 5-(N-
boc propanolamine)-2-pyridine carboxylic acid methyl ester 2.19 (2.4 g, 3.3 mmol) in CH2Cl2 (0.5 mL) 
was added TFA (0.5 mL) and the reaction stirred at room temperature for 1 hour. The reaction was 
allowed to dry in air to give a yellow oil and the crude product was purified by column 
chromatography (100% EtOAc then MeOH: CH2Cl2:triethylamine 10:85:5) to give the desired product 
2.20 as an orange oil (5.12 mg, 1.2 mmol, 36%). 1H NMR (400 MHz, CDCl3): δ(ppm) 8.30 (d, 4J = 2.9 
Hz, 1H, ArH), 8.07 (d, 3J = 8.7 Hz, 2H, ArH), 7.47 (dd, 3J = 8.8 Hz, 4J = 2.9 Hz,  1H, ArH),  4.22 (t, 3J = 5.8 
Hz, 2H, CH2), 3.89 (s, 3H, CH3), 3.09 (t, 3J =  7.2 Hz, 2H, CH2), 2.14 (m, 2H, CH2) ES-MS (+) 211 ([M+H]+) 
(100%). 
Synthesis of 2.21. To a solution of 5-propanolamine-2-pyridine carboxylic acid methyl ester 2.20 
(512 mg, 2.4 mmol)) and dansyl chloride (449 mg, 1.85 mmol) in anhydrous CH3CN (37 mL) was 
added anhydrous triethylamine (0.52 mL, 3.7 mmol) and the reaction stirred at room temperature 
overnight. Solvent was removed by rotary evaporation to give the crude product 2.21 which was 
purified by column chromatography (80% EtOAc/Hexane-100% EtOAc) to give the desired product 
2.21 as a yellow solid (540 mg, 1.3 mmol, 54%) .  1H NMR (400 MHz, MeOD): δ(ppm) 8.34 (dt, 3J = 8.6 
Hz, 4J = 1.1 Hz, 1H, ArH), 8.29(dt, 3J = 8.6 Hz, 4J = 1 Hz, 1H, ArH), 8.17 (dd, 3J = 7.3 Hz, 4J = 1.3 Hz, 1H, 
ArH),  7.92 (m, 2H, ArH), 7.49 (m, 2H, ArH), 7.13 (dd, 3J = 7.6 Hz, 4J = 0.9 Hz, 1H, ArH), 6.97 (dd, 3J = 
126 
 
8.8 Hz, 4J = 2.8 Hz, 1H, ArH), 3.93 (s, 3H, CH3),  3.82 (t, 3J =  5.9 Hz, 2H, CH2), 3.07 (t, 3J = 6.3 Hz, 2H, 
CH2), 2.79 (6H, s, CH3), 1.82 (m, 2H, CH2). ES-MS (+) 444 ([M+H]+) (100%). 
Synthesis of 2.22. To a solution of dansylated 5-propanolamine-2-pyridine carboxylic acid methyl 
ester 2.21 (540 mg, 1.3 mmol) in THF:MeOH:H2O (10:4.2:4.2) under N2 was added LiOH (117 mg, 4.9 
mmol) and the reaction stirred overnight. The solvent was removed by rotary evaporation and the 
yellow residue was diluted with H2O, and then the pH was lowered to approximately 3.5 with 1M 
HCl. The aqueous layer was extracted once with CH2Cl2, acidified further to pH 2.5 and extracted a 
further three times with CH2Cl2. The organic layer was dried over Na2SO4 and the solvent removed by 
rotary evaporation to give the desired product 2.22 as a yellow solid (454 mg, 1.06 mmol, 81%). 1H 
NMR (400 MHz, MeOD): δ(ppm) 8.36 (d, 3J = 8.5 Hz, 1H, ArH), 8.29 (d, 3J = 8.6 Hz, 1H, ArH), 8.16 (d, 3J 
= 7.3 Hz, 1H, ArH),  7.94 (m, 2H, ArH), 7.49 (m, 2H, ArH), 7.14 (d, 3J = 7.6 Hz, 4J = 1.3 Hz,  1H, ArH), 
6.98(dd, 3J = 8.8 Hz, 4J = 2.9 Hz, 1H, ArH), 3.81 (t, 3J = 6.0 Hz, 2H, CH2), 3.07 (t, 3J = 6.4 Hz, 2H, CH2),  
2.80 (6H, s, CH3), 1.82 (m, 2H, CH2). 13C NMR (100 MHz, d6-DMSO): δ(ppm) 165.7 (C), 156.8 (C), 151.3 
(C), 140.3 (CH), 137.7 (CH), 135.6 (C), 129.5 (C), 129.0 (2CH), 128.5 (CH), 127.8 (CH), 126.1 (C), 123.5 
(CH), 120.3 (CH), 118.9 (C), 115.0 (CH), 65.1 (CH2), 45.0 (CH2), 38.9 ((CH3)2), 28.5(CH2). Calc. for 
C21H23O5N3S.0.75H2O: C 56.94, H 5.57, N 9.49 Found: C 57.20, H 5.43, N 8.89. (Calc with 0.25 EtOAc : 
C 57.38, H 5.69, N 9.12). Fluorescence λmax(ex) 340 nm, λmax(em) 534 nm. 
Synthesis of 2.26. To a stirred suspension of N-(2-hydroxyphenyl)salicylaldimine (200 mg, 0.94 
mmol) in MeOH (14 mL) was added a solution of VO(acac)2 (124.4 mg, 0.47 mmol) in MeOH (6 mL). 
The solution became a dark red-brown colour and was left to stir at room temperature for 1 hour. 
The resulting suspension was filtered and the dark solid collected, washed with MeOH and dried 
overnight under vacuum (105 mg, 0.22 mmol, 24%). ESI-MS (+) 474 ([V(L)2+H), IR in cm-1 υ(C=N) 
1597. Anal. Calc. for C26H18N2O4V·0.5 H2O: C 64.74, H 3.97, N 5.81. Found: C 64.77, H 4.02, N 5.82. 
Synthesis of 1,5-(5-hydroxypyridine-2-carboxylic acid methyl ester) pentanediol 2.27. To a solution 
cooled on ice of 5-hydroxypyridine-2-carboxylic acid methyl ester (128 mg, 0.84 mmol), 
triphenylphosphine (438 mg, 1.67 mmol) and 1,5-pentanediol (0.044 mL, 0.42 mmol) in anhydrous 
THF (13.7 mL) was added diethyl azodicarboxylate (0.26 mL, 1.67 mmol) in anhydrous THF (1mL) and 
the reaction warmed to room temperature. The reaction was stirred overnight at room temperature 
after which the solvent was removed by rotary evaporation to give the crude product as a dark red 
oil. LC-MS (+) 375 ([M+H]+), 278 ([OPPh3+H]+), 154 ([SM+H]+). The crude mixture was separated by 
column chromatography (80% EtOAc/Hexane-100% EtOAc) to give the desired product 2.27 as a 
yellow solid (65 mg, 0.17 mmol, 40%). 1H NMR (400 MHz, CDCl3): δ(ppm) 8.39 (d, 4J = 2.8 Hz, 2H, 
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ArH), 8.11 (d, 3J = 8.7 Hz, 2H, ArH), 7.26 (m, 2H, ArH), 4.12 (t, 3J = 6.2 Hz, 2H, CH2), 3.92 (s, 6H, CH3) 
1.93 (m, 2H, CH2), 1.73 (m, 2H, CH2).  
Synthesis of 1,5-(5-hydroxypyridine-2-carboxylic acid) pentanediol 2.28. To a solution cooled on ice 
of compound 2.27 (65 mg, 0.17 mmol) in THF:MeOH (0.26 mL:0.1 mL) was added 6M NaOH (0.82 
mL, 0.48 mmol). The reaction was warmed to room temperature and stirred for 3 hours. The solvent 
was removed by rotary evaporation and the resulting residue diluted with H2O (4 mL) and extracted 
with EtOAc (2 × 5 mL). The aqueous layer was acidified to pH 3 with 6M HCl at which point the 
solution became cloudy. On addition of EtOAc for extraction a white solid formed that was collected 
by pipette filtration and analysis showed this was the desired product 2.28. (54 mg, 0.16 mmol, 
92%). 1H NMR (400 MHz, MeOD): δ(ppm) 8.04 (d, 4J = 2.8 Hz, 2H, ArH), 7.73 (d, 3J = 8.7 Hz, 2H, ArH), 
7.26 (dd, 3J = 8.8 Hz, 4J = 2.9 Hz, 2H, ArH), 4.00 (t, 3J = 6.3 Hz, 2H, CH2), 1.69 (m, 2H, CH2), 1.46 (m, 2H, 
CH2). ES-MS (+) 347 ([M+H]+) (15%). 
Synthesis of 2.31a. To a solution of 5-hydroxypyridine-2-carboxylic acid methyl ester (312 mg, 2.03 
mmol), triphenylphosphine (1068 mg, 4.07 mmol) and N-Boc diethanolamine (209 mg, 1.02 mmol) in 
anhydrous THF (15 mL), stirred on ice under N2, was added diethyl azodicarboxylate (0.64 mL, 4.07 
mmol) in anhydrous THF (1 mL). The resulting reaction mixture was stirred at room temperature for 
3 days. The solvent was removed by rotary evaporation to give the crude product 2.31a as an orange 
oil. The product was purified by silica gel column chromatography (70% EtOAc/Hexane – 3% 
MeOH/EtOAc) to yield a mixture (ca. 1:0.1) of 2.31a and triphenylphosphine oxide. This compound 
was used without further purification for the next step. The following spectroscopic data 
corresponds to the signals associated to 2.31a: 1H NMR (400 MHz, CDCl3): δ(ppm) 8.37 (d, 3J = 2.9 Hz, 
2H, ArH), 8.10 (d, 3J = 8.7 Hz, 2H, ArH), 7.26 (m, 2H, ArH), 4.24 (m, 4H, CH2), 3.98 (s, 6H, CH3),   3.77 
(t, 3J = 5.4 Hz, 4H, CH2), 1.46 (s, 9H, (CH3)3). 13C NMR (100 MHz, CDCl3): δ(ppm) 165.2 (C), 157.4(C), 
155.3 (C), 138.5 (CH), 138.3 (CH), 127.0 (C), 120.4 (CH), 67.4 (CH2), 52.9 (CH3), 48.2 (CH2), 28.6 (CH3). 
Signals corresponding to triphenylphosphine oxide are found as a multiplet between 7.40 and 7.75 
ppm. ES-MS (+) 476 ([M+H]+) (100%). 
Synthesis of 2.32a. To a solution of 2.31a (477 mg, 0.87 mmol) in dichloromethane (1 mL) was 
added TFA (1 mL) and the reaction stirred at room temperature for 1 hour. The solvent was removed 
under reduced pressure and the product purified by silica gel column chromatography (EtOAc then 
MeOH:dichloromethane:triethylamine 10:85:5) to give 2.32a as a pale pink solid. (326 mg, 0.87 
mmol, 100%). 1H NMR (400 MHz, CDCl3): δ(ppm) 8.33 (d, 4J = 2.8 Hz, 2H, ArH), 8.09 (d, 3J = 8.7 Hz, 2H, 
ArH), 7.52 (dd, 3J = 8.8 Hz, 4J = 2.9 Hz, 2H, ArH), 4.35 (t, 3J = 5.0 Hz, 4H, CH2), 3.91 (s, 6H, CH3), 3.36 (t, 
3J = 5.0 Hz, CH2). 13C NMR (100 MHz, MeOD): δ(ppm) 166.2 (C), 159.0 (C), 141.2 (CH), 139.5 (CH), 
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127.9 (C), 122.2 (CH), 67.5 (CH2), 53.0 (CH3), 47.9 (CH2). IR in cm-1 υ(C-H)/υ(N-H) 3059-2955, 
υ(C=N)/υ(C=C) 1735, 1668,1623, 1578, υ(C-O) 1303. LC-MS(+) 377 ([M+H]+) (100%).  
Synthesis of 2.33a. To a solution of 2.32a (100 mg, 0.27 mmol) and dansyl chloride (87 mg, 0.32 
mmol) in anhydrous CH3CN (8.5 mL) was added anhydrous triethylamine (0.08 mL, 0.54 mmol) and 
the reaction stirred at room temperature overnight. The solvent was removed by rotary evaporation 
to give a yellow residue. The crude mixture was purified by silica gel column chromatography (2% 
MeOH in dichloromethane) to give the desired product 2.33a as a yellow/green oil. (83 mg, 0.14 
mmol, 50%). 1H NMR (400 MHz, MeOD): δ(ppm) 8.50 (dt, 3J = 8.6 Hz, 4J = 1.0 Hz, 1H, ArH), 8.24 (dd, 3J 
= 7.3 Hz, 4J = 1.2 Hz, 1H, ArH), 8.21-8.18 (m, 1H, ArH),  8.01-7.90 (m, 4H, ArH), 7.52 (dd, 3J = 8.5, 7.3 
Hz, 1H, ArH) 7.41 (dd, 3J = 8.7, 7.6 Hz, 1H, ArH), 7.19 (dd, 3J = 8.8 Hz, 4J = 2.9 Hz, 2H, ArH), 7.13 (dd, 3J 
= 7.7 Hz, 4J = 0.8 Hz, 1H, ArH), 4.21 (t, 3J =  5.2 Hz, 4H, CH2), 3.91 (m, 10H, CH2, CH3),  2.81 (s, 6H, CH3). 
13C NMR (100 MHz, MeOD): δ(ppm) 166.2 (C), 158.8 (C), 153.2 (C), 140.8 (CH), 139.3 (CH), 136.1 (C), 
131.9 (C), 131.3, 131.2 (CH), 131.1 (CH), 129.2 (CH), 127.7 (C), 124.3 (CH), 121.8 (CH), 120.5 (C), 
116.4 (CH), 68.2 (CH2), 53.0 (CH3), 45.7 (CH2). ESI-MS (+) 609 ([M+H]+). IR in cm-1 υ(C=N)/υ(C=C) 1715, 
1573.  
Synthesis of 2.34a. To a solution of 2.33a (196 mg, 0.32 mmol) in THF:MeOH (0.8:0.3 mL) on ice was 
added 6M NaOH (0.15 mL, 0.90 mmol) and the reaction stirred for 3 hours at room temperature. 
The solvent was removed by rotary evaporation to give a bright yellow solid which was diluted with 
H2O and extracted with EtOAc. The organic layer was set aside and the aqueous layer acidified with 
2M HCl and re-extracted with EtOAc (4 x 10 mL). The organic layers were combined, dried over 
Mg2SO4 and the solvent removed by rotary evaporation to give the desired product 2.34a as a yellow 
solid. (98.5 mg, 0.17 mmol, 53%). 1H NMR (400 MHz, MeOD): δ(ppm) 8.51 (d, 3J = 8.6 Hz, 1H), 8.25 
(d, 3J = 7.4 Hz, 4J = 1.2 Hz, 1H, ArH), 8.20 (d, 3J = 8.7 Hz, 1H, ArH),  8.06-7.92 (m, 4H, ArH), 7.53 (dd, 3J 
= 8.5, 7.3 Hz, 1H, ArH), 7.42 (dd, 3J = 8.7, 7.6 Hz, 1H, ArH), 7.21 (dd, 3J = 8.7 Hz, 4J = 2.9 Hz, 2H, ArH), 
7.13 (d, 3J = 7.5 Hz, 1H, ArH), 4.21 (t, 3J =  5.2 Hz, 4H, CH2), 3.93 (t, 3J =  5.2 Hz, 4H, CH2), 2.83 (s, 6H, 
CH3). 13C NMR (100 MHz, DMSO-d6): δ(ppm) 165.7 (C), 156.5 (C), 151.4 (C), 140.6 (CH), 137.7 (CH), 
134.8 (C), 130.1 (C), 129.4, 129.2 (CH), 128.9 (CH), 128.1 (CH), 126.1 (C), 123.6 (CH), 120.6 (CH), 
118.8 (C), 115.2 (CH), 66.4 (CH2), 46.8 (CH3), 45.0 (CH2). ESI-MS (+) 581 ([M+H]+). IR in cm-1 
υ(C=N)/υ(C=C) 1690, 1573, υ(S=O) 1140. Fluorescence λmax(ex) 358 nm, λmax(em) 538 nm.  
Synthesis of N-boc diethanolamine 2.30b. A solution of 3-amino-1-propanol (6.8 mL, 90.00 mmol) 
and 1-chloro-3-hydroxypropane (3.8 mL, 45.00 mmol) in H2O (21 mL) was stirred at reflux for 19 
hours. The reaction was removed from the heat and KOH (2.5g) was added. The solvent was 
removed by rotary evaporation to give a yellow oil and white solid which were washed with 
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dichloromethane, filtered and the solid residue washed with acetone. The filtrate was dried over 
Na2SO4 and the solvent removed by rotary evaporation to give a yellow brown oil. To a solution of 
the oil (2 mmol) in dichloromethane (2.8 mL) was added slowly a solution of di-t-butyl dicarbonate 
(1091 mg, 5 mmol) in dichloromethane (2.8 mL). The reaction was stirred overnight. The solvent was 
removed by rotary evaporation to give a colourless oil. The crude mixture was purified by silica gel 
column chromatography (100% dichloromethane-5% MeOH in dichloromethane) and the product 
2.30b isolated as a pale yellow oil. 1H NMR (400 MHz, d6-DMSO): δ(ppm) 4.42 (t, 3J = 5.0 Hz, 2H, OH), 
3.38 (m, 4H, CH2), 3.15 (t, 3J = 7.3 Hz, 4H, CH2), 1.69-1.54 (m, 4H, CH2), 1.38 (s, 9H, CH3). 13C NMR (100 
MHz, d6-DMSO): δ(ppm) 155.7 (C), 78.2 (C), 58.5 (CH2), 44.2 (CH2), 31.9 (CH2), 28.1 (CH3). 
Synthesis of 2.31b. To a solution of 5-hydroxypyridine-2-carboxylic acid methyl ester (362 mg. 2.36 
mmol), triphenylphosphine (1241 mg, 4.72 mmol) and N-Boc dipropanolamine (276 mg, 1.18 mmol) 
in anhydrous THF (18 mL), stirred on ice under N2, was added diethyl azodicarboxylate (0.74 mL, 4.72 
mmol) in anhydrous THF (1.2 mL) and the reaction was stirred at room temperature overnight. 
Solvent was removed by rotary evaporation to give the crude product 10 as an orange oil. The 
product was purified by silica gel column chromatography (80% EtOAc/Hexane – 3% MeOH/EtOAc) 
to yield a mixture (ca. 1:0.2) of 2.31b and triphenylphosphine oxide. This compound was used 
without further purification for the next step. The following spectroscopic data corresponds to the 
signals associated to 2.31b: 1H NMR (400 MHz, CDCl3): δ(ppm) 8.37 (d, 4J = 2.9 Hz, 2H, ArH), 8.10 (d, 
3J = 8.7 Hz, 2H, ArH), 7.24 (dd, 3J = 8.8 Hz, 4J = 2.9 Hz, 2H, ArH), 4.13-4.08 (m, 4H, CH2), 3.97 (s, 6H, 
CH3), 3.41 (t, 3J = 6.9 Hz, 4H, CH2), 2.16-2.03 (m, 4H, CH2), 1.39 (s, 9H, CH3). Signals corresponding to 
triphenylphosphine oxide are found as a multiplet between 7.40 and 7.75 ppm. 
Synthesis of 2.32b. To a solution of 2.31b (421 mg, 0.95 mmol) in dichloromethane (1 mL) was 
added TFA (1 mL) and the reaction stirred at room temperature for 1 hour. The solvent was removed 
and the product 2.32b isolated pure by silica gel column chromatography (EtOAc then 
MeOH:dichloromethane:triethylamine 10:85:5) to give the desired product 2.32b as a pale pink 
solid. (279 mg, 0.67 mmol, 71%). 1H NMR (400 MHz, d6-DMSO): δ(ppm) 8.37 (d, 4J = 2.8 Hz, 2H, ArH), 
8.03 (d, 3J = 8.7 Hz, 2H, ArH), 7.50 (dd, 3J = 8.8 Hz, 4J = 2.9 Hz, 2H, ArH), 4.21 (t, 3J = 6.2 Hz, 4H, CH2), 
3.84 (s, 6H, CH3),   2.91 (t, 3J = 7.1 Hz, 4H, CH2), 2.00 (m, 4H, CH2). 13C NMR (100 MHz, d6-DMSO): 
δ(ppm) 164.8 (C), 157.2 (C), 139.5 (CH), 139.4 (CH), 126.4 (C), 120.6 (CH), 66.1 (CH2), 52.1 (CH3), 44.9 
(CH2), 27.1 (CH2). IR in cm-1 υ(N-H) 2804, υ(C=N)/υ(C=C) 1732, 1669, 1574, υ(C-O) 1316. ESI-MS (+) 
404 ([M+H]+), 426 ([M+Na]+). 
Synthesis of 2.33b. To a solution of 2.32b (270 mg, 0.67 mmol) and dansyl chloride (217 mg, 0.80 
mmol) in anhydrous CH3CN (21 mL) was added anhydrous triethylamine (0.28 mL, 2.0 mmol) and the 
130 
 
reaction stirred at room temperature for 48 hours. The solvent was removed by rotary evaporation 
to give a yellow residue. The crude mixture was purified by silica gel column chromatography (2% - 
3% MeOH in dichloromethane) to give the desired product 2.33b as a yellow solid. (317 mg, 0.50 
mmol, 75%). 1H NMR (400 MHz, MeOD): δ(ppm) 8.26 (dt, 3J = 8.6 Hz, 4J = 1.0 Hz, 1H ArH), 8.21 (dd, 3J 
= 7.4, 4J = 1.2 Hz, 1H, ArH), 8.13 (d, 3J = 8.7 Hz, 4J = 0.9, 1H, ArH),  8.04 (d, 4J = 2.9 Hz, 2H, ArH), 7.99 
(d, 3J = 8.8 Hz, 2H, ArH ), 7.54-7.46 (m, 2H, ArH,), 7.12 (dd, 3J = 8.7 Hz, 4J = 2.9 Hz, 2H, ArH), 7.09 (d, 3J 
= 7.7 Hz, 4J = 0.8 Hz, 1H, ArH,), 3.96-3.93 (m, 10H, CH2, CH3), 3.59 (t, 3J = 6.7 Hz, 4H, CH2),  2.77 (s, 6H, 
CH3), 2.08 (m, 4H, CH2). 13C NMR (100 MHz, MeOD): δ(ppm) 166.3 (C), 159.1 (C), 153.1 (C), 140.5 
(CH), 139.3 (CH), 135.3 (C), 131.9 (C), 131.7, 131.2 (CH), 130.9 (CH), 129.2 (CH), 127.7 (C), 124.1 (CH), 
121.6 (CH), 120.0 (C), 116.0 (CH), 66.7 (CH2), 53.0 (CH3), 45.7 (CH2), 43.6 (CH2), 28.0 (CH2). ESI-MS (+) 
637 ([M+H]+), 659 ([M+Na]+). 
Synthesis of 2.34b. To a solution of 2.33b (317 mg, 0.50 mmol) in THF:MeOH (1.3:0.5 mL) on ice was 
added 6M NaOH (0.23 mL, 1.90 mmol) and the reaction stirred for 2.5 hours at room temperature. 
The solvent was removed by rotary evaporation to give a pale yellow solid which was diluted with 
H2O and extracted with EtOAc. The organic layer was set aside and the aqueous layer acidified with 
6M HCl and re-extracted with EtOAc (3×6 mL) and dichloromethane (1 × 6 mL). The organic layers 
were combined, dried over Mg2SO4 and the solvent removed by rotary evaporation to give the 
desired product 2.34b as a yellow solid. (157 mg, 0.26 mmol, 52%). 1H NMR (400 MHz, MeOD): 
δ(ppm) 8.27 (d, 3J = 8.5 Hz, 1H, ArH), 8.22 (d, 3J = 7.4 Hz, 1H, ArH), 8.14 (d, 3J = 8.4 Hz, 1H, ArH), 8.06 
(d, 4J = 2.8 Hz, 2H, ArH), 8.02 (d, 3J = 8.8 Hz, 2H, ArH), 7.54-7.48 (m, 2H, ArH), 7.17 (dd, 3J = 8.7 Hz, 4J = 
2.9 Hz, 2H, ArH), 7.12 (d, 3J = 7.6 Hz, 1H, ArH), 3.96 (t, 3J =  5.8 Hz, 4H, CH2), 3.60 (t, 3J = 6.8, 4H, CH2), 
2.79 (s, 6H, CH3), 2.12 – 2.05 (m, 4H, CH2). 13C NMR (100 MHz, d6-DMSO): δ(ppm) 165.7 (C), 156.8 
(C), 151.4 (C), 140.3 (CH), 137.7 (CH), 134.2 (C), 130.1 (C), 129.4, 129.3 (CH), 129.1 (CH), 128.1 (CH), 
126.1 (C), 123.5 (CH), 120.4 (CH), 118.5 (C), 115.0 (CH), 65.4 (CH2), 45.0 (CH2), 43.1 (CH2), 27.0 (CH2). 
ESI-MS (+) 609 ([M+H]+). Fluorescence λmax(ex) 340 nm, λmax(em) 528 nm. 
Synthesis of 2.36. A solution of diethanolamine (400 mg, 3.8 mmol), 1-(2-Chloroethyl)piperidine 
hydrochloride (239 mg, 1.3 mmol) and KI (498 mg, 3.8 mmol) in anhydrous DMF was stirred at 111-
113 °C under N2 for 24 hours. Some DMF was removed by rotary evaporation and the residue diluted 
with saturated NaHCO3 and extracted with CHCl3. The pH of the aqueous layer was raised to 11-12 
and then further extracted with CHCl3. The organic layer was dried over Na2SO4 and the solvent 
removed by rotary evaporation to give the crude product as an orange oil. The reaction was purified 
by column chromatography (0.5% triethylamine, 10% MeOH in CHCl3) to give the product 2.36 as a 
brown oil (180 mg, 0.83 mmol, 64%). 1H NMR (400 MHz, MeOD): δ(ppm) 3.60 (t, 3J = 6Hz, 4H, CH2), 
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2.73 (t, 3J = 6 Hz, 4H, CH2), 2.70 (m, 2H, CH2), 2.50 (m, 6H, pipNH, CH2), 1.67 (p, 3J = 5.7 Hz, 4H,  
pipCH2), 1.49 (m, 2H, pipCH2) 
Synthesis of 2.37a. To a solution under nitrogen of 2.32a (267 mg, 0.71 mmol) and tosyl chloride 
(162 mg, 0.85 mmol) in anhydrous CH3CN (21 mL) was added triethylamine (0.3 mL, 2.13 mmol) and 
the reaction was stirred at room temperature overnight. Solvent was removed by rotary evaporation 
and the crude product was purified by column chromatography (2% MeOH/ CH2Cl2) to give the 
desired product 2.37a (90 mg, 0.17 mmol, 24%).  1H NMR (400 MHz, CDCl3): δ(ppm) 8.29 (d, 4J = 2.9 
Hz, 2H, ArH), 8.09 (d, 3J = 8.7 Hz, 2H, ArH), 7.68 (d, 3J = 8.3 Hz, 2H, ArH), 7.28 (d, 3J = 8.7 Hz, 2H, ArH), 
7.19 (dd, 3J = 8.7 Hz, 4J = 2.9 Hz, 2H, ArH), 4.30 (t, 3J = 5.7 Hz, 4H, CH2), 3.99 (s, 6H, CH3), 3.72 (t, 3J = 
5.7 Hz, 4H, CH2), 2.39 (s, 3H, CH3). ESI-MS (+) 530 ([M+H]+), 532 ([M+Na]+). 
Synthesis of 2.38a. To a solution of the 2.37a (78 mg, 0.13) in THF:MeOH:H2O (1.2:0.5:0.5 mL) under 
N2 was added LiOH (28 mg, 1.17 mmol) and the reaction stirred at room temperature for 18 hours. 
Solvent was removed by rotary evaporation to give a white residue which was dissolved in H2O. The 
solution was acidified to pH 4 with 1M HCl and washed with EtOAc at which point a white solid 
formed. The precipitate was collected by filtration, washed with H2O and dried to give the desired 
product 2.38a as a white solid. (44.5 mg, 0.09 mmol, 59%).  1H NMR (400 MHz, d6-DMSO): δ(ppm) 
8.18 (d, 4J = 2.8 Hz, 2H, ArH), 8.08 (d, 3J = 8.7 Hz, 2H, ArH), 7.77 (d, 3J = 8.3 Hz, 2H, ArH), 7.42 (dd, 3J = 
8.8 Hz, 4J = 2.9 Hz, 2H, ArH), 7.32 (d, 3J = 8.1 Hz, 2H, ArH), 4.35 (t, 3J = 5.4 Hz, 4H, CH2), 3.78 (t, 3J = 5.3 
Hz, 4H, CH2), 2.37 (s, 3H, CH3). 13C NMR (100 MHz, d4-MeOH): δ(ppm) 167.3 (C), 158.9 (C), 142.2 (C), 
141.6 (CH), 139.0 (CH), 138.0 (CH), 130.9 (CH), 128.4 (CH), 127.7 (C), 120.6 (CH), 118.8 (C), 115.2 
(CH), 66.4 (OCH2), 46.8 ((CH3)2), 45.0 (CH2NH). ESI-MS (+) 502 ([M+H]+).  
Synthesis of 2.37b. To a solution under nitrogen of 2.32b (123 mg, 0.3 mmol) and tosyl chloride (70 
mg, 0.37 mmol) in anhydrous CH3CN (9 mL) was added triethylamine (0.13 mL, 0.91 mmol) and the 
reaction was stirred at room temperature overnight. Solvent was removed by rotary evaporation 
and the crude product 2.37b was purified by column chromatography (2% MeOH/ CH2Cl2) to give the 
desired product (107 mg, 0.19 mmol, 63%).  1H NMR (400 MHz, d6-DMSO): δ(ppm) 8.34 (d, 4J = 2.9 
Hz, 2H, ArH), 8.09 (d, 3J = 8.8 Hz, 2H, ArH), 7.68 (d, 3J = 8.2 Hz, 2H, ArH), 7.28 (d, 3J = 8.0 Hz, 2H, ArH), 
7.21 (dd, 3J = 8.7 Hz, 4J = 2.9 Hz, 2H, ArH), 4.09 (t, 3J = 5.8 Hz, 4H, CH2), 3.98 (s, 6H, CH3), 3.34 (t, 3J = 
7.0 Hz, 4H, CH2), 2.38 (s, 3H, CH3), 2.13 (m, 4H, CH2). 
Synthesis of 2.38b. To a solution of the 2.37b (107 mg, 0,19 mmol) in THF:MeOH (0.8:0.3 mL) was 
added 6M NaOH (0.09 mL, 0.54 mmol) and the reaction stirred at room temperature for 3 hours. 
Solvent was removed by rotary evaporation to give a white residue which was dissolved in H2O. The 
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solution was extracted with EtOAc before acidifying to pH 2.5 with 6M HCl. The aqueous solution 
was again extracted with EtOAc (x4) and the pH carefully adjusted with 2M NaOH and 2M HCl to 
maintain at 2.5 throughout. The EtOAc layers from after acidification were dried over MgSO4 and the 
solvent removed by rotary evaporation to give the desired product 2.38b as a white solid (40 mg, 
0.08 mmol, 42%).  1H NMR (400 MHz, d6-DMSO): δ(ppm) 8.27 (d, 4J = 2.8 Hz, 2H, ArH), 8.11 (d, 3J = 
8.7 Hz, 2H, ArH), 7.70 (d, 3J = 8.3 Hz, 2H, ArH), 7.46 (dd, 3J = 8.8 Hz, 4J = 2.9 Hz, 2H, ArH), 7.31 (d, 3J = 
8.0 Hz, 2H, ArH), 4.15 (t, 3J = 5.9 Hz, 4H, CH2), 3.40 (t, 3J = 6.9 Hz, 4H, CH2), 2.35 (s, 3H, CH3), 2.10 (m, 
4H, CH2).  
 
6.3 Synthesis of metal complexes 
Synthesis of 2.39. To a suspension of 3-(4-phenylphenol)oxy-2-pyridine carboxylic acid 2.4 (115.4 
mg, 0.38 mmol) in H2O (2 mL) was added 2M NaOH to raise the pH to neutral and the reaction 
stirred for 1 hour. To the resulting solution was added VOSO4 (41 mg, 0.19 mmol). The reaction was 
stirred until all blue solid had disappeared leaving a suspension of green solid and the reaction 
stirred overnight. The reaction was filtered and the pale green solid washed with cold H2O and 
diethyl ether and left to dry in air and then in a desiccator overnight (71.5 mg, 0.1 mmol 28%). ESI-
MS (+) 676 ([M+H]+), 306 ([L+H]+). Anal. Calc. for C38H28O7N2V·2H2O: C 64.08, H 4.50, N 3.93 Found: C 
63.91, H 4.52, N 4.28. UV-vis (DMSO) λ/nm (ε/M-1.cm-1) 300 (1.12×104). IR in cm-1 υ(C=N)/υ(C=C) 
1668, 1640, 1580, υ(V=O) 966. 
Synthesis of 2.40. To a solution of dansylated 3-(propanolamine)-2-pyridine carboxylic acid 2.17 (150 
mg, 0.35 mmol) and VOSO4 (38 mg, 0.17 mmol) in H2O (3 ml) was added 10% NaHCO3 (2.3 mL, 0.26 
mmol). On addition of the base a green precipitate began to form. The reaction was left to stir for 2 
hours after which the solid was collected by membrane filtration and dried in air (131 mg, 0.14 
mmol, 83%). ESI-MS (+) 924 ([M+H]+). IR in cm-1 υ(C=N)/υ(C=C) 1632, 1575, υ(V=O) 964. Calc. for 
C42H44O6N11S2V: C 52.60, H 4.80, N 9.1 Found: C 48.88, H 4.52, N 7.71 
Synthesis of 2.41. To a solution of dansylated 5-(propanolamine)-2-pyridine carboxylic acid 2.22 (100 
mg, 0.23 mmol) and 10% NaHCO3 (0.15 mL, 0.17 mmol) in H2O (2 mL) was added VOSO4 (26 mg, 
0.12mmol). On addition of the vanadyl a green precipitate began to form. The reaction was left to 
stir for 2 hours after which the solid was collected by filtration and dried under vacuum (32 mg, 0.03 
mmol, 25%). ESI-MS (+) 430 ([L+H]+), 924 ([M+H]+). IR in cm-1 υ(C=N)/υ(C=C) 1643, 1592, 1573, 
υ(V=O) 964. Calc. for C42H44N6O11S2V.4H2O: C 50.65, H 5.26, N 8.44 Found: C 50.73, H 4.89, N 8.28. 
UV-vis (DMSO) λ/nm (ε/M-1.cm-1) 340 (7.42×103). Fluorescence λmax(ex) 340 nm, λmax(em) 520 nm. 
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Synthesis of 2.43a. To a suspension of 2.34a (167 mg, 0.29 mmol) in H2O (6 mL) was added 10% 
NaHCO3 (0.51 mL, 0.58 mmol) and the mixture stirred until all solid was dissolved. VOSO4 (63 mg, 
0.29 mmol) in H2O (4 mL) was added slowly over 2 minutes after which a precipitate began to form. 
After 1 week a green solid precipitated from the solution. This was collected by filtration and IR 
indicated a vanadyl complex had formed. Further characterisation by mass spectrometry indicated 
this was the desired complex 2.43a. (13 mg, 0.02 mmol, 7%). MALDI-MS (+) 668 ([M+Na]+). IR in cm-1 
υ(C=N)/υ(C=C) 1636, 1591, 1575, υ(S=O) 1136, υ(V=O) 965. Calc. for C28H26O9N4SV·3H2O: C 48.07, H 
4.61, N 8.01 Found: C 48.07, H 4.39, N 7.72. UV-vis (DMSO) λ/nm (ε/M-1.cm-1) 340 (5.96×103). 
Fluorescence λmax(ex) 356 nm, λmax(em) 536 nm. 
Synthesis of 2.43b. To a suspension of 2.34b (150 mg, 0.25 mmol) in H2O (6 mL) was added 10% 
NaHCO3 (0.44 mL, 0.49 mmol) and the mixture stirred until all solid was dissolved. A solution of 
VOSO4 (53.5 mg, 0.25 mmol) in H2O (3.5 mL) was added slowly over 2 minutes after which a 
precipitate began to form. The reaction was left to stir for 2 hours. After 2 days without stirring a 
green solid had precipitated from the reaction solution which was collected by filtration and IR 
indicated a vanadyl complex had formed. Further characterisation by mass spectrometry indicated 
this was the desired complex 2.43b. (42 mg, 0.06 mmol, 25%). IR in cm-1 υ(C=N)/υ(C=C) 1645,1591, 
1572, υ(S=O) 1134, υ(V=O) 961. MALDI-MS (+) 696 ([M+Na]+). Calc. for C30H30O9N4SV·3.5H2O: C 
48.92, H 5.06, N 7.61 Found: C 48.62, H 4.71, N 7.39. UV-vis (MeOH/DMF) λ/nm (ε/M-1.cm-1) 262 
(7.37×104), 340 (1.30×104). Fluorescence λmax(ex) 344 nm, λmax(em) 528 nm. 
Synthesis of 2.44. To a solution of 2.34a (58 mg, 0.1 mmol) and 2M NaOH (0.1 mL, 0.2 mmol) in H2O 
(1 mL) was added a solution of K2PtCl4 (41.5 mg, 0.1 mmol) in H2O (1 mL) and the reaction was 
stirred at 40 ºC for 3 hours. The temperature of the reaction was then increased to 60 ºC and the 
reaction stirred for a further 2 hours at which point a yellow precipitate had formed. The solid was 
collected by filtration and dried under vacuum. ESI-MS (+) 774 ([M+H]+). IR in cm-1 υ(C=N)/υ(C=C) 
1662,1597, 1574, υ(S=O) 1134. Calc. for C28H26O9N4SPt·3.5H2O: C 40.19, H 3.98, N 6.70; Found: C 
39.80, H 3.72, N 6.65. UV-vis (DMSO) λ/nm (ε/M-1.cm-1) 320 (3.16×104).  Fluorescence λmax(ex) 340 
nm, λmax(em) 556 nm. 
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Chapter 7: Biochemical Experimental Section 
7.1 Materials.  
Tris buffer, DTT, purified water, OMFP and pNPP were purchased from Sigma Aldrich. EDTA was 
purchased from VWR. Fluorescence data was collected using a Varian fluorescence spectrometer 
while fluorescence polarisation studies were performed with a Perkin-Elmer LS50B Luminescence 
Spectrometer. 
 
7.2 General procedure for phosphatase inhibition assays using OMFP.  
OMFP assays were performed as previously reported83 with some modifications. 3-O-
methylfluorescein phosphate (OMFP, 10 mM in DMSO) was diluted into a 1% DMSO/water solution 
to the required concentration. The vanadyl and platinum complexes or the corresponding ligands 
were dissolved in DMSO to 10 mM and further diluted into a 1% DMSO/water solution to the 
required concentrations. Vanadyl sulfate was dissolved in water to 10 mM and further diluted with 
water to the required concentrations. Assays were run in 100 mM Tris (pH7.4) containing 1 mM DTT 
at room temperature. The inhibitor solutions were incubated with the enzyme in the buffer for 10 
minutes at room temperature before reaction was initiated by addition of OMFP.  Enzyme free 
blanks were run to eliminate background effects of OMFP hydrolysis in solution. Hydrolysis of OMFP 
to OMF was monitored by measuring changes in fluorescence over 30 minutes at 60 s intervals 
(excitation 485 nm, emission 525 nm) using a Varian fluorescence spectrometer. 
Concentrations of enzyme, substrate and inhibitor used for each assay are specified in the figure 
legends. Where EDTA is used, concentration and time of addition is stated in the figure legends.  
7.2.3 Enzyme kinetics analysis in the presence of vanadyl compounds 
The assays were run using the conditions described above. A range of OMFP concentrations were 
used and assays were run using LMW-PTP only. The protocol used was based on a literature 
procedure83. In order to determine the concentration of OMF released in the assay, a calibration was 
carried out to compare fluorescence readout with OMF concentration for a range of 0-6 µM. These 
concentrations were selected as they covered the full range of concentrations of OMF released in 
the assays and were within the reading range of the fluorescence spectrometer (0-1000 a.u.) 
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Figure 58: Calibration curve for fluorescence readout against a range of concentrations of OMF. Data 
was collected using a Varian fluorescence spectrometer and analysed using Microsoft Excel. The 
values are recorded as the average of three readings ± standard deviation.  
 
7.3 Changes in fluorescence of complexes in presence of enzyme and/or EDTA.  
Vanadyl compounds were dissolved in DMF to 10 mM and further diluted in buffer containing 1% 
DMSO to 300 µM. Enzyme was added to a buffer solution of 100 mM Tris (pH7.4) containing 1 mM 
DTT, with or without 1 mM EDTA. Enzyme free controls consisted of buffer solution of 100 mM Tris 
(pH7.4) containing 1 mM DTT, with or without 1 mM EDTA. In a 96-well plate, the inhibitor solutions 
were added to wells containing one of the above mentioned buffers to a final concentration of 30 
µM. Data was recorded using a Varian fluorescence spectrometer with excitation slit widths of 5-10 
nm and emission slit widths of 10-20 nm. 
(a) Fluorescence emission spectra of vanadyl complexes were recorded in the range of 380-650 nm 
after excitation at 340 nm immediately after addition and after two hours incubation at room 
temperature 
(b) Emission of the vandyl compounds (excitation 340 nm, emission 560 nm) was recorded every 5 
minutes for 1 hour.  
 
7.4 Phosphatase inhibition assays using pNPP.  
The assays were run under the conditions used for OMFP assays. Para-nitrophenyl phosphate (pNPP, 
10 mM in miliQ water) was diluted with miliQ water to the required concentration. The platinum 
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complex was dissolved in DMSO to 500 µM and further diluted into a 1% DMSO/water solution to 
the required concentrations. The inhibitor solutions were incubated with the enzyme in the buffer 
for 10 minutes at room temperature before reaction was initiated by addition of pNPP. Hydrolysis of 
pNPP to pNP was monitored by measuring the increase in absorbance at 405 nm over 30 minutes at 
60 s intervals. Enzyme free blanks were run to eliminate background effects of pNPP hydrolysis in 
solution. 
Concentrations of enzyme, substrate and inhibitor used for each assay are specified in the figure 
legends. 
 
7.5 Fluorescence Anisotropy Measurements 
7.5.1 Incubation with enzyme and EDTA 
Vanadium complexes were dissolved in DMSO to 10 mM and further diluted in a 1% DMSO/water 
solution to the required concentration. A five-fold excess of enzyme was diluted in an aqueous 
solution of 1 mM DTT and 100 mM Tris (pH 7.4) and incubated with the inhibitor for 10 minutes. A 
50:50 glycerol-elution buffer (100 mM Tris, 250 mM NaCl, 20 mM reduced glutathione, 2 mM DTT, 
pH 7.4) mixture was used for the enzyme free control. Samples were then analysed for polarised 
fluorescence emission in a fluorescence cuvette (excitation 340 nm, emission 560 nm). 1 mM EDTA 
was then added to the enzyme containing solution and further readings were taken every 15 
minutes for 100-105 minutes.  
7.5.2 Enzyme titration 
Vanadium complexes were dissolved in DMSO to 10 mM and further diluted in a 1% DMSO/water 
solution to the required concentration before mixing with an aqueous solution of 1 mM DTT and 100 
mM Tris (pH 7.4). A fluorescence anisotropy reading was taken at excitation 340 nm, emission 560 
nm. LMW-PTP was the titrated into the mixture increasing from 0.36 equivalent to 3.6 equivalents 
with a fluorescence anisotropy reading taken after 1 minute incubation with each enzyme addition.  
 
7.6 Cell uptake studies.  
NIH3T3 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 
newborn calf serum in an atmosphere of 10 % CO2 at 37ºC.  Cells were seeded in a plastic 24-well 
plate.  After 16 hours the compound was added to the cells in fresh media at 1, 5 and 10 µM (final 
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DMSO concentration 1 % v/v for all wells), and incubated for 24 hours at 37ºC and 10% CO2.  The 
media was then removed and the cells washed three times with sterile Dulbecco’s phosphate 
buffered saline (PBS, EDTA-free).  The cells were fixed by adding 4% paraformaldehyde (PFA) for 15 
minutes at room temperature.  The coverslips were then washed a further three times with PBS and 
processed to fluorescence microscopy experiments using a Zeiss Axiovert 200 inverted microscope 
with filter for FITC (excitation wavelength 465 – 495 nm, emission wavelength 515 – 555 
nm).  Images were acquired using a Hammamatsu Flash 4 (2048x2048 pixel) camera for each 
channel separately and processed using Volocity Software. 
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Appendix 
Compound 2.4 
 
Figure A1: 1H NMR spectrum of compound 2.4  
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Compound 2.17 
 
Figure A2: 1H NMR spectrum of compound 2.17 
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Compound 2.22 
 
Figure A3: 1H NMR spectrum of compound 2.22 
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Compound 2.26 
 
Figure A4: IR spectrum of compound 2.26 showing the absence of a vanadyl stretch at 940-960 cm-1  
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Compound 2.31a 
 
Figure A5: 1H NMR spectrum of compound 2.31a. The peaks associated with OPPh3 are highlighted 
(blue circle). 
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Compound 2.32a 
 
Figure A6: 1H NMR spectrum of compound 2.32a. The absence of peaks associated with OPPh3 is 
highlighted (blue circle).  
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Compound 2.34a 
 
Figure A7: 1H NMR spectrum of compound 2.34a. 
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Compound 2.34b 
 
Figure A8: 1H NMR spectrum of compound 2.34b. 
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Compound 2.39 
 
Figure A9: IR spectrum of compound 2.39 showing the presence of a vanadyl stretch at 955 cm-1  
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Compound 2.41 
 
Figure A10: IR spectrum of compound 2.41 showing the presence of a vanadyl stretch at 954 cm-1 
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Compound 2.43a 
 
Figure A11: IR spectrum of compound 2.43a showing the presence of a vanadyl stretch at 965 cm-1 
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Compound 2.43b 
 
Figure A12: IR spectrum of compound 2.43b showing the presence of a vanadyl stretch at 960 cm-1 
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Compound 2.44 
 
Figure A13: IR spectrum of compound 2.44 showing the absence of a vanadyl stretch at 940-960 cm-1 
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Figure A14: Concentration-response plots using a logarithmic concentration scale for complex 2.43a. 
Data is plotted using GraFit software as the mean ± standard deviation of triplicate repeats.   
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Figure A15: Concentration-response plots using a logarithmic concentration scale for complex 2.43b. 
Data is plotted using GraFit software as the mean ± standard deviation of triplicate repeats.   
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Figure A16: Concentration-response plots using a logarithmic concentration scale for complex 2.41. 
Data is plotted using GraFit software as the mean ± standard deviation of triplicate repeats. 
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 Figure A17: Concentration-response plots using a logarithmic concentration scale for complex VOSO4. 
Data is plotted using GraFit software as the mean ± standard deviation of triplicate repeats. 
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Figure A18: Effects on the activity of activity of (a) VHR and (b) PTP1B PTPs on incubation with a range 
of concentrations of complex 2.44. The compound was incubated with the enzyme for 10 minutes 
before addition of OMFP ((a) 150 µM, (b) 15 µM) to initiate the reaction. Data is shown as a 
percentage of uninhibited enzyme activity. Error bars are the standard deviation of 6 data points over 
two independent experiments.  
 
Volume of glycerol 
added/µL 
Fluorescence 
Anisotropy/a.u. 
0 0.29 
1.8 0.29 
4.5 0.30 
9 0.28 
Figure A19: Table showing the fluorescence anisotropy reading for complex 2.43a in the presence of 
increasing amounts of glycerol. Values are shown as the average of three readings.  
 
 
Figure A20: Table showing the p-values obtained from statistical analysis (t-test) of fluorescence data 
(Figure 44). 
Comparison p-value with enzyme p-value with EDTA 
2.34a and 2.43a 0.0168 0.8099 
2.34b and 2.43b 0.0028 0.4251 
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Figure A21: Table showing the p-values obtained from statistical analysis (t-test) of fluorescence 
anisotropy data (Figure 46, Figure 47). 
 p-value for comparison with “buffer + compound” 
Time of EDTA incubation 2.43a 2.43b 
0 minutes 0.00007 0.00047 
15 minutes 0.00002 0.01396 
30 minutes 0.00269 0.05607 
45 minutes 0.01320 0.04275 
60 minutes 0.30679 0.20229 
105 minutes 0.74660 0.61808 
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